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Parkinson’s disease (PD) is a neurodegenerative disease characterised by accumulation of α-
synuclein protein and loss of midbrain dopaminergic (mDA) neurons of the Substantia nigra 
(SN), resulting in motor dysfunction. Mutations and multiplications of the SNCA locus, which 
encodes α-synuclein, have been associated with familial Parkinson’s Disease. Using 
lentiviruses to overexpress wild-type and mutant α-synuclein in mDA neuron models, the 
transcriptomic and functional changes associated with increased α-synuclein burden were 
investigated. 
The SH-SY5Y cell line was employed to study gene expression, by profiling actively translated 
mRNAs isolated by translating ribosome affinity purification (TRAP). Differential expression 
analysis in α-synuclein overexpressing cells identified actin cytoskeleton, mitochondrial and 
oxidative stress response proteins, as well as a key protein involved in miRNA biogenesis, 
DGCR8, to be key pathways affected by α-synuclein overexpression. Validation using 
molecular biology techniques was able to partially validate some of these targets. 
mDA neurons derived from human induced pluripotent stem cells (iPSC) were employed to 
study functional phenotypes, differentiation capacity and neurite dynamics, in response to 
overexpression of wild-type and mutant α-synuclein. Whilst the capacity for iPSC cells to 
differentiate into mDA neurons expressing mature neuronal and dopaminergic markers was 
not affected, both neurite extension and axonal branching was seen to be reduced in α-
synuclein overexpressing cultures. Furthermore, these models were used to interrogate 
alterations in expression of microRNAs (miRNA) associated with mDA function and PD 
pathogenesis. Intracellular miRNA analysis resulted in the identification of differential 
expression of miRs-34b, -34c, -155 and -494, known to be associated with regulation of 
neuroinflammation, oxidative stress response and post-transcriptional regulation of α-
synuclein mRNA. 
The data presented implicates several pathways, genes and miRNA that are perturbed in 
response to α-synuclein overexpression. Further study of these pathways will contribute to 
our understanding of mechanisms underlying α-synuclein pathology and may represent 
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Chapter 1 – General Introduction 
1.1 Parkinson’s disease: A historical perspective 
1.1.1 Parkinson’s disease classification and disorder-anatomy associations   
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder after 
Alzheimer’s disease (AD). The current understanding of the pathophysiology of PD has taken 
many years to unfold and is probably best understood from a historical perspective (Table 
1.1).  
Observation Implication Publication 
Patient with midbrain 
tuberculoma caused 
Parkinsonism 
Identification of Substantia nigra (SNc) 
as a pathological site in PD 
(Blocq et al. 1893) 
Synthesis of Dopamine Dopamine only thought of as precursor 
to Adrenaline and Noradrenaline 
(Barger and Ewins 
1910) 
Described the characterstic 
anatomical feature of PD ‘the 
Lewy Body’ 
Abnormal eosinophilic cytoplasmic 
inclusions consisting of radiating fibrils 
surrounding a dense core 
(Lewy 1912) 
Detailed descriptions of 
decrease in size and 
pigmentation of SNcp neurons in 
PD 
Midbrain atrophy and destruction of 
nerve cells associated with PD 
(Foix et al. 1925) 
Discovery of substance “X” 
found in varying concentrations 
in the brain 
Substance “X” found to be identical to 
dopamine 
(Montagu 1957) 
Drug respirine causes severe loss 
of catecholamines, causing 
tranquilisation 
L-DOPA (dopamine precursor) injection 
alleviates respirine induced 
tranquilisation 
(Carlsson et al. 1957) 
Highest levels of dopamine in 
the mammalian brain were 
found in the corpus striatum 
Distribution of dopamine in brain 
implicates a role for the corpus striatum 
in the control of motor function 
(Bertler et al. 1959; 
Sano et al. 1959) 
Patients with PD showed severe 
dopamine deficits in the caudate 
and putamen 
Confirmation of the association of 
dopamine deficiency within the caudate 
and putamen in PD 
(Ehringer et al. 1960) 
Intravenous injections of 
levodopa to 20 PD patients 
relieved symptoms 
Complete abolition or reduction in 
akinesia by drug therapy 
(Birkmayer et al. 1961) 
Dopamine markedly reduced in 
neostriatum following lesions to 
SNpc 
Identification of nigrostriatal 
dopaminergic pathway 
(Andén et al. 1964) 
Table 1.1 – A history of PD. A history of the main discoveries which have led to the understanding of the anatomical and 
chemical disruptions associated with Parkinson’s disease 
PD was first expounded in an essay entitled ‘An Essay on the Shaking Palsy” by James 




by writers in general to describe cases of palsy accompanied by involuntary tremors. In his 
treatise, Parkinson defined this slow progressing disease by symptoms apparent at different 
stages of disease progression beginning with a “slight sense of weakness” with a “proneness 
to trembling in some particular part” with symptoms gradually increasing over the usually 
long duration of the disease. The “malady” is defined as: 
“Involuntary tremulous motion, with lessened muscular power, in parts not in action 
and even when supported; with a propensity to bend the trunk forward, and to pass 
from a walking to a running pace: the senses and intellects being uninjured” 
The work of the French neurologist Jean-Martin Charcot was instrumental to the 
characterisation of PD, identifying bradykinesia as a cardinal clinical feature, replacing 
weakness, as it was noted that patients had a slowness of execution and not marked 
weakness (Figure 1.1A). This was one of the reasons Charcot rejected the previous label of 
“shaking palsy” and assigned it the eponymous title “Parkinson’s Disease”.   
In 1893, a case study reported a 38 year old with PD, at autopsy, as having a hazelnut size 
enucleated tuberculoma which selectively damaged the substantia nigra (SN) (Blocq et al. 
1893). This midbrain lesion was thought to cause the Parkinsonian symptoms. This led to the 
hypothesis that the SN was the major pathological site in PD and that lesions of the SN was 
directly related to aetiology of PD (Figure 1.1B). In the early 20th century, Friedrich Lewy 
identified and described the characteristic anatomical feature of PD, by performing 
exhaustive post-mortem examinations on PD patients. This was the abnormal eosinophilic 




In 1919 a Soviet scientist, Constantin Tretiakoff, noticed a marked loss of pigmented 
substantia nigra pars compacta (SNpc) neurons, as well as cell body swelling and 
neurofibrillary alterations whilst examining 54 autopsied brain sections. Surviving SN cells 
were noted as having inclusions which he named Lewy bodies, in recognition of Freidrich Lewy 
(Trétiakoff 1919). These results were confirmed in 1925 (Foix et al. 1925) and SN lesions were 
studied in detail in idiopathic and post-encephalitic Parkinsonism in 1953 (Greenfield et al. 
1953). However, it would not be until the discovery of the dopaminergic nature of the 
nigrostriatal neurons, and the characteristic depletion of dopamine in the basal ganglia in 
general, that a further understanding of the anatomical pathways relating to movement could 
be reached. 
 
Figure 1.1 – Symptoms and anatomical abnormalities in PD. A) Motor abnormalities characteristic of Parkinson’s disease 
(Figure adapted from (Gowers 1901)). Illustration of a PD patient from William Gower seminal book ‘Manual of the 
Diseases of the Nervous System’.  B) Schematic diagram representing normal, healthy midbrain dopaminergic neuron 
projections (red line) from the SN to the striatum (putamen and caudate nucleus) with black arrows point to normal 
neuromelanin pigmentation of midbrain SN dopaminergic neurons (left). Parkinson’s disease brains with a loss of 
midbrain SN dopaminergic neurons and subsequent loss of synaptic innervation to the striatum (dashed red line). Black 






1.1.2 The discovery of dopamine 
Many important discoveries that would lead to the discovery of the dopaminergic nature of 
the basal ganglia, and in turn lead to the development of the first directed treatments for PD 
symptoms, were undertaken in parallel to the anatomy-disorder association studies 
(described in section 1.1.1) (Table 1.1). The first major milestone in the understanding of the 
pathophysiology of PD was the synthesis of Dopamine (Barger and Ewins 1910) which was 
found to have weak sympathomimetic properties (Barger and Dale 1910). A year later, D,L-
dopa was synthesised chemically (Funk 1911) and 2 years later, the dopamine precursor 3:4-
Dihydroxyphenylalanine (ʟ-Dopa) was isolated from fava beans (Vicia faba) (Guggenheirn 
1913). However, for many years after its initial synthesis, this newly discovered catecholamine 
was thought to be only an intermediate product for the metabolism of adrenaline and 
noradrenaline (Figure 1.2). It was not until 1938, that the enzyme dopa decarboxylase (DDC) 
was discovered to produce dopamine from ʟ-Dopa in cells taken from mammalian tissue 
(Holtz et al. 1938). Thus, it was in 1957, whilst determining levels of catecholamines in 
mammalian brain extracts using a sensitive quantitative fluorometric technique, that 
dopamine was identified as present in varying concentrations in brain tissue (Montagu 1957). 
Up to this point, dopamine loss in the striatum was not yet considered to be related to the 
pathogenesis of PD. Later, two independent studies characterising regional distribution of 
dopamine in the mammalian brain found highest levels in the striatum (Bertler et al. 1959; 
Sano et al. 1959). This observation led the investigators to conclude that dopamine may have 







Figure 1.2 – Catecholamine synthesis and metabolism pathways. Phenylalanine is converted to tyrosine by phenylalanine 
hydroxylase which, in turn, is converted to L-dopa by tyrosine hydroxylase (TH). Further processing by dopa decarboxylase 
(DDC) converts L-dopa to dopamine. Noradrenaline can then be synthesised from dopamine by the action of dopamine-
β-hydroxylase.  Finally, noradrenaline can be converted to adrenaline by the action of phenylethanolamine N-
methytransferase (adapted from (Daubner et al. 2011)). 
1.1.3 The development of the first targetted Parkinson’s disease treatment 
The discovery of the anatomical and chemical disruptions associated with parkinsonism set 
the stage for the development of the first therapy for PD. In 1957 researchers investigating 
the drug Reserpine, which causes catecholamine depletion and induces tranquilisation in 
mice, discovered an important clue. Intraperitoneal injection of L-Dopa into catecholamine 
depleted mice was found to antagonise the action of Reserpine such that they were normal 
or even overactive upon injection (Carlsson et al. 1957). Furthermore, the intravenous 
addition of L-Dopa resulted in a marked increase in dopamine brain content and central 




Further analyses of dopamine content in freshly dissected autopsied brain tissue from 
patients with motor symptoms (6 PD patients, 6 patients with symptoms of unknown 
aetiology and 2 Huntington’s patients) showed that only the PD patients had severe dopamine 
deficits in the striatum (Figure 1.1B)(Ehringer et al. 1960). Following this, a clinical trial was 
conducted to deliver intravenous injections of levodopa to 20 PD patients. The results were 
astonishing, as patients who received levodopa showed a complete abolition or reduction in 
akinesia. The effects lasted for 3 hours at full intensity and then dissipated over the next 24 
hours (Birkmayer et al. 1961). It was not until 1967, with the publication of a seminal clinical 
paper that described effective administration of L-dopa therapy, that the era of dopamine 
replacement dawned. Here, Cotzias used larger, sustained oral doses of L-dopa, administered 
to induce sustained beneficial improvements in Parkinsonism symptoms such as tremor and 
rigidity (Cotzias et al. 1967). This was a huge milestone in clinical research and for the first 
time, perturbations in a chemical in a specific brain region was associated with a characterised 
degenerative disorder.   
1.1.4 Identification of the nigro-striatal dopaminergic pathway 
The discovery that PD is characterised by loss of dopamine in the basal ganglia greatly 
stimulated research on the basal ganglia, in particular the SNpc. Thus, it was in 1961, that the 
very first descriptions of striatopallidal-nigral degeneration in a case of PD was reported 
(Adams et al. 1961). It was later found that lesions in the SNpc induced a reduction in striatal 
dopamine and the existence of a nigro-striatal dopaminergic pathway was identified, 
originating in the substantia nigra, through the internal capsule and terminating in the 
neostriatum (Figure 1.3) (Andén et al. 1964; Poirier et al. 1965). It was noted specifically that 
the reduction in dopamine content following SNpc lesions was akin to the reduction in 





Figure 1.3 – Reduction of dopamine in PD. 18F-dopa PET images of the striatum in a healthy individual (left) and a patient 
with Parkinson’s disease (right) which shows a loss of the dopaminergic tracer in the putamen and caudate nucleus (Figure 
taken from (Piccini et al. 2004)). 
In 1964, the first accurate maps of anatomical organisation of dopaminergic neuronal systems 
and their projections was mapped by Dahlstrom and Fuxe (Dahlström et al. 1964), who 
studied the localisation, distribution and morphology of amine-containing neurons (Falck et 
al. 1962). The catecholaminergic neurons of the mesencephalon were divided topographically 
into groups A8-A10, with the A9 group being of importance, as these were the neurons that 
send fibres to the neostriatum via the nigro-striatal pathway. Together, these midbrain 
dopaminergic (mDA) neurons represent approximately 75% of all DA neurons in the adult 
brain, with a single mDA neuron being able to form wide-spread and dense axonal branching 
in the neostriatum (Figure 1.4)(Matsuda et al. 2009). 
 
Figure 1.4 – Dopaminergic neurons produce dense dendritic arborisations. Camera lucida reconstruction of a single rat 





Together, these studies represent the academic discoveries of the past 200 years that have 
led to a preliminary clinical understanding of the pathophysiology of PD. The genetic era 
would bring with it a tide of fast-paced academic literature on PD. These contemporary 
studies would be accompanied by advances in multiple disciplines, such as molecular biology, 
imaging and computer modelling, to bring about a deeper understanding of the aetiology and 
the molecular and cellular mechanisms responsible for the development of PD.   
1.2 Parkinson’s disease classification and current treatments 
1.2.1 Parkinson’s disease symptoms and incidence 
PD is a clinical syndrome characterised by motor disturbances of which the 3 main symptoms 
are: a slowness of movement (bradykinesia), resting tremor and muscle stiffness (rigidity). 
The estimated prevalence of PD in Europe varies considerably and ranges from 66-
12,500/100000, probably due to issues with diagnosis and the clinical heterogeneity of the 
disease (von Campenhausen et al. 2005). A higher incidence has been associated with 
increased age and in males compared to females (Van Den Eeden et al. 2003; Pringsheim et 
al. 2014; Hirsch et al. 2016). Environmental factors such as pesticide exposure and head injury 
have been observed to correlate with increased risk (Noyce et al. 2012). Motor symptoms 
arise when approximately 30% of mDA neurons are lost (Fearnley et al. 1991; Ma et al. 1997) 
with a corresponding reduction in striatal dopamine levels of approximately 80% (Scherman 
et al. 1989). 
These parkinsonian symptoms arise because of loss of neuromelanin-containing A9 midbrain 
dopaminergic neurons of the SNpc, resulting in a loss of dopamine to the neostriatum. It is 
characterised histologically by the presence of abnormal, insoluble protein aggregates, 




synphilin, ubiquitin, neurofilament protein and occasionally tau but are predominantly 
composed of α-synuclein protein (Figure 1.5). These α-synuclein Lewy bodies are also found 
in patients with Dementia with Lewy Bodies (DLB) and α-synuclein is also found in glial 
cytoplasmic inclusions that are characteristic of Multiple Systems Atrophy (MSA). Together, 
these diseases are grouped together into a family of neurodegenerative disorders termed 
synucleinopathies.   
 
Figure 1.5 - Immunohistochemical labelling of midbrain dopaminergic neurons for α-synuclein and ubiquitin, identifying 
Lewy bodies which have a distinct halo shape (Figure taken from (Dauer et al. 2003)). 
The motor symptoms experienced by patients are often accompanied by secondary non-
motor symptoms such as autonomic, gastrointestinal and neuropsychiatric symptoms (Zhang 
et al. 2016). LB/LN pathology is thought to be able to spread through the brain caudo-rostrally 
through the vagal connections of the gut (described in section 1.4.4). These non-motor 
symptoms may be linked to the spreading of LB/LN pathology through different anatomical 
regions. Parkinson’s disease associated dementia, for example, has been previously 
correlated to LB distribution and density in the cortex and is thought to affect 30% of PD 
patients, representing approximately a 4-6-fold increase from the general population 




1.2.2 Current treatment options for PD 
As mentioned in section 1.1.3, the first targeted treatment for PD motor symptoms was 
dopamine replacement therapy. Alternative pharmacological treatments have been 
developed such as dopamine agonists that function like dopamine to activate dopamine 
receptors. Other treatments include monoamine oxidase B or catechol-O-methyltransferase 
inhibitors that can prevent the degradation of dopamine, thus increasing striatal dopamine 
levels. These drugs can relieve motor symptoms associated with PD but cannot slow, stop or 
reverse PD pathological changes like SNpc neuron degeneration (reviewed in (Connolly et al. 
2014)).   
More recently, brain derived neurotrophic factors such as nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF) have shown 
promising results in pre-clinical and clinical studies as neuroprotective agents for 
neurodegenerative diseases. These treatments can slow down disease progression by 
enhancing survival and regeneration of mDA neurons but require invasive procedures to 
direct proteins to affected regions (reviewed in (Allen et al. 2013)). In an α-synuclein 
overexpression rat model, it was shown that increased α-synuclein burden resulted in the 
reduction of the GDNF receptor component RET tyrosine kinase, revealing a possible 
mechanism of pathology (Decressac, Kadkhodaei, et al. 2012). In a recent human trial, 41 PD 
patients were administered intraputamenal GDNF via a transcutaneous port and monitored 
over 40 weeks. The study reported a large, clinically relevant improvement in motor function 
in 43% of PD patients given GDNF compared to PD patients given a placebo, whilst none of 
the patients given placebo showed any significant improvement. However, overall, there was 
no significant difference in motor function between the GDNF and placebo groups (Whone et 




As motor symptoms arise after 30% of mDA neurons have degenerated, the prodromal phase 
of PD offers a therapeutic window to delay or prevent the disease. c-Abl tyrosine kinase 
inhibitors, which can prevent phosphorylation of α-synuclein, has had some preclinical 
success in protecting dopaminergic neurons from degeneration and improving motor 
behaviour (Hebron et al. 2013; Karuppagounder et al. 2014). Direct stimulation of basal 
ganglia activity via deep brain stimulating electrodes in the subthalamic nucleus has also 
shown some efficacy in improving motor symptoms (Volkmann et al. 2001). 
These therapeutic strategies are not as effective in the later stages of the disease when a 
substantial number of neurons have degenerated. Fetal mesencephalic grafts into PD patient 
brains have previously shown some evidence of functional motor improvements and, 
encouraged by results, stem cell-derived transplantation strategies are currently being 
developed for early phase clinical trials (Barker et al. 2017).  
1.3 Midbrain Dopaminergic (mDA) neurons 
1.3.1 Development of the midbrain dopaminergic neurons 
1.3.1.1 Neuralisation 
The mDA neurons of the SNpc are derived from the ventral midline, termed the floorplate, of 
the neural tube. Formation of the early nervous system begins during the gastrulation event 
early in embryogenesis and the appearance of a more complex three-layered structure 
consisting of endoderm, mesoderm and ectoderm, as well as a structure termed the 
notochord. The notochord secretes growth factors that stimulate the ectoderm layer, which 
begins to differentiate into neuroectoderm cells. It is at this point that the process of 
neurulation begins with the formation of a neural plate that separates from the surface 




nearly all the neurons and glia of the central nervous system (CNS) of vertebrates. The 
anterior portion of the neural tube then begins to swell and develop the three primary 
vesicles which give rise to the forebrain (prosencephalon), midbrain (mesencephalon) and 
hindbrain (rhombencephelon) (Figure 1.6).   
 
Figure 1.6 - Schematic representing the three embryonic vesicles of the neural tube that develop into the five secondary 
vesicles and their adult derivatives. The prosencephalon gives rise to the telencephalon and diencephalon, and 
subsequently forebrain structures such as the cerebral hemispheres and the thalamus, respectively.  The mesencephalon 
gives rise to midbrain structures including the substantia nigra.  The Rhombencephalon gives rise to the metencephalon 
and myelencephalon, and subsequently hindbrain structures such as the pons/cerebellum and medulla, respectively 
(Figure adapted from (Jinkins 2000)) 
Early investigations into the processes that drive stem cell specification used isolated 
embryonic tissue at different stages of early embryogenesis to attempt to discover the 
prospective fate of the isolated tissue. Hans Spemann and Hilde Mangold in 1924 (Spemann 
et al. 2001) transplanted the dorsal lip of the Triton species of newt blastopore embryo at 
gastrulation stage into the ventral side of a different pigmented embryo and showed that 
instead of developing into mesodermal notochord, the graft induced the formation of neural 
tissue from ectoderm and  dorsalisation of the ventral mesoderm. This resulted in the 
formation of a twin embryo at the graft site, containing cells of both pigmentations. This 
experiment provided the first evidence for a process termed induction, whereupon cells 




within the developing embryo. In 1991, Smith and Harland systematically screened for mRNAs 
that encode proteins which have a role in neural induction in ventralised Xenopus embryos 
(Smith et al. 1991). They identified  a number of potential candidates, the most interesting of 
which was a novel mRNA that they named Noggin (Smith et al. 1992). This mRNA was later 
identified in mammals and was shown to be expressed in the dorsal lip and the notochord 
and could recapitulate neural induction and formation of the neural plate without the 
presence of the mesoderm (Smith et al. 1993; Valenzuela et al. 1995).   
Around the same time, other potential neural induction candidates were being studied. For 
example, Activin, a member of the TGF-B family, was shown to inhibit neural induction 
(Hemmati-Brivanlou et al. 1994). Interfering with Activin signalling disrupted normal 
mesoderm development but also induced neuralisation. Subsequently, Follistatin was 
identified from the reproductive system as an antagonist of Activin and could induce 
neuralisation (Hemmati-Brivanlou et al. 1994).   
Finally, an important neural induction signalling network was identified using Drosophila 
models in 1995 by De Robertis et al.  Chordin was shown to have neuralising activity that was 
antagonised by bone morphogenic factor BMP-4 (a member of the TGF-B superfamily) (Sasai 
et al. 1995; Piccolo et al. 1996). Importantly, inhibition of endogenous BMP-4 was able to 
drive neuralisation. Thus, the critical Neural-inducing factors identified in the Mangold-
Spemann organizer were bone morphogenic protein (BMP) inhibitors, including Chordin, 
Follastatin and Noggin (Figure 1.7). 
In 2000, a role for fibroblast growth factor (FGF) signalling in neuralisation was identified in 
chick embryo development studies. Fgf8 was able to enhance expression of an early activated 




neurons (Streit et al. 2000). This response was not associated with BMP antagonism, and an 
FGF inhibitor blocked early neural induction prior to gastrulation.     
 
Figure 1.7 – Developmental pathways directing towards a neural fate. Activation of the BMP pathway induces ectoderm 
transition to epidermis, termed the default model.  Inhibition of BMP, Activin and TGF-β signalling by Noggin, Chordin and 
Follistatin inactivates downstream signalling, resulting in transition to neuroectoderm, directing cells to a neural fate. 
(Adapted from (Muñoz-Sanjuán et al. 2002)) 
1.3.1.2 Specification of differentiating neural tube cells towards a midbrain fate 
Specification along the dorsal-ventral axis is mediated by the notochord ventrally whilst dorsal 
specification is mediated by the epidermis. In an attempt to identify lethal mutations in 
Drosophila melanogaster, Nusslein-Volhard identified 15 genetic loci that altered the 
segmentation pattern of developing larvae and generated distinct anatomical phenotypes 
(Nüsslein-Volhard et al. 1980). One of these genetic loci, the hedgehog locus, was excreted 
by the notochord and regulated CNS polarity in vertebrate models (Roelink et al. 1994; 
Echelard et al. 1993). Sonic Hedgehog (Shh), a member of the hedgehog protein family and a 
ligand of the hedgehog signalling pathway, is cleaved to release the amino-terminal active 
form which induces formation of the floorplate of the neural tube (Figure 1.8A). The floor 
plate, once formed, can also secrete Shh in a gradient and acts as a secondary organiser 




within the neural tube (Hynes et al. 1995). In mouse embryos harbouring a GFP tagged Shh 
from the endogeneous locus shows that Shh generates a dynamic gradient along the dorso-
ventral axis (Chamberlain et al. 2008). The graded concentration of Shh protein induces 
different groupings of neurons to arise, expressing divergent combinations of transcription 
factors and activated genes to specify cell fate (Ribes et al. 2010; Dessaud et al. 2007) (Figure 
1.8A). This is thought to be mediated by combinations of genes which either require Shh 
signalling and expressed ventrally such as NKX.2 (Lei et al. 2006) or are repressed by Shh 
signalling such as PAX6 which is expressed dorsally (Ericson et al. 1997). SHH knockout mice 
have shown pronounced defects in floor plate and notochord establishment (Chiang et al. 
1996).  
An important transcription factor involved in specification is the hepatocyte nuclear factor 
HNF-3β (FOXA2) that is expressed in the notochord and the floorplate (Figure 1.8B). FOXA2 
has been associated with the regulation, by a feedback loop, of SHH transcription to specify 
ventral midbrain progenitor fate (Epstein et al. 1999; Mavromatakis et al. 2011; Sasaki et al. 
1997). Furthermore, FOXA2 has recently been shown to directly induce Shh expression in the 
floor plate by binding to an enhancer region in the regulatory region of Shh (Cho et al. 2014). 
Deletion of the FOXA2 gene resulted in the loss of notochord development, disrupted dorsal-
ventral patterning and caused embryonic lethality in a mouse model (Ang et al. 1994). 
FOXA1/FOXA2 double knock-out mice identified a dramatic reduction in Neurog2 levels (Ferri 
et al. 2007), which is required for mDA progenitor maturation during specification (Kele et al. 
2006). A study of FOXA2 binding sites identified sites associated with 5409 genes, with 
positive regulation identified for key determinants of mDA neurons (Metzakopian et al. 2012). 




synergistically with Nurr1 in mDA neurogenesis from progenitors (Yi et al. 2014; Lee et al. 
2010). Additionally, FOXA2 overexpression in mouse embryonic stem cells (mESCs) promoted 
the generation of dopaminergic neurons (Kittappa et al. 2007). Furthermore, a one allele 
deletion of FOXA2 gives rise to a mouse model with parkinsonism and disrupted mDA 
development (Ferri et al. 2007; Kittappa et al. 2007).  
Importantly, a role for Wnt1, which is expressed in the presumptive midbrain, has been 
proposed for regulation of anterior-posterior specification along the midbrain-hindbrain axis 
(Figure 1.8). Mouse models with global disruption of the WNT1 gene resulted in mice with 
severe abnormalities in midbrain, hindbrain and cerebellar development, elucidating a role 
for Wnt signalling in early specification (McMahon et al. 1990; Thomas et al. 1990). Disruption 
of Wnt/β-catenin signalling in the ventral midbrain in a conditional mouse mutant showed an 
expansion of progenitors and reduced expression of both SHH and FOXA2 and a reduction in 
generation of dopaminergic neurons and thus a role in neurogenesis (Joksimovic et al. 2009; 
Tang et al. 2010). Interestingly, midbrain activation of Wnt/β-catenin signalling in mouse 
models showed a pronounced disruption of anterior-posterior and dorso-ventral patterning 
and a further reduction of dopaminergic neurons (Chilov et al. 2010; Nouri et al. 2015). These 
studies suggest that endogeneous Wnt signalling is optimised to establish an mDA progenitor 
character and allow for proper mDA neurogenesis.  
Wnt1 has been shown to antagonise Shh signalling  and forms an autoregulatory feedback 
loop with the transcription factor LIM Homeobox Transcription Factor 1 Alpha (LMX1A) to 
regulate Otx2 and ventral midbrain cell fate during development (Chung, Leung, et al. 2009). 




LMX1A sufficient to induce ectopic expression of mDA neurons in chick embryos and (Figure 
1.8) (Andersson et al. 2006).  
In conclusion, there is evidence that stage-specific expression of these extrinsic and intrinsic 
early patterning factors can induce genes involved in midbrain development.  Shh and Wnt1 
are the main extrinsic signals involved in mDA development, with an activation of the Wnt1 
pathway resulting in loss of Shh expression (Tang et al. 2010). This suggests that a balance 
between Wnt and Shh signalling mediates progression of ventral midbrain progenitors to 
dopaminergic neurons. These extrinsic factors initiate the expression of intrinsic transcription 
factors such as Lmx1a and Foxa2 which can act cooperatively to induce activation of mDA 
genes and mDA neuron specification (Figure 1.8B)(Lin et al. 2009; Nakatani et al. 2010). Other 






Figure 1.8 – Floorplate and mDA development. A) Development of the neural tube and the floor plate. The notochord 
secretes Shh and BMP antagonists such as Chordin, Noggin and Folastatin whilst Shh, Foxa2 and Lmx1a are co-expressed 
in the ventral floorplate of embryos. Neural progenitor subtypes are orderly patterned along the dorso-ventral axis by the 
gradients of Shh from the notochord (N) and floor plate (FP) and Wnts/Bmps produced by the roof plate (RP) (from 
reference (Ulloa et al. 2010)).  B) Molecular factors involved at different stages of development of mDA neurons (adapted 
from reference (Hegarty et al. 2013)). Factors are colour coded according to their role. In red are factors which play roles 
in establishing the midbrain/hindbrain junctions and floor plate. In green are diffusible signalling factors which induce 
mDA neurogenesis in radial glial-like cells. In blue are the induced factors expressed due to inductive signalling in green. 
Shh-Foxa2 and Wnt1-Lmx1a autoregulatory loops are involved in mDA neurogenesis in the floor plate. In pink are factors 
which promote differentiation of neural progenitor cells to post-mitotic neurons and induce expression of proteins that 
give the dopaminergic neurotransmitter phenotype of mDA neurons. Molecules in black are not in the correct timepoint. 
Anterior-posterior patterning is regulated by Wnt1 and Fgf8, restricting expression of Otx2 to the ventral midbrain.  Lmx1a 
transcription factor is involved in the regulation of Wnt1 signaling.  Dorso-ventral patterning is regulated by the graded 





1.4 Alpha-Synuclein  
1.4.1 Association of α-synuclein with familial PD and Lewy bodies 
Following its clinical characterisation, PD was thought of as an idiopathic disease with mainly 
non-genetic etiological factors. The majority of twin studies showed no evidence for 
heritability (Tanner et al. 1999; Duvoisin et al. 1981; Ward et al. 1983). Reports of familial 
aggregation had been documented (Elbaz et al. 1999; Spellman 1962) and clinical genetic 
studies reported some evidence of increased risk of transmission of PD (Lazzarini et al. 1994; 
Spellman 1962; Maraganore et al. 1991). These studies suggested that, if familial PD has a 
genetic basis, segregation and pedigree analyses suggest an autosomal dominant inheritance 
of a gene or genes with reduced penetrance. 
In 1996 scientists first reported the identification of genetic markers on chromosome 4q21-
q23 that was linked to autosomal dominant PD  in a large kindred of Italian descent (The 
Contursi Kindred) (Polymeropoulos et al. 1996; Golbe et al. 1990; Golbe et al. 1996). This loci 
contained the SNCA gene that encodes α-synuclein and sequence analysis of the fourth exon 
revealed a single base pair change at position 209 from G to A (G209A), which resulted in an 
alanine to threonine substitution at position 53 (Ala53Thr). This mutation showed complete 
segregation with the PD phenotype in the Italian kindred as well as 3 independent PD families 
(Polymeropoulos et al. 1997). Based on these observations and the identification of α-
synuclein in AD amyloid plaques (Uéda et al. 1993), the authors hypothesised that this alanine 
to threonine substitution may disrupt the α helix structure, inducing formation of β-pleated 
sheets and aggregation into amyloid-like structures. The Italian kindred PD clinical phenotype 
was thought to be typical for sporadic PD, except for a relatively earlier age of onset of illness 




penetrance and suggested that a single gene defect was sufficient to induce the PD 
phenotype. 
In the same year, a group reported strong staining of LBs from idiopathic Parkinson’s and DLB 
patients using two antibodies, which correspond to α-synuclein residues (Jakes et al. 1994; 
Spillantini et al. 1997). The group suggested that α-synuclein might be the main component 
of PD LBs. Importantly, the PD cases studied were non-familial, therefore concluding that 
aggregation of α-synuclein is common in the aetiology and pathogenesis of all cases of PD. 
Since LBs are diagnostic of synucleinopathies, these discoveries set the foundations for the 
research into mechanisms of cellular dysfunction and pathological pathways. 
1.4.2 Clinical heterogeneity of α-synuclein mutations 
The discovery of a missense mutation in SNCA that can cause rare autosomal dominant 
inheritance of familial PD and the finding that synuclein aggregates are the main component 
of Lewy bodies has fuelled a great deal of research in this area.  More missense mutations as 
well as duplication, triplication and multiplication of the SNCA gene have been reported to be 
linked to the aetiology of the disease (Table 1.3; Figure 1.9). Additionally, a multitude of 
posttranslational modifications, including phosphorylation, ubiquitination, nitration and 
truncation, as well as alternative splicing events, have been discovered and the myriad of 





Figure 1.9 – Mutations in SNCA. Schematic showing protein structure of α-synuclein and PD-related mutations A30P, E46K, 
H50Q, G51D, A53T/E.  α-synuclein, a 140-amino-acid protein, is composed of three domains including an amphipathic N-
terminal domain, a non-amyloidogenic component (NAC) with a hydrophobic core and an acidic C-terminal domain.  The 
amphipathic and NAC domains contain KTKEGV repeats.  Figure taken from (Devoto et al. 2017). 
   
Age of onset Mutation Clinical symptoms/Biological effect 
19-60 G51D Early onset, rapid progression, dementia, LB and tau pathology, glial cytoplasmic α-synuclein inclusions 
20-50 Triplication Early onset, rapid progression, cognitive decline and dementia, hallucinations and autonomic dysfunction, LB and tau pathology 
36-62 A53E Early onset, rapid progression, dementia, LB/tau pathology, glial cytoplasmic α-synuclein inclusions 
20-85 A53T Early onset, rapid progression, dementia, myoclonus, LB and tau pathology 
31-77 Duplication Rapid progression, dementia, LB pathology, hallucinations 
54-76 A30P Hallucinations, mild dementia, LB pathology 
59-69 E46K REM sleep disorder, cognitive decline, hallucinations, LB pathology 
60-71 H50Q Cognitive decline, various psychiatric symptoms, LB and tau pathology 
Table 1.2 - SNCA multiplications and mutations associated with PD and their clinical presentations. 
In 1998, another missense mutation in the SNCA gene was linked to autosomal dominant PD 
(AD-PD). Researchers identified a G88C substitution in German familial PD patients, which 
caused an alanine to proline change at amino acid 30 (A30P). Clinically, these patients 
developed signs of “typical” PD in their 50s. The authors noted that proline is involved in the 
acquisition of protein secondary structure, and hypothesised that this mutation would be 





In 2003, studies revealed that a family with an apparently autosomal dominant PD showed 
triplication of the SNCA gene leading to increased dosage (Spellman 1962; Muenter et al. 
1998). Clinically, the pathological course of this pedigree was rapidly progressive and 
characterised by young onset of parkinsonism (average 34 years of age), followed by 
dementia, with widespread LB pathology (Singleton et al. 2003). A year later in 2004, the gene 
dosage mechanism was further elaborated on by the identification of SNCA duplications 
which resulted in familial parkinsonism with a clinical phenotype reminiscent of idiopathic PD 
in age of onset and disease progression and lack of atypical features on autopsy (Chartier-
Harlin et al. 2004; Ibanez et al. 2004). Cognitive decline and dementia were not prominent 
features of the progression of the disease compared to SNCA triplication carriers (Singleton 
et al. 2003).  
Another missense mutation associated with AD-PD, with a base pair change at 188 from G to 
A (G188A) was identified, causing a glutamate shift to lysine at position 46 (E46K) in 
individuals from a large Spanish family (Zarranz et al. 2004). Clinically, the patients from this 
kindred presented with PD with an age of onset typical for sporadic PD, dementia and later 
onset visual hallucinations, with cognitive deficits found in the majority of patients. Strikingly, 
Lewy body pathology was found in cortical and subcortical areas that are associated with 
cognitive symptoms (Gomez-Tortosa et al. 1999; Harding et al. 2001).   
In 2013, another 2 SNCA missense mutations were discovered. The first, a base pair change 
at 150 from T to G encoding a histidine to glutamine substitution at amino acid 50 (H50Q) in 
exon 4 of SNCA (Appel-Cresswell et al. 2013). This was only found in one patient, of 
English/Welsh origin, who presented at age 60 and showed combination motor and cognitive 




base 152 (G152A) causing a glycine to aspartic acid shift at residue 51 (G51D) (Lesage et al. 
2013; Kiely et al. 2013). Patients with this mutation presented with a very young onset of 
motor symptoms (19-39 years of age), tremors and dementia. Most interestingly, post-
mortem showed unique striatal and neocortical pathology, as well as LB pathology and glial 
cytoplasmic inclusions of MSA. This represented the first genetic link to MSA, another 
synucleinopathy.   
More mutations have been found in familial PD patients including a C to A mutation leading 
to a alanine to glutamate shift (A53E) which shows a severity of pathology most comparable 
to that of G51D mutations (Pasanen et al. 2014). A summary of the SNCA mutations is 
provided in Table 1.3. 
1.4.3 Modifications: truncation, phosphorylation and nitration 
Partially truncated and high molecular weight aggregates of α-synuclein have also been 
recovered from LBs, suggesting other mechanisms by which α-synuclein may be modified and 
rendered either insoluble or more prone to aggregate (Baba et al. 1998). Further research has 
elucidated an association between C-terminal truncated wild-type and mutated α-synuclein 
and promotion of aggregation and fibril formation (Murray et al. 2003; Ulusoy et al. 2010). 
Additionally, there is evidence for the existence of numerous and diverse post-translational 
modifications of α-synuclein such a nitration (Yu et al. 2010; Liu et al. 2011), phosphorylation 





1.4.4 Spreading of α-synuclein 
The Lewy body pathology staging classification for PD was outlined by Heiko Braak in 2004 
(Braak et al. 2004). Braak and colleagues noted 6 stages of LB pathology outlined in Table 1.4 
and Figure 1.10. 
Stage Affected tissues Description of pathology 
Pre-clinical 




The least affected brains, Stage I, showed LB/LN (mainly LNs at 
this stage) pathology restricted entirely to the dorsal IX/X 
motor nucleus and/or intermediate reticular zone.  Olfactory 
bulb and anterior olfactory nucleus lesions also begin to 
develop. The key feature of Stage II is the appearance of LBs 
and LNs in neurons of the caudal raphe nuclei and the reticular 
formation, particularly the gigantocellular reticular nucleus, 
with LNs preceeding the appearance of LBs. 
Stage III & IV Midbrain 
Stage III is characterised by the appearance of LNs and LBs in a 
subset of midbrain neuromelanin-containing neurons of the 
substantia nigra, initially restricted to posterolateral and 
posteromedial subnuclei.  Stage IV shows marked degeneration 
of the substantia nigra neurons and involvement of the 
magnocellular nuclei of the basal forebrain. By this stage 
severe damage to the anterior olfactory bulb has occurred. 
Stage V & VI Neocortex 
Neurodegeneration in structures noted in Stages I-IV 
continues.  Stage V shows LB/LN pathology in the allocortex 
with severe LNs pathology in first, second and third Ammon’s 
Horn sectors. Cortical pathology appears to originate from the 
mesocortex into adjacent neocortex, insular cortex, cingulate 
cortex and prefrontal areas. Finally, stage VI involves the entire 
neocortex with milder pathology in primary motor area and 
primary motor field as well as first order sensory association 
and primary sensory areas. 
Table 1.3 – The staging of α-synuclein pathology as described by Braak et al. Propagation of α-synuclein pathology 
beginning in the olfactory bulb and medulla oblongata in early stages I & II.  Later, α-synuclein pathology was observed to 





Figure 1.10 - Schematic representing the spreading and propagation of α-synuclein LN/LB pathology in idiopathic PD.  A) 
Pathology is hypothesised to start in the olfactory bulb (yellow arrows) or from the gastrointestinal tract via the vagus 
nerve (red arrows).  As the disease progresses spreading is seen to the midbrain and cortical regions.  Figure taken from 
(Hansen et al. 2012). B) Caudorostral spreading of α-synuclein LN/LB pathology related to early pre-symptomatic and 
symptomatic stages with dark colours representing early stages of PD and the light colours representing later stages of 
disease progression.  Figure taken from (Pacheco et al. 2012). 
Pathology is thought to begin in medullary structures in the brain stem and olfactory system 
in Stage I & II. LB pathology is then thought to cross into the SNpc, characterised by mDA 
degeneration, and the amygdala and thalamus, as well as in the anterior olfactory nucleus in 




areas in Stage V & VI. The staging scheme proposed by Braak, with its depiction of a temporal 
sequence of pathological events, has had a huge influence on the development of early 
diagnosis and identification of potential biomarkers for PD (Figure 1.10).  
The spreading of α-synuclein outlined by Braak et al. hinted at a mechanism of cell-to-cell 
propagation similarly to prions, infectious proteins whose pathological folding properties is 
transmissible to other prion proteins (Braak et al. 2003). Significant to this hypothesis, both 
aggregated and non-aggregated forms of α-synuclein can be isolated from cerebro-spinal 
fluid (CSF) and blood of PD patients (Borghi et al. 2000; El-Agnaf et al. 2003). This theory was 
given further credence by the discovery of a host-to-graft propagation of α-synuclein in post-
mortem sections of PD human patients who had undergone fetal mesencephalic 
dopaminergic neuron grafting (Kordower et al. 2008; Li et al. 2008; Kurowska et al. 2011). 
Extracellular α-synuclein is released via exocytosis (Lee et al. 2005) and taken up by cells via 
endocytosis or exosomal transport, with these mechanisms thought to be important to 
progression of disease pathology (Desplats et al. 2009; Hansen et al. 2011; Angot et al. 
2012)(Desplats 2009; Hansen 2011; Angot 2012). Moreover, it was found that spreading of 
LN/LB pathology could be initiated by α-synuclein transfer into the vagal nerve and halted by 
resectioning of the vagal nerve connecting the gut to the CNS (Ulusoy et al. 2013; Pan-
Montojo et al. 2012). 
Another potential mechanism for α-synuclein secretion is via exosomes, membrane-bound 
vesicles which are released by many types of cells and found in body fluids. It has been shown 
that certain prion proteins can be released within exosomes which can be transferred to 
recipient cells, initiating propagation of pathology (Fevrier et al. 2004; Vella et al. 2008). 




et al. 2010; Angot et al. 2012) with an increase in release linked with lysosomal dysfunction 
(Alvarez-Erviti et al. 2011). Exosome-associated α-synuclein has been shown to be more 
readily taken up by recipient cells and capable of inducing increased toxicity (Danzer et al. 
2012). Indeed, exosomes from PD patients injected into immune-deficient mice induced mild 
features of parkinsonism compared to exosomes from healthy control (Han et al. 2016). 
1.4.5 Structure and aggregation properties of α-synuclein 
The discovery of a link between mutations of SNCA and familial PD, as well as the inclusion of 
α-synuclein protein aggregates in LBs, the histological hallmark of PD, spurred research into 
the physiological function of α-synuclein. α-synuclein is a 140-amino-acid protein that 
contains a hydrophobic NAC domain, a positively charged N-terminal containing a repeating 
11-amino-acid sequence with a conserved hexameric KTKEGV motif as well as an acidic C-
terminal tail (Figure 10) (Uéda et al. 1993). Although thought of as a “natively unfolded 
protein” (Weinreb et al. 1996), the N-terminal is thought to be able to induce an α-helical 
structure with this conformational adoption linked to a phospholipid binding function (Jenco 
et al. 1998; Ahn et al. 2002).   
α-synuclein belongs to a family of synucleins which includes α, β (Nakajo et al. 1993) and γ 
(Akopian et al. 1995) synucleins. Whilst α and β synucleins are concentrated at nerve 
terminals of the central nervous system, γ-synuclein is present in the peripheral nervous 
system (Akopian et al. 1995). β and γ synucleins are 62% and 55% identical in amino acid 
sequence to α-synuclein respectively. Importantly, it has been shown that these proteins have 
differential, cell-specific expression profiles and only α-synuclein is present at a high intensity 
in areas of the CNS affected by PD such as the SN and basal ganglia (Li et al. 2002). β-synuclein 




neurodegeneration, inhibiting its aggregation and fibrilisation (Hashimoto et al. 2001; Park et 
al. 2003; Fan et al. 2006). Although β and γ synucleins have not been associated with PD, 
recent studies have suggested that β-synuclein may have aggregative properties 
(Taschenberger et al. 2013) and a link between a mutation in β-synuclein and 
neurodegeneration in a mouse model has been shown (Fujita et al. 2010). Α α and β-synuclein 
double Knock-out (KO) mouse model has been generated and shows a mild phenotype, with 
a reduction in striatal dopamine levels, whilst a single KO of either α or β-synuclein did not 
show this phenotype (Chandra et al. 2004).   
α-synuclein can be conformationally organised into β-pleated sheets that are resistant to 
proteolysis thus increasing its probability of polymerisation (Serpell et al. 2000; Conway et al. 
2000). Notably, a study identified α-synuclein multimers in brain lysates of PD patients who 
harbour the A53T mutation, though not in sporadic PD or control samples, hinting at an 
association between mutant A53T α-synuclein and a potential pathological mechanism 
(Langston et al. 1998). Later studies have reported that the predominant soluble form of α-
synuclein exists in the native tetramer form which resists aggregation (Bartels et al. 2011; 
Wang et al. 2011). Thus, it may be that reduced stability of oligomers increases the availability 
of more readily aggregated monomer and fibrils associated with the development of LB 
pathology (Bucciantini et al. 2002; Volpicelli-Daley et al. 2011). Furthermore, it has been 
noted that normal brain samples contain abundant α-synuclein tetramers, with PD-associated 
mutations linked to a shift from tetramer to monomer and subsequent neurotoxicity 
(Dettmer et al. 2015). This oligomeric species has been observed to have specific membrane 




et al. 2008). Thus, formation of toxic oligomers is associated with protein misfolding and 
oligomeric secondary structures (Figure 1.11).  
 
Figure 1.11 – Amyloid fibril formation and aggregation dynamics. Polymerisation of α-synuclein can be divided into “on-
pathway” or “off-pathway” in relation to toxic fibril formation. Oligomer toxicity is thought to be associated with higher 
levels of β-pleated sheet structure and fibril elongation. Blue circles- Little or no β-structure; Red circles- High β-structure.  
Figure taken from (Roberts et al. 2015). 
1.4.6 Protein degradation pathways  
Protein degradation is an important process regulating intracellular homeostasis, which is 
undertaken by both the autophagy-lysosomal pathway (ALP) and the ubiquitin proteasome 
system (UPS). Autophagy itself consists of 3 main mechanisms of autophagic degradation, 
namely chaperone-mediated autophagy (CMA), macroautophagy and microautophagy. 
Suppression of autophagy in transgenic mouse models leads to a neurodegenerative 
phenotype in the absence of disease-associated proteins (Hara et al. 2006; Komatsu et al. 
2006), with ultrastructural evidence of autophagic degeneration reported in PD patients 
(Anglade et al. 1997). Thus, it is not surprising that degradation of monomeric α-synuclein has 
been reported to be processed by both the proteasome and autophagy in an in vitro PC12 
model (Webb et al. 2003). More specifically, it was reported that wild-type α-synuclein 




binding to lysosome-associated membrane protein 2 (LAMP2A) autophagy receptor, with 
poor degradation of α-synuclein pathogenic mutations (Cuervo et al. 2004). Furthermore, 
when CMA is blocked, the macroautophagy pathway is activated to compensate and clear 
aggregates.   
The UPS is also known to degrade misfolded proteins by a process in which ubiquitinated 
substrates are cleaved into smaller peptides before passing through the proteasome. 
Wildtype and mutant α-synuclein was reported to both be degraded by the UPS in a 
neuroblastoma model, with slower degradation of mutant pathogenic α-synuclein (Bennett 
et al. 1999). Stable expression of both mutant and wild-type α-synuclein have been recently 
been shown to impair proteasome activity directly in another neuroblastoma model 
(Lindersson et al. 2004; Zondler et al. 2017). Moreover, an autosomal dominant point 
mutation in the ubiquitin carboxy-terminal hydrolase L1 (UCHL1) gene, associated with the 
generation and stabilisation of monoubiquitin in neurons (Osaka et al. 2003), has been 
associated with familial PD (Leroy et al. 1998). Perturbing UCHL1 function induces a build-up 
of α-synuclein (Liu et al. 2002; Cartier et al. 2012). One study even reported a direct 
interaction between UCHL1 and LAMP2A, the lysosomal receptor for CMA (Kabuta et al. 2008) 
and a more recent study reported the existence of feedback between the two systems (Yang 
et al. 2013). 
1.4.7 Function of α-synuclein 
1.4.7.1 Neurotransmitter release  
How α-synuclein may affect the pathological process (Figure 1.12) has been the subject of 
intense study. The presynaptic localisation of α-synucleins, its association with mDA neuronal 




synaptic vesicle binding. The first SNCA KO mouse model reported perturbations in striatal 
dopamine (Abeliovich et al. 2000). Overexpression of synuclein led to an inhibition of 
neurotransmitter release in murine PC12 cells (Larsen et al. 2006) and in primary neuronal 
cultures (Nemani et al. 2010), by perturbing vesicle docking or synaptic vesicle reclustering 
(Diao et al. 2013). Synaptic vesicle membrane docking and fusion requires membrane fusion 
machinery, a main component of which is soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE). In an elegant transgenic mouse study, α-synuclein was 
found to display chaperone activity and promoted SNARE complex assembly by direct binding 
to SNARE proteins (Burré et al. 2010). It can also function downstream of another presynaptic 
chaperone protein, CSPα, and rescue the neurodegenerative phenotype caused by CSPα-KO 
(Chandra et al. 2005).   
  
Figure 1.12 – Pathways associated with α-synuclein pathology. Functional disruption of organelles: nucleus, mitochondria, 
ER/Golgi, lysosome and synaptic dysfunction (purple box). Mitochondria-associated ER membrane and subsequent 





1.4.7.2 Mitochondria and Reactive oxygen species 
α-synuclein has been reported to directly bind to mitochondrial lipid membranes influencing 
mitochondrial fission and fusion dynamics associated with the regulation of mitochondrial 
health (Nakamura et al. 2008; Nakamura et al. 2011). Nuclear α-synuclein has been reported 
to bind to the promoter of the master mitochondrial transcriptional activator, PGC1α, leading 
to repression of transcription and regulating mitochondrial function (Siddiqui et al. 2012). 
iPSC-derived neurons expressing mutant A53T α-synuclein was also shown to induce a 
dysfunction in PGC1α transcriptional networks (Ryan et al. 2013).   
Major sources of cellular reactive oxygen species (ROS) in mDA neurons are thought to be 
both mitochondria and the metabolism of dopamine.  ROS is thought to be linked to an 
increase in mitochondrial DNA (mtDNA) damage in high-energy demand tissues (Bender et al. 
2006). Increased ROS has been reported to influence α-synuclein conformation and 
aggregation (Esteves et al. 2009), with dopamine possibly playing a role in these 
conformational changes (Outeiro et al. 2009). α-synuclein protein has been shown to be 
localised to the mitochondrial membrane, in dopaminergic neurons, with accumulation of α-
synuclein protein to the mitochondria impairing normal mitochondrial function and 
increasing mitophagy (Li et al. 2007; Chinta et al. 2010) as well as mitochondrial dysfunction 
association with α-synuclein mutant transgenic mouse models (Martin et al. 2006). 
1.4.7.3 ER-Golgi trafficking 
Anterograde transport of synthesised proteins from the endoplasmic reticulum, a major site 
of protein folding, to the Golgi has been shown to be disrupted by α-synuclein in a dose-
dependent manner (Gitler et al. 2008), including trafficking of the dopamine transporter 




stress response (Colla et al. 2012). α-synuclein can also be localised to mitochondria-
associated ER membranes (Guardia-Laguarta et al. 2014).   
1.4.7.4 Axonal transport and neurite dynamics 
Axonal transport dysfunction and changes in expression of motor proteins, kinesin and 
dynein, have been reported in response to mutant A30P and A53T α-synuclein overexpression 
in rat PD models (Chung, Koprich, et al. 2009; Chu et al. 2012). Overexpression of synuclein 
has been shown to impair microtubule-dependent trafficking (Lee et al. 2006) and it has been 
shown that α-synuclein can interact with tubulin, influencing its polymerisation and 
microtubule dynamics in neurons (Zhou et al. 2010). Different pathological mutations can 
impair microtubule assembly, affecting tubulin-kinesin interplay, and neurite network 
morphology (Prots et al. 2013) which has a downstream effect on neurite outgrowth 
(Takenouchi et al. 2001; Liu et al. 2013). In a recent study, neurite analysis of rat primary 
dopaminergic neurons showed that neurons transfected with wild-type, A53T and A30P α-
synuclein had the effect of impairing neurite length whilst increasing the number of primary 
neurites from neuronal soma (Koch et al. 2015). However, a similar study showed early 
changes, with increased neurite length associated with an increase of wildtype synuclein but 
not for mutant strains (Liu et al. 2013). These results suggest that α-synuclein may be involved 
in neurite elongation or initiation with a possible role for wild-type α-synuclein in facilitation 
of tubulin polymerisation. It was later demonstrated that synuclein can interact with tubulin 
tetramers inducing a structural reconfiguration which promotes nucleation and growth rate 
of microtubules. Synuclein mutations associated with PD do not undergo this folding and 
induce aggregation of tubulin. This study suggested that synuclein can act as a novel 





Post-mortem studies in PD patient brains identified increased neuroinflammation and 
microglial activation (McGeer et al. 1988) as well as in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced (mechanism described in section 1.6.1) parkinsonism in 
humans (Langston et al. 1999) and animals (Członkowska et al. 1996). This was supported by 
positron emission tomography (PET) on PD patient brains that showed a significant increase 
in activated microglia (Ouchi et al. 2005; Gerhard et al. 2006). Furthermore, pro-inflammatory 
cytokines have been identified as being upregulated in PD post-mortem SNpc (Mogi, Harada, 
Kondo, et al. 1994; Mogi, Harada, Riederer, et al. 1994) as well as in serum (Brodacki et al. 
2008) and CSF (Blum-Degena et al. 1995).   
In vivo and in vitro evidence suggests that α-synuclein itself can activate microglia (Zhang, 
Wang, et al. 2005; Su et al. 2008; Austin et al. 2006). Furthermore, pathogenic mutant 
synucleins (A30P and A53T) can produce an elevated microglial activation, with associated 
increases in ROS and inflammatory cytokines (Zhang et al. 2007; Rojanathammanee et al. 
2011; Hoenen et al. 2016). It is thought that extracellular α-synuclein, as a result of apoptosis 
or other mechanisms of release, can be engulfed by microglia, by phagocytosis in an attempt 
to clear deposits (Lee et al. 2008; Cao et al. 2012), or can be processed as an antigen on direct 
contact with cell surface receptors such as toll-like receptors (TLRs) (Fellner et al. 2013; Kim, 
Ho, et al. 2013). Thus, increased α-synuclein load and increased degeneration and release of 
α-synuclein may stimulate increased microglial activation. Although this microglial activation 
is necessary for clearing extracellular deposits, it may also contribute to increased 




In summary, α-synuclein can function in a variety of cellular processes and molecular 
pathways including neurotransmitter release, mitochondrial function, ER-Golgi trafficking, 
axonal dynamics and inflammation. As well as this, α-synuclein is targeted by several protein 
degradation mechanisms, with aggregation inducing the formation of multimeric α-synuclein 
species which are resistant to these proteolytic pathways. Thus, an accumulation of these 
misfolded degradation-resistant proteins is thought to contribute to pathological 
mechanisms of PD.         
1.5 Genetic loci associated with PD  
Mutations in other genetic loci have been associated with PD. These mutations are associated with 
several molecular pathways which can lead to the development of PD and associated Lewy body 
pathology. The potential interactions between genes known to be mutated in familial forms of PD and 
α-synuclein pathology is outlined in Figure 1.13 and discussed further in this section. 
 
Figure 1.13 – Potential interactions between PD-associated disease genes. Mutations and multiplications of the SNCA gene 
leads to the accumulation of α-synuclein. This promotes oligomerisation of α-synuclein and subsequent activation of the 
ubiquitin-proteasome system (UPS) and endosomal-lysosomal pathways. Parkin and DJ1 are involved in UPS function and 
DJ1 is further linked to oxidative stress response. UCHL1 is a ubiquitin hydrolase and ligase which is also associated with 
UPS function. Parkin, PINK1 and DJ1 are associated with mitochondrial function which synthesis the ATP required for 
normal UPS function. The Leucine-rich repeat kinase 2 (LRRK2) plays a role in cellular trafficking, phosphorylation and 
intracellular signalling. Cytoskeletal dysregulation may also perturb clearance of accumulated protein further leading to 






Identified by genome-wide linkage analysis, mutations in the Leucine-rich repeat kinase 2 
(LRRK2; PARK8), located in chromosome 12p11.2-q13.1, have also been associated with 
autosomal dominant PD (Hasegawa et al. 2001; Funayama et al. 2002; Zimprich et al. 2004; 
Paisán-Ruıź et al. 2004). Using high-resolution recombination mapping and candidate gene 
sequencing, six disease-associated mutations in the LRRK2 gene locus were identified 
(Zimprich et al. 2004).  
LRRK2 was found to co-immunoprecipitate with PD-associated protein parkin (Smith et al. 
2005). LRRK2 has been shown to regulate autophagy via a calcium-dependent mechanism 
(Gomez-Suaga et al. 2011) and mutant LRRK2 has been shown to increase mitochondrial 
clearance by LC3-II mediated autophagy due to a deficit in calcium recovery after 
depolarisation (Cherra III et al. 2013). Thus, LRRK2 function is associated with regulation of 
mitochondria and its pathology linked to oxidative stress (Heo et al. 2010).   
1.5.2 Parkin  
As well as the autosomal dominant transmission seen with the SNCA and LRRK2 mutations, 
many accounts of familial juvenile parkinsonism (fJP) have been published (Martin et al. 1971; 
Matsumine et al. 1997) with a higher risk in offspring of consanguineous marriages (Ota et al. 
1958; Takahashi et al. 1994; Ishikawa et al. 1996), suggesting autosomal recessive 
transmission. Genome-wide linkage analysis in probands with fJP identified a microdeletion 
in chromosome 6q25.2-27 which encodes a 12 exon, 465 amino acid protein, aptly named 
Parkin (Matsumine et al. 1997; Kitada et al. 1998). Parkin protein is thought to interact with 




of polyubiquitin and proteasomal degradation pathways (Morett et al. 1999; Shimura et al. 
2000).   
Parkin mutations are associated with a slow progression and a typical age of onset of under 
40, with post-mortem histological analysis showing selective loss of nigral neurons and 
irregular appearance of LB pathology (Farrer et al. 2001). Parkin mutations account for up to 
50% of fJP cases and a wide variety of parkin mutations are associated with different clinical 
phenotypes (Abbas et al. 1999; Lücking et al. 2000; Lohmann et al. 2003; Hedrich et al. 2001; 
Hedrich et al. 2002; Kann et al. 2002). A significant role for Parkin in the pathological process 
is its recruitment to damaged mitochondria to promote autophagy (Narendra et al. 2008).  
1.5.3 PINK1 
Association mapping of other autosomal recessive fJP patients, with clinical features similar 
patients with Parkin mutations, identified mutations in the PTEN-induced putative kinase 1 
(PINK1; PARK6), located on chromosome 1p35-36 (Valente et al. 2001; Valente et al. 2004; 
Hatano et al. 2004). The PINK1 gene was further found to contain 8 exons and encode for a 
protein of 581 amino-acids, which localises to mitochondrial membranes.   
PINK1 can act as a sensor of damaged mitochondria and its kinase activity can induce the 
translocation and recruitment of Parkin, from the cytoplasm, to depolarised mitochondria to 
initiate mitophagy (Matsuda et al. 2010; Geisler et al. 2010). Overexpression of WT, but not 
mutant PD-linked PINK1 has been found to have a neuroprotective effect in neurons (Valente 
et al. 2004).  Silencing of PINK1 has been found to induce mitophagy, dysregulation of 
mitochondrial morphology dynamics, membrane potential loss and an increase in oxidative 




PINK1 knock-down induces mitochondrial respiration deficits and can impair proteasome 
function along with an increase of α-synuclein aggregation (Liu et al. 2009).   
1.5.4 DJ1 
Homozygosity mapping from probands with autosomal recessive fJP led to localisation of a 
deletion and a point mutation in a gene locus encoding DJ1 protein (Bonifati et al. 2003), 
previously associated with a redox sensor activated in response to endogenous ROS 
(Mitsumoto et al. 2001). Later studies would elucidate the neuroprotective role of DJ1 in 
response to oxidative stress (Taira et al. 2004; Guzman et al. 2010). DJ1 function has also been 
linked to modulation of α-synuclein aggregation and response to α-synuclein-induced toxicity 
(Zhou et al. 2005; Batelli et al. 2008; Batelli et al. 2015). DJ1 has been noted to localise to 
mitochondria (Canet-Avilés et al. 2004; Junn, Jang, et al. 2009) with loss of DJ1 leading to 
perturbed mitochondrial function and dynamics (Krebiehl et al. 2010). Furthermore, DJ1 is 
thought to act with PINK1/Parkin to regulate mitophagy pathways by forming a ubiquitin E3 
ligase complex (Xiong et al. 2009) or in parallel pathways (Thomas et al. 2010).  
1.6 Modelling of Parkinson’s disease 
PD results from the degeneration and loss of the dopaminergic neurons of the SNpc that 
synthesise dopamine and project to the striatum, with leading to striatal dopamine loss. The 
etiology of PD remains unclear with a range of diverse factors implicated including age, 
environmental exposures and genetic factors associated with susceptibility. As such, models 
have been generated to recapitulate mechanisms of PD induction and initiation of the PD 
neurodegenerative process. Pre-clinical modelling of PD has generally tended to use either 
neurotoxin-induced models to induce selective degeneration of these neurons or the 




1.6.1 Classic neurotoxin models 
Early modelling of the degeneration of mDA neurons mostly used neurotoxin induced animal 
models (Table 1.5). One of the first of these models to study parkinsonism was the 6-
Hydroxydopamine (6-OHDA) model.  Developed by Ungerstedt in 1968 (Ungerstedt 1968), 
administration of this neurotoxin into the substantia nigra of rats induced degeneration 
within the nigro-striatal system causing perturbations in motor behaviour (Luthman et al. 
1989). 6-OHDA is preferentially taken up by catecholaminergic neurons via catecholaminergic 
transporters including the dopamine transporter (DAT) and has been shown to interact with 
mutated forms of α-synuclein, increasing the degenerative phenotype (Lehmensiek et al. 
2006). 
Neurotoxin Type Mechanism 
6-OHDA Hydroxylated analogue of dopamine 
Interferes with Complex I of the mitochondrial 
electro transport chain producing increased reactive 
oxygen species and dopaminergic cell death. Uptake 
by DAT or noradrenergic transporter NAT (no 
evidence of this for Rotenone) 
MPTP 
(MPP+) 
Neurotoxin contaminant produced 
during synthesis of the synthetic 
opioid MPPP 
Rotenone Insecticide, piscicide, pesticide 
Paraquat Herbicide, Pesticide 
CCCP Chemical inhibitor of oxidative phosphorylation 
Effects proton gradient in electron transport chain – 
interfering with mitochondrial membrane potential. 
Induces the PINK1-Parkin pathway 
Table 1.4 – Table of neurotoxins used to generate models of PD 
The neurotoxin MPTP, a by-product of the synthesis of a synthetic heroin substitute 1-methyl-
4-phenyl-propion-oxypiperidine (MPPP), was accidentally administered to drug users 
inducing irreversible idiopathic parkinsonism (Langston et al. 1983). MPTP is the most 
commonly used neurotoxin in animal models. Unlike 6-OHDA, MPTP is able to cross the blood-
brain barrier (BBB) and is taken up by astrocytes where it is converted to its active MPP+ form 
and can selectively target the nigro-striatal system via uptake by DAT (Javitch et al. 1985; 




Agricultural chemicals such as rotenone (Sherer et al. 2003), and N,N’-dimethyl 1-4-4-
4’bypiridinium (paraquat) (Rappold et al. 2011) which are also able to cross the BBB can also 
induce parkinsonism and selective loss of nigral neurons in animal models with evidence of 
formation of LB-like inclusions in rats (Manning-Bog et al. 2002). Uncoupling reagents such as 
carbonyl cyanide m-chlorophenylhydrazone (CCCP), which causes mitochondrial membrane 
depolarisation and induces recruitment of the PD-associated ubiquitin ligase Parkin to 
mitochondria, has been used to assess mitophagy (Narendra et al. 2008). However, 
neurotoxin models rarely mimic the etiology and progression of PD and thus insights from 
studies using these models can be limited. 
1.6.2 Genetic mouse models 
The discovery of a mutation in the SNCA locus that was associated with familial autosomal 
dominant PD, and other familial PD associated loci spurred a genetic approach to PD 
modelling recapitulating disease associated genes. The mouse is the most commonly used 
transgenic model for pre-clinical study disease modelling and will be the subject of focus here, 
however there are many other non-vertebrate models and vertebrate models which are 
generated using the same principles outlined here.  
The SNCA KO mouse model that has been generated showed a very subtle phenotype with 
an altered release of DA and a reduction in striatal DA levels (Abeliovich et al. 2000). Mouse 
models overexpressing WT α-synuclein reported accumulation of α-synuclein (Rockenstein et 
al. 2002) and olfactory dysfunction (Fleming et al. 2008). More recently, α-synuclein 
overexpression models have been able to recapitulate the age-dependant mDA neuron loss 
and motor impairments seen in humans (Janezic et al. 2013). A53T mutant expressing 




(Gispert et al. 2003) and aggregation of the mutant synuclein (Giasson et al. 2002; Kahle et al. 
2000). Mouse models expressing truncated α-synuclein, which has been linked to increased 
aggregation propensity, have been characterised as having reduced striatal dopamine, whilst 
mDA loss was not apparent (Michell et al. 2007; Daher et al. 2009).   
These studies represent some of the different α-synuclein KO, overexpression and mutation 
murine models which recapitulate distinct degenerative phenotypes resembling the familial 
human forms and can be used to characterise specific molecular neurodegenerative 
pathways. Many models have been generated to perturb expression of WT or mutant forms 
of different PD-associated genetic loci such as LRRK2 (Li et al. 2009; Kitada et al. 2009; 
Ramonet et al. 2011), Parkin (Goldberg et al. 2003), PINK1 (Moisoi et al. 2014), and DJ-1 (Pham 
et al. 2010). Furthermore, a triple-KO parkin/DJ-1/PINK1 mouse model has been generated, 
although surprisingly, no evidence of mDA neuron loss or reduction in striatal dopamine levels 
in aged triple-KO was observed (Kitada et al. 2009).  
1.6.3 In vitro modelling of Parkinson’s disease 
Compared to animal models, cellular models are generally less costly, avoids the ethics of 
animal research and can be easier to manipulate, pharmacologically or genetically, and 
analysed using techniques such as microscopy. With these characteristics, cell lines can be 
used more efficiently to model disease for basic research as well as for high-throughput drug 
screening.   
Both the pheochromocytoma cell line PC12, which expresses high levels of the 
catecholaminergic enzyme tyrosine hydroxylase (Greene et al. 1976), and the human 
neuroblastoma cell line SH-SY5Y which expresses dopamine-β-methyltransferase (Biedler et 




differentiated towards a neuronal phenotype and can take up and release catecholamines 
(Balasooriya et al. 2007). The SH-SY5Y line is preferred as it is a human cell line and has been 
shown to upregulate neuronal and dopaminergic markers upon differentiation including 
Tyrosine hydroxylase (TH) and DAT (Lopes et al. 2010; Korecka et al. 2013). SH-SY5Y have been 
used to model disease using the classic neurotoxin models such as MPP+ exposure (Wu 2009), 
as well as to generate genetic models such as α-synuclein PD models (Hasegawa et al. 2004; 
Desplats et al. 2009; Ding et al. 2013; Melo et al. 2017).   
A noteworthy alternative line is the mouse immortalised neural progenitor line MN9D which 
has also been shown to have dopaminergic (Hermanson et al. 2003) and neuronal properties 
(Choi et al. 1999). This line is advantageous compared to primary neurons from embryonic 
mammalian mesencephalon as they are easier to obtain and can be maintained with 
reproducibility and consistency. 
1.6.4 Pluripotent stem cell models: hESC and hiPSC 
Mammalian genomes can be highly conserved and animal models have proven invaluable to 
study disease however, humans and mice for example harbour developmental, genetic and 
physiological differences. An alternative to the use of the animal models and cell lines 
mentioned in section 1.6.3 presented itself when embryonic stem cells (ESCs) were first 
isolated from the inner cell mass of pre-implantation mouse embryos by Martin in 1981. 
These cells were able to form teratocarcinomas containing derivatives of all three germ layers, 
including undifferentiated stem cells, endoderm, connective and epithelial tissues (Evans et 
al. 1981). It was much later, in 1998, that researchers were able to isolate human embryonic 
stem cells (hESCs) from cleavage stage embryos produced from in vitro fertilisation, 




renewing pluripotent cells offered scientists an unlimited quantity of easily obtainable cells 
with the potential to be differentiated into any cell fate for in vitro modelling (Figure 1.14). 
These cells were shown to express cell surface markers SSEA3 (Shevinsky et al. 1982), SSEA4 
(Kannagi et al. 1983), TRA-1-60 and TRA-1-81 (Andrew et al. 1984), characteristic of human 
embryonal carcinoma lines and nonhuman primate stem cells  (Thomson et al. 1995). These 
ESCs have been found to express the core transcriptional regulatory circuitry characteristic of 
pluripotency (Boyer et al. 2005) which include the pluripotency genes OCT4 (Nichols et al. 
1998), SOX2 (Yuan et al. 1995; Avilion et al. 2003), NANOG (Chambers et al. 2003; Mitsui et 
al. 2003).   
A method for reprogramming adult somatic cells to induce a phenotype characterised by the 
expression of stem cell specific pluripotency genes and cell surface markers was discovered 
by Takahashi et al. in 2006, originally in mouse cells (Takahashi et al. 2006) and later from 
human somatic cells (Takahashi et al. 2007). These cells were reprogrammed by retroviral 
induction of 4 genes (Oct3/4, Sox2, Klf4 and c-Myc). They were phenotypically characteristic 
of embryonic stem cells with normal karyotypes and the ability to express stem cell markers, 
self-renew and differentiate into any cell type. Whilst ESCs require genetic manipulation or 
pre-implantation genetic screening to model diseases, iPSCs offered the use of somatic cells 
from patients who harbour mutations and therefore more physiologically-relevant disease 
modelling. Many patient-derived iPSC-lines have been generated with PD-associated gene 
defects for SNCA (Devine et al. 2011; Byers et al. 2011) as well as LRRK2 (Nguyen et al. 2011), 
PINK1 and Parkin (Chung et al. 2016). Modern genome editing technologies has also enabled 
the generation of isogenic controls, differing exclusively in disease-associated gene 




autologous patient-derived cells and differentiate them offered the opportunity to study 
disease mechanisms in vitro with the added benefit of providing a model in which cell-specific 
phenotypes could be analysed.   
 
Figure 1.14 - Sources for cell replacement therapies and modelling of Parkinson’s disease.  Sources of cells include human 
fetal mesencephalic tissue, pluripotent stem cells (ESCs and iPSCs) differentiated towards mDA neurons and direct 
fibroblast to mDA neuron reprogramming.  Fetal cells and mature neurons can them be transplanted directly into the 
adult brain. mDA neurons can then be used for PD modelling for investigating disease aetiology or for novel drug 
discovery. Neural plate (NP), neuroepithelial cells (NEP), midbrain floor plate (mFP), midbrain dopaminergic (mDA), 
midbrain dopaminergic progenitors (mDP), mDA postmitotic neuroblasts (mDNb).  Figure taken from (Arenas et al. 2015) 
1.6.4.1 Differentiation of stem cells towards a midbrain dopaminergic fate 
PD is characterised clinically by loss of dopaminergic neurons of the substantia nigra and thus, 
to model PD, ESCs and hiPSCs would need to be driven towards a generalised neural fate and 
specified to a ventral midbrain fate. To achieve this, researchers have attempted to 
recapitulate developmental cues (described in section 1.3.1). Earlier studies using mESCs used 
co-culture with stromal cell lines (Kawasaki et al. 2000) or transplantation of undifferentiated 
cells into mouse rat striatum (Björklund et al. 2002) to achieve a neural fate. Other methods 
included the sequential addition of FGF8 and SHH patterning molecules, recapitulating 




of transgenes to express mDA-specific transcription factors such as Nurr1 or FOXA2 (Kim et 
al. 2002). Concurrently, derivation of dopaminergic neurons from hESCs was being evaluated 
and early studies showed promising mDA differentiation potential of hESCs with the use of 
stromal co-culture lines as well as sequential addition of patterning molecules such as FGF8 
and SHH (Perrier et al. 2004) or neurotrophic factors (Park et al. 2004) and demonstrated that 
ESC fates can be relatively easily manipulated by the addition of exogeneous factors.   
As in normal development, inhibition of BMP antagonist noggin, found in the Spemann 
organiser, was shown to promote neuralisation in hESC cultures (Pera et al. 2004; Gerrard et 
al. 2005; Chiba et al. 2008). Inhibition of Activin/Nodal signalling was also able to drive hESCs 
towards a neuroectoderm fate using a Nodal (TGF-β family) receptor antagonist (SB431542) 
(Smith et al. 2008). The combination of Noggin and inhibition of Activin/Nodal signalling by 
SB431542 generated a highly efficient process of neuralisation in hESC cultures (Chambers et 
al. 2009). SMAD signalling is the main signalling transducer for TGF-β receptors and combining 
these two compounds was able to block SMAD 2/3 and SMAD1/5/8. Modest mDA patterning 
was also reported by activation of SHH/FGF8 signalling.  
Highly efficient generation of mDA neurons from pluripotent stem cells has recently been 
described from hESCs and hiPSCs (Figure 1.15). This was achieved by the dual SMAD inhibition 
protocol combined with dose-specific activation of SHH signalling alongside a potent GSK3β 
inhibitor and activator of Wnt signalling. Canonical Wnt played an important role in 
generating FOXA2/LMX1A expressing mDA progenitors whilst Fgf8 signalling did not play a 
significant role in specifying mDA progenitors from pluripotent stem cell-derived cultures 
(Kriks et al. 2011; Kirkeby et al. 2012). The specified neural precursors were terminally 




neuron-specific class III β-tubulin (TUJ1) and dopaminergic markers TH. The induction of 
mature neuronal morphologies was achieved by the synergistic action of the Notch inhibitor 
DAPT (Crawford et al. 2007) and dibutyryl-cAMP (db-cAMP) (Sharma et al. 1990; Stachowiak 
et al. 2003; Kim et al. 2011). For functional maturation, growth factors, GDNF and BDNF were 
included after specification to increase the survival (Sautter et al. 1998; Erickson et al. 2001).   
In conclusion, to generate mDA neurons from pluripotent stem cells, soluble factors can be 
used to control the main signalling pathways implicated in the specification of mDA neurons 
(BMP, SHH, WNT) during normal development and to achieve a functional maturation to 
neurons a mix of neurotrophic factors, Notch and CREB signalling can enhance and promote 
mDA neuron development in ESC cultures in vitro. 
 
Figure 1.15 – Differentiation towards specific neural cell types.Schematic showing generalised principles of A) specification 
of pluripotent stem cells towards specific neural lineages by in vitro recapitulation of neurodevelopmental molecular 
signalling pathways. B) The in vitro process is thought to recapitulate organisation related to neural tube development. C) 
Specified cells can be matured in culture to generate distinct neuronal sub-types as well as somatic lineages.  Figure taken 




1.6.5 Utility of lentiviral vectors for disease modelling 
Overexpression of synuclein by viral vector gene delivery, commonly adeno-associated 
viruses (AAV) and lentiviruses (LV), offers an alternative to generate models and for gene-
therapy therapeutic approaches. These vectors are highly efficient in transducing neurons and 
stem cells for stable, sustained transgene expression in both dividing and non-dividing cells. 
Although transgenic mice have been generated to model synuclein associated-PD, the mouse 
models do not always produce the same prominent, progressive neurodegenerative 
phenotype of the human disease. For example, some synuclein models lacked LB pathology 
or TH neuron degeneration (Masliah et al. 2000). The same is true for patient-derived iPSC, 
where mild phenotypes have been reported for patient-derived lines with an SNCA 
triplication (Byers et al. 2011) and the A53T mutation (Ryan et al. 2013; Haenseler et al. 2017), 
probably due to the progressive, age-dependent changes usually associated with the human 
disease.   
Rodent models of synucleinopathy generated with the use of viral vectors have been able to 
recapitulate the main SNpc-associated characteristic phenotype of PD including progressive 
mDA cell loss, LB-like inclusions and motor impairments (Kirik et al. 2003; Bianco et al. 2002; 
St Martin et al. 2007; Decressac, Mattsson, et al. 2012; Oliveras-Salvá et al. 2013). In vivo 
disease modelling using viral vectors requires injection of vectors to the site of required 
expression which can introduce some variability, however, the use of cell-specific promoters 
can be used to drive cell-type specific expression and give increased control of gene 
expression. Due to the heterogeneity of many models, neuron-specific promoters have been 
employed to drive transgene expression in neurons (Dittgen et al. 2004). Furthermore, the 




et al. 2002; Han et al. 2011), primary neurons (Tönges et al. 2014) and iPSCs (Mazzulli et al. 
2016) to model disease or for testing of efficacy of therapeutic agents.   
In this study, 3rd generation lentivirus vectors were used to as delivery tools of mutated α-
synuclein for PD modelling in SH-SY5Y cells and iPSC-derived neurons (Naldini et al. 1996). 
Lentiviruses, a genus of retroviruses, are able to stably integrate into host genome of both 
dividing and non-dividing mammalian cells and, as such, have been widely used as gene 
delivery vectors. Lentiviral vectors have been used to transduce a wide variety of CNS neurons 
(Consiglio et al. 2004; Jakobsson et al. 2003; Dittgen et al. 2004). Vectors contain 2 copies of 
positive viral ssRNA, have been generated to be safe and provide sustained expression of 
transgenes for gene therapy and overexpression models. The 3rd generation lentiviral vectors 
include only 3 of the 9 HIV-1 genes and these are contained within the 4 separate trans acting 
plasmid vectors (Figure 1.16) that include: 
1) a packaging plasmid which contains the gag (group-specific antigen) HIV-1 gene that 
produces matrix, capsid and nucleocapsid structural proteins and the pol (DNA 
polymerase) HIV-1 gene whose products include reverse transcriptase, integrase and 
protease. 
2) An envelope plasmid containing a heterologous env gene of another virus encoding 
the G-protein of the vesicular stomatitis virus (VSV-G) protein in a separate vector. 
The envelope protein enables attachment to host cell, fusion with the endosomal 
membrane and viral entry. This particular G-protein confers upon the lentiviral particle 
a broader tropism, as VSV-G interacts with a ubiquitous cellular receptor 
(Mastromarino et al. 1987; Mifune et al. 1982). VSV-G can also increase the stability 




3) A regulatory construct containing the rev (regulator of expression of virion proteins) 
HIV-1 gene, important for synthesis of viral proteins and promotes the cytoplasmic 
accumulation of viral transcripts thus aiding in production of viral proteins. Rev 
connects a Rev-responsive element (RRE) RNA motif to nuclear export machinery. 
4) A lentiviral backbone or transfer vector plasmid, driven by a strong promoter, with 
long terminal repeats (LTRs), which mediates integration of retroviral DNA into host 
genome. The lentiviral backbone used in this study was the pRRL self-inactivating 
recombinant system, wherein the U3 promoter in the 3’-LTR is deleted, which is 
integrated into the genome resulting in transcriptional inactivation. This backbone 
contains a chimeric Rous sarcoma virus (RSV)-HIV-1, truncated 5’ LTR, the packaging 
signal Psi (ψ) which regulates packaging of retroviral RNA genome into the viral capsid 
and the RRE motif. It contains a simian virus 40 (SV40) polyadenylation and origin of 
replication sequence downstream of the 3’ LTR and a Woodchuck hepatitis virus 
posttranscriptional regulatory elements (WPRE) inserted just before the 3’ LTR to 






Figure 1.16 – Schematic representing the structure of a lentivirus and the plasmids used to express the different 
components to generate lentiviruses.  Essential components include structural proteins encoded by a packaging plasmid 
(rev, gag and pol), an envelope protein encoded by the envelope plasmid, as well as the protein of interest encoded by a 
a lentiviral transfer plasmid flanked by an LTR which is integrated into the host genome during transduction. 
1.7 Summary and objectives 
The neurodegenerative disorder PD is an incurable disease, causing devastating motor 
symptoms which can have a severe impact on a patient’s health and wellbeing, with limited 
therapies. Thus, understanding the etiology of the disease and the pathways which are 
perturbed during pathology is paramount to the development of new therapies, especially 
ones which may help to prevent or slow disease progression. Research has identified many 
aspects of the pathological pathways associated with PD, including associated genetic loci and 
functional disturbances in mitochondrial, protein degradation and neurite dynamics.   
Animal and cellular PD models have been developed to determine disease-associated 
pathways. These models can be generated using different pharmacological or genetic 
manipulations including the use of lentiviral vectors to perturb different systems. Most 
recently, human pluripotent stem cells, differentiated towards midbrain dopaminergic 




molecular mechanisms of disease progression. Recent advancements in genome-wide 
analysis of gene expression including large dataset analysis pipelines have been developed 
and employed to characterise disease-associated molecular perturbations in order to identify 
novel biomarkers or new therapies. Furthermore, gene expression may be regulated at the 
translational levels and thus techniques to study actively translating mRNA have been 
developed in conjunction with next generation sequencing (NGS) technologies. These 
translatomic preparations reflect the actual functional genomic readout of a given cell type. 
In order to further understand the molecular mechanisms and pathways that are activated by 
-synuclein to contribute PD pathology, this PhD will describe a body of work with the 
following aims: 
1) to establish cellular models of -synuclein overexpression using genetic tools and iPSC 
technology; 
2) to determine genome-wide translatomic changes in cellular human PD models by NGS 
technology, in conjunction with translating mRNA purification; and 
3) to profile miRNA levels in human iPSc neuron cultures that overexpress wild type and 





Chapter 2 - Materials and Methods 
2.1 Generating lentiviral plasmids and particles for affinity purification, promoter 
testing and disease modelling 
For this project numerous plasmids were generated for the production of lentiviral particles 
to infect both SH-SY5Y cells and differentiated iPSC cells. Lentiviruses were generated to test 
different promoters in their ability in maintaining long-term expression of transgenes in these 
cell types (Table 2.1; Figure 2.1). Once the optimal promoter was ascertained, this was cloned 
into a lentiviral backbone plasmid (Naldini et al. 1996) for disease modelling and driving 







Disease modelling and 
TRAP in SH-SY5Y 
Disease modelling in 
iPSC-derived neurons 
CAG-EGFP CAG-EGFP CMV-L10a-EGFP SYN1-Empty control 
CMV-EGFP CMV-EGFP CMV-α-synucleinWT SYN1-α-synucleinWT 
EF1α-EGFP EF1α-EGFP CMV-α-synucleinA53T SYN1-α-synucleinA53T 
PGK-EGFP PGK-EGFP  SYN1-α-synucleinG51D 
 SYN1-EGFP   
Table 2.1 -List of lentiviral backbone plasmids and lentiviral particles cloned and generated for promoter testing and 
disease modelling in both SH-SY5Y cells and iPSC-derived neurons.  The CMV-EGFP, PGK-EGFP lentiviral backbone plasmids 
were gifts from Dr. Liang-Fong Wong and the CMV-α-synucleinWT, CMV -α-synucleinA53T and the CMV-L10a-EGFP lentiviral 




Figure 2.1 – Lentiviral backbone plasmids. Schematic of the lentiviral backbone plasmids used to generate lentiviral 
particles to drive A) EGFP expression for promoter testing and L10a-EGFP expression for TRAP and B) α-synuclein for 




The 3rd generation lentiviruses were produced using 4 separate trans acting plasmid vectors 
to express the necessary machinery to create lentiviral particles. These are the packaging, 
envelope and regulatory plasmids as well as a lentiviral backbone plasmid (Figure 2.1). 
2.1.1 Polymerase chain reaction (PCR) 
To produce double stranded DNA fragments for cloning into the lentiviral backbone plasmid, 
the Fast start high fidelity PCR kit (Roche) was employed. A no template control was always 
included, and reaction reagents and conditions are included (Table 2.1 and 2.2). 
 
PCR reagents Quantity Supplier 
10x Reaction Buffer (+Mg2+) 5μl Roche 
Template 50ng (1μl) Roche 
DMSO 4μl Roche 
Forward Primer (10μM) 1μl Eurofins genomics 
Reverse Primer (10μM) 1μl Eurofins genomics 
dNTPs 1μl New England Biolabs 
Taq Polymerase enzyme mix 0.5μl Roche 
H2O 36.5μl Sigma 
Total 50μl  
PCR cycle conditions Temperature Time 
Initial denaturing 95°C 3 mins 
40 cycles:   
Denature 95°C 30 secs 
Anneal  55-65°C 30 secs 
Extension 72°C 90 secs 
Final extension 72°C 10 mins 
Table 2.2 – Fast start high fidelity PCR kit reagents used for PCR of fragments for cloning and conditions used for the PCR 
reaction.  50ng of template was used with forward and reverse primers designed to add restriction sites to the end of the 
fragment insert of interest. 
Annealing temperatures used were between 55-65°C according to primer pair melting 
temperature.  Final extension was 10 mins as the plasmid used was approximately 10kb in 
size (1min/kb). 
2.1.2 Electrophoresis of PCR product 
To separate and isolate the PCR insert fragment for cloning, PCR product was loaded into a 




dissolving Ultrapure™ Agarose (Invitrogen; 15510-027) in 1x 40mM tris-acetate, 1mM EDTA 
(TAE buffer; Geneflow; B9-0030) diluted in ultrapure H2O and heated in a microwave.  
Ethidium bromide (Sigma; E1510; 0.5μg/ml) was added to the gel mix prior to casting and a 
comb inserted for loading of PCR product. The gel was left to set and then placed in an 
electrophoresis tank filled with 1x TAE buffer and the comb removed. The PCR product was 
then mixed with a 6x DNA gel loading dye (NEB; B7025S) and loaded into the wells alongside 
a 1kb molecular weight marker ladder (NEB; N3232L). The bands were visualised with a UV 
transilluminator and captured using GelDoc-It bioimaging system (UVP) with VisionWorks 
analysis software. 
2.1.3 DNA extraction from Gel and determination of concentrations 
Once PCR product was visualised with a UV transilluminator and molecular weight ladder used 
to confirm appropriate size, the bands were excised with a scalpel and weighed in a 1.5ml 
Eppendorf using the QIAquick gel extraction kit (QIAgen; #28706) was used to isolate 
fragment of interest according to manufacturer’s instructions.  Briefly, 3x volume of buffer 
QG was added (100mg gel ~ 100μl) and incubated at 50°C until gel dissolved.  1 gel volume of 
isopropanol was added and DNA bound to a QIAquick centrifuge column by centrifugation 
and washed with buffer PE with another centrifugation step. A quick centrifugation was 
applied to remove residual ethanol from buffer PE and 30-50μl of H2O was applied to the spin 
column to elute the DNA into a fresh tube. All centrifugation steps were performed at 10,000g 
and flow-through was discarded. The DNA concentration was determined using the Nanodrop 




2.1.4 Restriction enzyme digestion of DNA for recombinant DNA cloning 
Restriction enzymes (NEB; Roche) were used on PCR product (insert fragment) and plasmid 
vector DNA to produce linearised plasmid vector backbone DNA with complimentary sticky 
ends to the PCR product that can be manipulated for cloning by ligation by formation of 
hydrogen bonds (Figure 2.2). Thus, DNA was digested by suitable restriction enzymes using 
>1 Unit of restriction enzyme for each 1μg of DNA, in recommended reaction buffer provided 
by the manufacturer, for a minimum of 2 hours to overnight at 37°C. Digested plasmid vector 
DNA was electrophoresed on a 1% agarose gel as in section (2.1.2) and the linearised 
backbone DNA extracted from gel as in section (2.1.3) and eluted in 30-50μl H2O. Digested 
PCR product was purified with the QIAquick PCR purification kit (QIAgen; #28106) according 
to manufacturer’s instruction. Briefly, 5 volumes of buffer PB was added to 1 volume of PCR 
product and bound to QIAquick spin column by centrifugation. DNA was washed with buffer 
PE and then centrifuged for another minute to remove excess ethanol from buffer PE and 30-
50μl H2O applied to the spin column and eluted by centrifugation into a fresh tube. The DNA 





Figure 2.2 – Cloning strategy for cloning EF1α promoter into a plasmid which contains the CMV promoter to express EGFP. 
A) Schematic of the lentiviral backbone plasmid with cut sites. B) SerialCloner software virtual cutter tool showing the two 
restriction enzymes used, cut sites and fragments generated.  After linearising the plasmid and cutting out the promoter, 
the linearised plasmid was run on an electrophoresis gel and extracted for ligation of different promoters. C) The primers 
used to PCR the EF1α promoter, whilst adding complimentary restriction enzyme cut sites for ligation with the linearised 
backbone plasmid for cloning. 
2.1.5 Ligation of DNA 
To create a stable circular plasmid, insert fragments and linearised lentiviral backbone 
plasmids with complimentary sticky ends were ligated together prior to transformation. 
Ligations were performed using the Rapid DNA Ligation Kit (Roche; #11635379001) according 
to manufacturer’s instructions. The equation used to calculate the ratio of vector to insert 
















Briefly, a 1:1, 1:3 and 1:5 ratio of vector (150ng starting concentration) as well as an insert 
only and a vector only controls were mixed together in a centrifuge tube and H2O added to 
8μl. 2μl of 5x DNA dilution buffer was added to bring to a 1x concentration and mixed. 10μl 
of DNA ligation buffer was added to this and mixed. 1μl of the T4 DNA ligase enzyme was then 
added and incubated at room temperature (RT) for 10 minutes and then placed on ice to stop 
the reaction.   
2.1.6 Transformation into chemically competent Escherichia coli 
DH5α (Invitrogen; #18265-017) bacterial cells (or SCS110 Competent Cells (Stratagene; 
#200247) for plasmids with methylated sticky end sites) were used for transforming ligated 
plasmid DNS (section 2.1.5). Transformations were performed around a Bunsen burner, using 
aseptic technique. For minipreps 50μl aliquots of DH5α bacterial cells in plastic centrifuge 
tubes were thawed on ice and 10 μl of the ligase reaction was mixed in and incubated on ice 
for 30 minutes. Following this the cells and ligation mix was heat shocked at 42°C in a water 
bath for up to 60 seconds and placed back on ice for 2 minutes. 100pg of pUC18 control 
plasmid was applied to an aliquot of cells and the same protocol performed in parallel as a 
positive control. 1ml of Lysogeny broth was added and incubated at 37°C for an hour with 
frequent mixing every 10 minutes (Table 2.3). Following this the cell/LB mix was centrifuged 
at 5000rpm for approximately 45 seconds and 900μl removed with the remaining mix used 
to resuspend bacterial pellet. The mixture was plated onto agar plates with ampicillin 
(100μg/ml) and plates left in an incubator overnight at 37°C (Table 2.3).  
After overnight culture, single bacterial colonies were picked and transferred into 5ml LB with 




cultures were then centrifuged and minipreparation was continued using the Qiaprep spin 
miniprep kit (Qiagen; #27104) as per manufacturer’s guidelines. Briefly, overnight cell/LB mix 
was centrifuged at 6800g for 3 minutes to harvest cells. Pelleted bacterial cells were lysed in 
250μl buffer P1 with RNase A. 250μl of buffer P2 was then added and mixed by inversion 
followed by 350μl of buffer N3 and mixed likewise. This mix was centrifuged at 17,900g and 
800μl of supernatant applied to a QIAquick spin column and centrifuged for 60 seconds to 
bind DNA. Buffer PE was used to wash the DNA and centrifuged again for 1 minute to remove 
excess ethanol from buffer PE and then 30-50μl of H2O applied to the spin column and 
centrifuged in a new centrifuge tube to collect purified DNA. For SCS110 competent cells, the 
same procedure was used but 1.7μl of 50mM β-mercaptoethanol added to each aliquot of 





Table 2.3 – LB Broth components for growing transformed E. coli and Agar components for plating transformed E. Coli.  
For Agar, LB broth components had Agar added and mixed prior to plating. 
2.1.7 Maxi Preparations 
Maxi preparations were used to isolate larger concentration yields of lentiviral plasmid DNA 
encoding the different promoter-EGFP constructs, as well as L10-EGFP, and α-synuclein. Maxi 
preparations were also used to amplify packaging plasmids (Gag/pol & Rev) and envelope 
plasmids (VSV-G) from bacterial cultures. A plasmid encoding L10a-EGFP was generated and 
kindly provided by Dr. Helen Scott. 
For maxi preparations, 200ng miniprep product was transformed into an aliquot of OneShot 
Stbl3 (Thermo Fisher; #C7373-03) E. coli bacterial cells as with DH5α (section 2.1.6) with heat 
Lysogeny Broth Quantity 
Tryptone 1g 
Yeast Extract 0.5g 
NaCl 0.5g 
1mM NaOH 0.1ml 





shock for 45 seconds and plated onto agar plates with 100μg/ml ampicillin and incubated at 
37˚C overnight. The next day, a single colony was picked and transferred into 5ml LB with 
100μg/ml of ampicillin and placed in a rotating incubator at 180rpm at 37˚C for 8 hours. 
Following this, the incubated LB/cells culture was transferred into 500ml LB with ampicillin in 
a large conical flask and incubated in a rotating incubator at 180rpm at 37˚C overnight. 
The next day, overnight LB culture was pelleted at 4000rpm for 30mins at RT. Following 
pelleting, supernatant was disposed, and pellet resuspended in 18ml Solution 1 and 2ml 
Lysozyme (Table 2.4) and 40ml Solution 2 and mixed by inversion 6 times and incubated for 
10mins at RT. After 10mins, 20ml of ice cold Solution 3 was added and mixed and incubated 
on ice for 10mins. After a further 10 minutes incubation, the mixture was centrifuged at 
4000rpm for 20mins at 4˚C. Supernatant was filtered through Whatman filter paper, and 0.6 
volumes of isopropanol was added and mixed gently and left to incubate at RT for 10mins. 
After 10mins, filtrate was centrifuged at 6000rpm for 20mins at RT. Supernatant was then 
disposed and pellet was allowed to dry for 10mins and resuspended in 3ml TE buffer (10mM 
Tris-Cl, pH8.0, 1mM EDTA) on a shaking platform.  
Once dissolved, 2-step Caesium Chloride-Ethidium Bromide gradient centrifugation was used 
to purify DNA in TE buffer (Garger et al. 1983). Briefly, 3g of CsCl was added to the 3ml of DNA 
in TE buffer followed by the addition of ethidium bromide (0.08ml per ml of DNA in TE/CsCl). 
Once, CsCl was dissolved, the mixture was centrifuged at 6000rpm for 12 minutes at RT. 
Supernatant was placed into an OptiSeal Ultracentrifuge tube and TE/CsCl added to fill the 
tube. The tubes were centrifuged at 65000rpm for 16 hours at 20°C using an NVTi65 Rota, 
Optimal LE-80k Ultracentrifuge; Beckman Coulter). Once removed from the centrifuge, the 




and again TE/CsCl used to fill to the top and, this time, centrifuged for 6 hours with the same 
parameters. The purified band was excised with a syringe and H2O saturated butanol added 
to equal volume of DNA/EtBr and mixed vigorously followed by transferring of the purified 
DNA band to a fresh tube 3 times. H2O was added to a volume of 10ml and 35ml Ethanol was 
mixed with inversions. This mixture was left to stand at 4°C in a fridge for an hour and spun 
at 6000rpm for 20mins at 4°C. After spin, supernatant was decanted and 750ul of 70% ethanol 
was added to the pellet and centrifuged at 6000rpm at 4°C for a further 5mins. Ethanol was 
then removed and pellet allowed to air dry to remove excess ethanol. The pellet was finally 
resuspended in 300μl H2O by allowing pellet to slowly dissolve overnight. Concentration was 
determined by spectrophotometry. 
Table 2.4 -List of solutions used to isolate plasmid DNA transformed and amplified by transformation into Stabl3 
competent E. Coli by Maxi preparation. 
2.1.8 Culture of HEK293T cells and lentiviral preparation 
 
 
Figure 2.3 – Schematic of the self-inactivating (SIN) lentiviral backbone plasmid with ampicillin resistance used as 
visualised by SerialCloner graphics visualisation tool. 
Solution 1 100ml Lysozyme 10ml Solution 2 100ml Solution 3 100ml 
Glucose 0.9g Lysozyme 0.1g 10M NaOH 2ml 5M Potassium Acetate pH4.8 60ml 
1M Tris pH8.0 2.5ml 1M Tris pH8.0 100ul 20% SDS 93ml 
Glacial Acetic 
Acid 11.5ml 
O.5M EDTA 2.0ml H2O 9.9ml H20 5ml H2O 28.5ml 




Transgenes and promoters were cloned into a self-inactivating (non-replicating) 3rd 
generation lentiviral backbone vector (pRRL.SIN.cppt) (Naldini et al. 1996)(Figure 2.3). 
HEK293T cells (passage < 25), maintained in media containing DMEM with 10% FBS 
supplemented with 1:100 Glutamax, Non-Essential Amino Acids (NEAA) (Gibco; #11140-050) 
were trypsinised (Trypsin-EDTA; Gibco; #15400-054) and 8 x 106 cells were counted on a 
haemocytometer plated onto 15cm2 plates, and incubated at 37°C/5% CO2. Lentiviral 
backbone plasmid DNA (10µg), Gag/Pol plasmid DNA (10µg), Rev plasmid DNA (2µg) and VSV-
G (3.4µg) were mixed in 1.125ml and added 140µl 2M CaCl2. 1.125ml of Hepes-buffered saline 
(HBS; 50mM HEPES, 280mM NaCl, 1.5mM Na2HPO4) was mixed in dropwise and mixed and 
mixture was left at RT for 30mins to create DNA precipitate of which 2.4ml of DNA/HBSS mix 
is added onto HEK293T cells in 15cm2 plates, dropwise and dispersed, and incubated 
overnight at 37°C for uptake by endo/phagocytosis (Table 2.5).  
The following day, media was replaced with HEK293T maintenance media with 10mM Sodium 
Butyrate for 6 hours to increase DNA release into the cytoplasm. The media was harvested 
and placed at 4°C overnight and media was replaced with normal HEK293T maintenance 
media. The next day, media was harvested and pooled and centrifuged at 1000rcf for 5 mins 
(Megafuge-20R; Heraeus Sepatech) and filtered supernatant using a filter bottle. The filtrate 
was spun at 4°C at 6000g overnight in a JLA10.5 rotor (Beckman Coulter). Supernatant was 
disposed safely and pellet resuspended in ice cold  Phosphate Buffered Saline (PBS; Thermo 
Fisher; #14190-144) and transferred into ultraclear ultracentrifuge tubes and spun at 
20,000rpm for 90mins at 4°C, in a SW40Ti rotor (Beckman Coulter). Supernatant was gently 
poured off and pellet resuspended by covering with 100μl TSSM buffer consisting of 




5hrs followed by the use of gentle pipetting and making up to 192μl and aliquoted for storage 
at -80°C. 
 Backbone plasmid Gag/Pol Env Rev 2M CaCl2 H2O HBS 2x 
For 1 








125ug 125ug 42.5ug 25ug 1.75ml Make up to 15ml 15ml 
Table 2.5 -Quantities of each plasmid and media for lentiviral particle generation in HEK293T cells for 1 plate and the 12.5x 
master mix used for 12 plates. 
2.1.9 Lentiviral titering by fluorescence activated cell sorting (FACS) 
HEK293T cells were cultured as per section 2.1.8 and then seeded into 10 wells of a 12 well 
plate at 7.5 x 104/well for each lentivirus for titering and incubated overnight. The next day 
these wells were transduced using serial dilutions of 10-3–10-6 of concentrated lentivirus in 
TSSM buffer, as well as an untransduced control (all in duplicates) in 500μl HEK293T culture 
media for 2 hours and then topped up with 1ml media. An untransduced control well was 
trypsinised and dissociated to single cells suspension and counted for subsequent calculation.  
On day of flow cytometry, cells from each well individually were trypsinised, centrifuged at 
1000rcf for 2mins, had supernatant removed and pellet washed with PBS and centrifuged 
again. Following PBS wash, cells were fixed by resuspending in 1ml of 4% paraformaldehyde 
solution (Sigma; #P6148) in PBS for 15 minutes. Cells were then pelleted, washed and 
resuspended in 1 ml of PBS and transferred to flow cytometry tubes (BDBioscience; #352052) 
for flow cytometric analysis of expression of EGFP using the FACS Canto II (BD Bioscience). 
After recording the percentage of GFP positive cells for each dilution, titre was calculated 










2.1.10 Lentiviral titering by Taqman qPCR 
To determine the titre of the non-EGFP expressing lentiviruses, a Taqman (ThermoFisher) 
qPCR-based approach was used in which the number of integration sites was analysed using 
a standard curve from plasmid DNA of known concentrations (10-4-10-9). HEK293T were 
cultured (as described in section 2.1.8), and plated at 7.5 x 10-4 cells per well of a 12 well plate.  
Wells were transduced, in duplicate, with the lentivirus for titring and with a lentivirus of 
known titre (by FACS) at a dilution of 1:1000 and 1:5000 diluted in 500μl of HEK293T culture 
media and after 2 hours topped up with 1ml of culture media. An untransduced control was 
also included. After 3 days, wells were passaged at a ratio of 1:5 and passaged further every 
2-3 days at this ratio 3 more times to remove any unintegrated lentiviral particles in 
suspension. These cells were collected by centrifugation and washed with 1ml PBS and finally 
extracted using the Wizard DNA extraction kit (Promega) using manufacturer’s instructions. 
PCR reactions were set up, in triplicate, using 100ng of genomic DNA from duplicates of each 
dilution of lentivirus and diluted plasmid DNA to create a standard curve (Table 2.6). 






PCR MasterMix 2X 12.5 Temp Time Cycles 
Forward Primer 10µM 1.25 95°C 10 min 1 
Reverse Primer 10 µM 1.25 95°C 15 sec 40 
Probe 6.25 µM 1 60°C 2 min  
H2O - 4 
DNA 20ng/ µL 5 
Total  25 
Table 2.6 -Taqman qPCR reaction components and cycling conditions for qPCR-based lentiviral titre determination 
2.2 Generating cellular PD models 
To test our TRAP platform we are using a well-established cellular model for PD: the SH SY-5Y 




neurodegenerative disease research because this cell line possesses many characteristics of 
DAergic neurons. Indeed, most of the major PD disease pathways are intact in the SH-SY5Y 
genome. For TRAP, having large quantities of phenotypically homogenous cells is a major 
advantage. Furthermore, this cell line can be differentiated into a functionally mature 
neuronal phenotype, with increased neuritic outgrowth, in the presence of Retinoic Acid (RA). 
Upon differentiation, SH-SY5Y cells stop proliferating and a constant cell number is 
subsequently maintained. Gene overexpression of SNCA would allow the study of these genes 
in a model which preserves many neuronal and dopaminergic pathways.   
2.2.1 Culturing SH-SY5Y cells 
SH-SY5Y cells were cultured in media consisting of Dulbecco’s Modified Eagle’s Medium 
(DMEM; Sigma; #D6546) supplemented with 10% Fetal Bovine Serum (FBS; ThermoFisher; 
#10500064), 1% Glutamax (Gibco; #35050-061) and 1% non-essential amino acids 
(ThermoFisher; #11140035), incubated at 37°C/5% CO2. Cells were allowed to proliferate until 
they reached approximately 80% confluency with culture media changed once every 3 days.  
At 80% confluency, media was aspirated and cells washed with PBS and incubated with 
Trypsin (Trypsin-EDTA; Gibco; #15400-054) for 3-5 minutes. Cells were then mechanically 
lifted off the plate and added to 4x volume of culture media, to inactivate the Trypsin, in a 
15ml centrifuge tube (Thermo Fisher; #05-539-12). Cells were pelleted at 1000rpm for 5 
minutes. Supernatant was aspirated and cells resuspended in culture media and replated 
onto appropriate tissue culture vessels. 
2.2.2 Differentiation of SH-SY5Y cultures 
Cultured, undifferentiated SH-SY5Y cells were passaged at a density of 12 x 103 cells/cm2 and 




initiated by changing media to SH-SY5Y differentiation media consisting of 1:1 DMEM 
Ham’s/F12 (Thermo Fisher; #21331-020) and Neurobasal (Thermo Fisher; #21331-020) 
supplemented with 0.5% Glutamax and 0.5% N2 supplement (Table 2.7) and 10 µM Retinoic 
Acid (Sigma; #R2625) for 14 days (Figure 2.4). 
                
Figure 2.4 - Schematic outlining the SH-SY5Y differentiation protocol towards an mDA phenotype.  Culture media was 
replaced with differentiation media supplemented with RA for 14 days prior to TRAP RNA isolation 
Component Manufacturer Catalogue No. Stock Final Conc. In 10ml 
Insulin Sigma I-1882 25mg/ml 2.5mg/ml 
Apo-transferrin Sigma T-1147 100mg/ml 10mg/ml 
Bovine serum albumin Gibco 15260-037 75mg/ml 7.5mg/ml 
Progesterone Sigma P-8783 0.6mg/ml 0.00198mg/ml 
Putrescine Sigma P-5780 160mg/ml 1.6mg/ml 
Na Selenite Sigma S-5261 3mM 1:100 
DMEM:F12 Gibco 21331-020  6.875ml 
Table 2.7 – Components used to make N2 supplement for differentiation of SH-SY5Y cells 
2.2.3 Culturing of iPSCs 
Undifferentiated iPSC lines derived from reprogrammed dermal fibroblasts of a member of 
the Iowa kindred carrying a triplication in the SNCA locus (AST23) and an unaffected member 
without the mutation as a control (NAS2) were kindly donated by Dr. Tilo Kunath (Edinburgh 
University). iPSCs were cultured on vitronectin (Life Technologies; #A14700) coated tissue 
culture vessels in Essential 8 (E8) and E8 supplement (Gibco; #A1517001) culture media and 
DMEM 
10% FBS 
DMEM:Ham’s F12 1:1 
N2 supplement 
10µM Retinoic Acid 
Day 0 differentiation: Cells 
seeded at 12 x 103 
cells/cm2  
Day 15 




incubated at 37°C/5% CO2. Cells were allowed to proliferate until they reached approximately 
80% confluency with culture media changed every day.  
Cells were allowed to reach 80% confluency and then passaged by removing of culture media, 
followed by washing with PBS and adding UltraPure 0.5 mM EDTA pH 8.0 (Sigma, #15575-
020) in PBS until colonies began to lift off (2-3 minutes). At this stage, the EDTA solution was 
aspirated and E8 media with E8 supplement was replaced and cells mechanically lifted off the 
well by mechanical action with a P1000 pipette. 
2.2.4 Differentiation of iPSCs towards a midbrain dopaminergic fate 
To initiate differentiation, 3 wells of a 6 well plate of iPSC cultures, at 80% confluency, were 
dissociated from the culture plate using StemPro Accutase (Gibco; #A11105-01). After cells 
had begun to lift off the surface of the well, Accutase solution was aspirated and replaced 
with differentiation media. iPSC colonies were mechanically resuspended in neural ventral 
initiation media (NVIM) consisting of a 1:1 ratio of DMEM Ham’s F12 /Neurobasal 
supplemented with 1:100 glutamax, 1:50 N2 (Gibco; #17502-048) and 1:50 B27 without 
Vitamin A) (Gibco; #12587-010) and pooled together in non-adherent culture conditions to 
start embryoid body (EB) formation (Figure 2.5). Along with this base media, factors which 
direct differentiation towards a neural ventral midbrain (Table 2.8), as well as Y-27632 (10µM) 






Figure 2.5 - Schematic outlining the iPSC differentiation protocol towards an mDA phenotype. NB – Neurobasal; SHH- Sonic 
Hedgehog; BDNF – Brain-derived neurotrophic factor; GDNF – Glial-derived neurotrophic factor; cAMP – cyclic adenosine 
monophosphate. 
 
Table 2.8 – Factors added to NVIM for specification of midbrain dopaminergic fate in iPSCs and factors added to NVMM 
to maintain neurons 
After four days of EB formation, EBs were plated on 6 well plates coated in Poly-L-Ornithine 
(PLO)(Sigma #P3655), Laminin (10µg/ml; Invitrogen; #23017-015) and Fibronectin (10µg/ml; 












inhibition of TGF-β 
signalling 
Dual inhibition for 
improved 
neuroectoderm 
induction LDN-193189 100nM 
Stemgent; 04-
0074-10 







































factor Regulation of growth, 
maintenance and 




ascorbic Acid (AA; 
Vitamin C) 






db-cAMP 500µM Sigma cat no. 
D0627 
activates cAMP dependent 
protein kinase (PKA) induce mature 
neuronal 






factors were stopped. Two days later, EBs had grown large monolayers of outgrowing cells, 
and these were dissociated thoroughly using accutase and replated in a new well of a 6 well 
plate coated with PLO-L-F with NVIM changed to Neurobasal supplemented with B27 (-Vit. A) 
(neural ventral maintenance media; NVMM). NVMM was supplemented with factors to 
maintain neuronal cultures for the rest of the duration of differentiation (Figure 2.5). 
2.2.5 Immunoflourescence staining in SH-SY5Y and iPSC cells 
For determining optimal promoter for stable long-term expression of transgenes in SH-SY5Y 
and iPSC-derived cultures, cells on coverslips had culture media removed and were fixed with 
4% Paraformaldehyde (PFA) for 15 minutes (Day 14 for SH-SY5Y cells and Day 30/35 for iPSC-
derived cells). Fixed cells on coverslips were then washed with PBS twice. For 
immunofluorescent staining, coverslips in 4 well plates were blocked in PBS with 0.1% Triton-
X (Sigma; X100; PBS-TX) with 10% Normal Donkey Serum (NDS) or Normal Goat Serum and 
2% BSA for 1 hour. Primary antibodies (Table 2.9) were added to antibody diluent consisting 
of PBTX with 1% NDS and 0.2% BSA and incubated on a shaker overnight at 4°C. After 
overnight incubation, cells were washed with PBS-TX 3 times and incubated in secondary 
antibody (Table 2.9) in antibody diluent for 1 hour at RT. Cells were then washed 3 times with 
PBS-TX and then mounted onto slides with vectashield mounting medium with 4’, 6-
Diamidino-Phenylindole Dihydrochloride (DAPI; Vector laboratories; #H-1200) which stains all 
cell nuclei.  Immunoflourescent images were taken using a Leica microscope (LEITZ 
DMRD/DMRB) equipped with a Leica Digital FireWire Camera System for Fluorescence 
Microscopy (DFC-340) and Leica application suite (V3.3.0). Cell counting from 3 fields of view 




differentiation capacity of iPSC-derived neurons, cells were stained for TH and TUJ1 and DAPI 
to analyse percentage of dopaminergic neurons in each culture on day 35 of differentiation. 
Primary antibody Host Cat. No. Manufacturer 
anti-FOXA2 (HNF-3β) Mouse sc-101060 Santa Cruz 
anti-dopaminergic marker 
Tyrosine Hyrdroxylase (TH) 
Rabbit AB152 Millipore 
anti-Neuron-specific class III 
beta-tubulin (TUJ1) 
Mouse MS435P Covance; 
anti-Enhanced Green 
Flourescent Protein (EGFP) 
Chicken ab13970 Abcam 
anti-6His tag Chicken PA1-9531 ThermoFisher 
Secondary antibody Host Cat. No. Manufacturer 
Green 488 -  anti-mouse Goat A11029 Invitrogen 
Green 488 – anti-chicken Goat A11039 Invitrogen 
Red 568 – anti-mouse Goat A21124 Invitrogen 
Red 568 – anti-rabbit Donkey A10042 Invitrogen 
Far-red 660 - anti-mouse Goat A21054 Invitrogen 
Table 2.9 – List of antibodies used for immunofluorescence analysis of cultured SH-SY5Y and iPSC-derived cultures 
2.2.6 Western Blot for characterisation of -synuclein expression in cellular models 
Differentiating iPSC-derived PD models were collected on day 30 of differentiation and lysed 
with 100µl RIPA buffer (Table 2.10) by vortexing (Corning LSE; #10-320-807) and incubated on 
ice for 30mins. The suspension was then centrifuged at 12000rpm for 20mins at 4°C, on a 
table-top centrifuge (Eppendorf; #5424R) and supernatant collected in fresh microcentrifuge 
tube on ice. Protein quantification was determined by Pierce BCA protein assay kit 
(ThermoFisher; #23225), and equal quantities of sample mixed with equal parts 2x loading 
buffer (Table 9) by vortexing and then heated on a heating block (Techne; #DB2D) at 100°C 
for 5 minutes. Protein samples were loaded and resolved on a polyacrylamide gel (Table 2.10) 
alongside a protein molecular weight ladder (Geneflow; #S6-0024), using the mini-PROTEAN 
cell (Bio-rad; 1#658000EDU). The tank was filled with running buffer (Table 2.11) and then 
sealed and connected to a power supply (Bio-Rad Powerpack 200; #1655052) and run until 




Electrotransfer of resolved proteins on SDS-PAGE gels onto polyvinylidene difluoride (PVDF; 
Roche; #12886700) membrane was achieved using the 2-gel tetra Mini-transblot cell and 
blotting module (Bio-Rad; #1660827EDU). The tank filled with transfer buffer (table 11) and 
run at 200A for 90 minutes. Membrane was then blocked in 5% w/v milk in PBS-T (Table 2.11). 
After blocking, the membrane was placed in 1% w/v milk in PBS-T (antibody diluent) with 
primary antibody, and incubated overnight at 4°C. Membrane was then washed 3 times with 
PBS-T and film was incubated in antibody diluent with secondary antibody for 1 hour at room 
temperature (RT). Membrane was washed again 3 times in PBS-T and treated with Pierce 
Enhanced Chemiluminescent (ECL) Western Blotting Substrate (ThermoFisher; #32209) for 
detection of HRP, following manufacturer’s instructions. Scientific imaging film (Amersham 
hyperfilm; #GE 28906837) was exposed to the membrane and film was developed using a 
medical film processor (Konica Minolta; #SRX-101A). The membrane was then stripped in 
restore stripping buffer (Thermo Fisher; 21059), washed 3 times in PBS-T and rebrobed with 
housekeeping proteins (-actin, -tubulin) and reimaged. Analysis of gel and normalisation 




and cat. No. 
 
2x Loading buffer 
reagents 
Manufacturer 
and cat. No. 
 
IGEPAL CA-630 Sigma; I3021 1% Tris-HCl pH 6.8  100mM 
sodium 
deoxycholate 
Sigma; D6750 0.5% SDS Sigma; L37711 4% 
SDS Sigma; L37711 0.1% 
Bromophenol 
Blue 










1 tablet for 
10 ml RIPA 
(added fresh) 





Table 2.10 – Table listing components of RIPA buffer for lysis of cells and 2 x loading buffer for mixing with protein samples 





10% Resolving gel reagents Volume 
(ml) 
Stacking gel reagent Volume (ml) Manufacturer 










0.67 Geneflow (EC-890) 
1.5M Tris in ddH2O, pH 8.8 2.5 
1M Tris in ddH2O, 
pH 6.8 
0.5  
10% SDS 0.1 10% SDS 0.04 Sigma (L3771) 
10% ammonium persulphate 
APS 




N, N, N’, N’-
tertramethylethylenediamine 
TEMED 
0.004 TEMED 0.004 Sigma (T9281) 
Total Volume 10ml Total Volume 4ml  
Table 2.11 – Composition of resolving and stacking gels for SDS-PAGE 
1x running 
buffer 
 1x transfer 
buffer 
 Manufacturer Blocking 
buffer 
  






Glycine 250mM Glycine 39mM Sigma; G0709 PBS tablets 5 tablets 
Sigma; 
18912014 
SDS 0.1% SDS 0.037% Sigma; L37711 Tween-20 0.1% Sigma; 
P5927 
  Methanol 20% Sigma; 32213 in 1L ddH2O   
in ddH2O To 1L in ddH2O To 1L  
Table 2.12 – Composition of running buffer for resolution of SDS-PAGE proteins, transfer buffer for electrophoretic transfer 
of proteins onto PVDF membranes and blocking buffer for immunoblotting 
For -synuclein protein expression Manufacturer Concentration 
Mouse anti-α-synuclein antibody BDBioscience; 610787 1:1000 
Loading control antibodies Manufacturer Concentration 
β-actin-HRP conjugated antibody abcam; ab20272 1:5000 
Mouse anti--Tubulin Sigma; 1:1000 
Secondary antibodies Manufacturer Concentration 
anti-mouse Horseradish peroxidase conjugate HRP; Promega; W4021 1:7000 
Table 2.13 – antibodies used to probe protein expression with Western blotting 
2.2.7 RNA extraction and cDNA generation 
RNA was extracted using the mirVana RNA extraction kit (Invitrogen; #AM1560) as per 
manufacturer’s instructions. RNA concentration was measured and 2μg of cDNA was 
generated with the SuperScriptIII reverse transcriptase cDNA kit (Invitrogen; 4376357) using 
random hexamer priming. cDNA reverse transcribed. The cDNA generation protocol is briefly 
outlined in table 2.14 and quantitative PCR (qPCR) reaction and thermal cycling parameters 





Added following Quantity 
RNA template 2μg 
Random primers 1μl 
10mM dNTP mix 1μl 
H2O To 13μl 
Mixture heated to 65˚C for 5 minutes and incubated on ice for 1 minute 
5x First Strand Buffer 4μl 
0.1 M DTT 1μl 
RNaseOUT recombinant RNase inhibitor 1μl 
Superscript III RT enzyme 1μl 
Enzyme mixture added to primer/template mixture and incubated at 25˚C for 5 minutes 
Incubated at 50˚C for 60 minutes 
Reaction inactivated by heating mixture to 70˚C for 15 minutes 
RNase H 1μl (2 Units) 
Incubated at 37˚C for 20 minutes 
Table 2.14 -Protocol for cDNA generation using Superscript III cDNA kit 
Component Volume 
Power SYBR Green PCR Master Mix (2x) 25μl 
Forward Primer (10μM) 2μl 
Reverse Primer (10μM) 2μl 
Template 10ng 
Water To 25μl 
qPCR cycling conditions 
Step Hold 
Temperature 95˚C 
Step PCR Cycles x40 
 Denature Anneal/Extend 
Temperature 95˚C 60˚C 
Time 15 seconds 1 minute 
Table 2.15 -SYBR green qPCR reaction and thermal cycling conditions 
 
2.3 Statistical analysis 
All statistical analyses were performed using Prism software. Where appropriate, one-way 
ANOVA with the suitable post-hoc test was utilised. A p-value of below 0.05 was considered 
statistically significant and all probabilities were detail. Further statistical details will be 




Chapter 3 – Cellular models of Parkinson’s disease 
3.1 Introduction 
Parkinson’s disease (PD) is a neurodegenerative disease that currently has no cure. PD is a 
clinically and etiologically heterogeneous disease that eventually leads to degeneration of the 
dopaminergic neurons in the SNpc. The histopathological marker common to most PD cases, 
whether idiopathic or of known genetic cause, is the appearance of α-synuclein aggregates.   
Familial PD is thought to account for only 15% of all PD cases and is associated with a number 
of genetic loci, including SNCA, the gene that encodes α-synuclein. Perturbations in α-
synuclein expression have been shown to disrupt several cellular pathways but its 
physiological function is, as of yet, not fully elucidated. Multiplications and mutations of the 
SNCA gene locus have been associated with a younger age of onset and more aggressive 
pathology compared to idiopathic PD.   
Given the relative importance of α-synuclein in PD etiology, many models of α-synuclein have 
been explored, ranging from in vitro cellular models to in vivo rodent models. In this 
dissertation we chose to use a well-established cellular model for studying PD-associated 
neurodegeneration: the SH-SY5Y neuroblastoma cell line (described in section 1.6.3). This cell 
line was originally isolated as a subclone from a neuroblastoma bone marrow biopsy with 
dopamine-β-hydroxylase activity (Biedler et al. 1973; Biedler et al. 1978).   
The SH-SY5Y cell line is a popular cell model for neurodegenerative disease research because 
it possesses many characteristics of dopaminergic neurons. These cells also have the 
advantage of being proliferative in their undifferentiated state, are relatively homogeneous, 
easy to culture and manipulate. Having a homogenous cell line has the advantage of providing 




the dopamine transporter and dopamine receptors  with differentiation inducing an increase 
in levels of dopaminergic markers DAT and TH as well as neuronal markers such as MAP2 
(Presgraves et al. 2004; McMillan et al. 2007; Lopes et al. 2010; Constantinescu et al. 2007). 
As in substantia nigra neurons, this cell line is sensitive to compounds which induce 
parkinsonism (Chen et al. 2005; Wei et al. 2013). SH-SY5Y cells can be differentiated into a 
functionally mature neuronal phenotype, with increased neuritic outgrowth, in the presence 
of Retinoic acid (RA). PD modelling in this cell line can thus allow for the study of disease-
associated genes in a model which preserves many neuronal or dopaminergic pathways. 
Indeed, studies have previously explored phenotypes relating to wild-type and mutant α-
synuclein overexpression in this cell line (Hasegawa et al. 2004; Desplats et al. 2009; Ding et 
al. 2013; Melo et al. 2017). 
Given the usefulness of the SH-SY5Y model, we developed overexpressing wildtype (WT) and 
A53T mutant α-synuclein SH-SY5Y cultures by lentiviral transduction. These models can be 
used in further experiments to determine differential gene expression as a result of a-
synuclein overexpression (described in Chapter 4). In order to facilitate gene expression 
analyses using the TRAP technique, the cells would need to express the L10a ribosomal 
protein (RBP) fused to EGFP protein; this was also achieved by lentiviral vector transduction. 
This will enable the actively translated mRNAs at the time of harvest to be affinity purified 
with anti-EGFP antibodies.   
Although the SH-SY5Y cell line has many features which make it a useful PD model, it has some 
limitations. The cell line is not strictly dopaminergic and studies have shown that RA 
differentiation generates phenotypes with dopaminergic, cholinergic and adrenergic 




are human dopaminergic neurons that can be derived from hESCs and hiPSCs (described in 
section 1.6.4 & 1.6.4.1). Furthermore, stem cell-derived neurons have previously been shown 
to demonstrate pathological phenotypes when α-synuclein is overexpressed via viral vectors 
(Schneider et al. 2007; Zasso et al. 2018). Thus, within the scope of this dissertation was the 
development of an iPSC-derived dopaminergic neurons as an alternative PD model.   
Since the advent of iPSC technology, protocols have been developed to differentiate 
pluripotent stem cells towards defined cellular phenotypes. Thus, iPSC-derived neurons offer 
an unlimited source of cells in which to study disease mechanisms in vitro, due to their 
pluripotency and ability to proliferate indefinitely (1.6.4). Recently, two labs have developed 
a robust “floorplate” method to differentiate iPSCs towards midbrain dopaminergic neurons, 
the neurons that degenerate (Kirkeby et al. 2012; Kriks et al. 2011), leading to motor 
symptoms associated with PD  (described in section 1.6.4.1). These iPSC-derived neurons offer 
the advantage of being more accessible than primary post-mitotic neurons and can be 
generated from human somatic cells.   
 iPSC-derived midbrain dopaminergic (mDA) neurons can be obtained from patient specific 
iPSCs and these can be compared to age and sex matched controls or non-affected family 
members. However, results from these comparisons can be confounded by normal genetic 
variability. To minimise genetic variability, viral transduction of disease-associated genes can 
be used to produce relevant models with the original, non-transduced line used as a control.   
It has been previously reported that the exogeneous expression of PD-associated α-synuclein 
mutants can perturb normal neurite dynamics (described in detail in section 1.4.6.5). 
Moreover, α-synuclein overexpression has been shown to impair differentiation of iPSCs 




Oliveira et al. 2015; Zasso et al. 2018). In this chapter, the iPSC-derived midbrain dopaminergic 
neurons will be analysed for expression of TH and TUJ1, as a proxy for differentiation capacity, 
as well as neurite dynamics including length and number of primary neurites and branching 
neurites, in response to perturbed α-synuclein expression.  
3.1.1 – Aims 
The aim of the experiments described in this chapter relate to the generation of SH-SY5Y 
and iPSC-derived neurons that overexpress wild-type and mutant α-synuclein, specifically 
the aims of this chapter are to: 
1) generate lentiviral constructs expressing α-synuclein and L10a-EGFP from different 
promoters; 
2) assess the efficiency of transgene expression from the various lentiviral vectors in 
SH-SY5Y and iPSC-derived neurons; and  
3) characterise the virally transduced cell lines, including levels of α-synuclein protein, 
and for the iPSC-derived neurons, differentiation capacity and neurite dynamics. 
These cell lines were used for further evaluation of α-synuclein-associated perturbations in 





3.2 Materials and Methods 
3.2.1 Promoter testing for stable long-term expression of transgenes in SH-SY5Y cells 
and iPSCs 
For SH-SY5Y cultures, undifferentiated SH-SY5Y cells were cultured (section 2.2.1) and were 
seeded at a density of 2 x 105 cells onto culture plates and separately transduced with 
lentiviral particles to express Enhanced Green Flourescent Protein (EGFP) under the control 
of different promoters (CMV, CAG, EF1α, PGK) at a multiplicity of infection (MOI) of 2 and 5 
(generation of lentiviral particles is described in section 2.1).  SH-SY5Y cells were then 
dissociated and pelleted and fixed by resuspending in 1ml of 4% paraformaldehyde solution 
(Sigma; #P6148) in PBS for 15 minutes. Cells were then pelleted, washed and resuspended in 
1 ml of PBS and transferred to flow cytometry tubes (BDBioscience; #352052) for flow 
cytometric analysis of expression of EGFP using the FACS Canto II (BD Bioscience)(n=1). An 
MOI of 2 was deemed adequate at driving EGFP expression in SH-SY5Y cells sufficiently for 
subsequent FACS sorting (Appendix 1 Table). 
To prepare for FACS sorting, undifferentiated SH-SY5Y cells were transduced at an MOI of 2 
(n=1) with lentiviruses with different promoters on T25 culture flasks (Thermo-Fisher; 
#156367), were allowed to reach 80% confluency, and then washed, dissociated thoroughly 
in Accutase and pelleted at 1000rpm for 5 minutes in 15ml tubes. Cells were then washed 
with PBS, pelleted and resuspended in FACS buffer consisting of 25mM HEPES (Sigma; 
#H3375), 2.5mM EDTA (Sigma; #E5134) and 0.5% Bovine Serum Albumin (BSA; Sigma; 
#A7906) in PBS and transferred into flow cytometry tubes.  Cells were then sorted for EGFP 
expression using a BD Influx high speed flouresence activated cell sorter (BDBioscience) 




FBS and then resuspended in SH-SY5Y culture media supplemented with 1% Penicillin-
Streptomycin (Thermo Fisher; #15070-063). 250,000 cells per sample were collected for each 
condition and seeded onto a T25 flask. 
FACS sorted samples were passaged onto coverslips, in triplicate, at a density of 12 x 103 
cells/cm2 in 4 well plates (Thermo Fisher; #176740) in culture media and incubated for 48 
hours to adhere.  Differentiation was then initiated by changing media to SH-SY5Y 
differentiation media as described in section 2.2.2, for 14 days. Cells were immunostained for 
EGFP and DAPI and cell counts analysed (described in section 2.2.5). 
iPSCs were cultured and differentiated as described in section 2.2.3 and 2.2.4. On day 20 of 
differentiation cells were passaged onto coverslips, in triplicate, in 4 well plates at a density 
of 1.5 x 105 per coverslip and allowed 48 hours to settle.  On day 22 of differentiation cells 
were separately transduced with lentiviral particles which drive expression of EGFP under the 
control of different promoters (CMV, CAG, EF1α, PGK and hSYN1) at an MOI of 2, and allowed 
3 days for expression on a protein level (generation of lentiviral particles is described in 
section 2.1).  Cells were further cultured for 10 days, followed by immunofluorescent analysis 
of EGFP expression on day 35 (described in section 2.2.5).  
3.2.2 Transduction of SH-SY5Y and iPSC-derived neurons cells with α-synuclein 
To generate SH-SY5Y synucleinopathy models, we transduced cells with the lentiviral particles 
to drive expression of either wildtype or mutant α-synuclein, under the control of the CMV 
promoter.  SH-SY5Y cells in culture media were trypsinised and 2 x 105 cells were seeded into 
a 6 well plate and transduced with lentivirus particles expressing wildtype α-synuclein 
(wildtype overexpression; WT1-3), mutant A53T α-synuclein (A53T mutant overexpression; 




had reached 80% confluency, they were passaged onto 2 x T25 plates, separately for each 
sample; one for protein isolation and western characterisation and one for further processing 
with L10a-EGFP transduction for TRAP. 
To generate and characterise an iPSC PD model, day 11 differentiating NAS2 iPSCs, were 
passaged onto 6 well plates at a density of 2.5 x 105 cells/well.  These cells were transduced 
with lentiviral particles that express Wildtype, A53T and G51D mutant α-synuclein, as well as 
an empty vector control, at an MOI of 5 (n=4 for each group).  Western blotting and 
densitometry analysis was used (section 2.2.6) to analyse expression of α-synuclein. Statistical 
testing used was one-way ANOVA with Tukey’s post-hoc test. 
To analyse the differentiation capacity of iPSC-derived neurons synucleinopathy models, cells 
were stained for TH and TUJ1 and DAPI to analyse percentage of dopaminergic neurons in 
each culture on day 30 of differentiation. 
3.2.3 qPCR analysis of differentiation markers in differentiating iPSC-derived neurons 
RNA was extracted and cDNA generated as per section 2.2.7. qPCR was performed on 
differentiating iPSC-derived neurons on day 0, 11, 23 and 35 for the genes LMX1A, FOXA2, 
MAP2, DDC and ACTB was used as a housekeeping gene (primers listed in table 3.1). qPCR 
was performed on the StepOnePlus Real Time PCR system (ThermoFisher) and results 








Marker Forward/Reverse Primer sequence  
LMX1A Forward GCAAAGGGGACTATGAGAAGGA 
 Reverse CGTTTGGGGCGCTTATGGT 
FOXA2 Forward GGAGCAGCTACTATGCAGAGC 
 Reverse CGTGTTCATGCCGTTCATCC 
MAP2 Forward CTCAGCACCGCTAACAGAGG 
 Reverse CATTGGCGCTTCGGACAAG 
DDC Forward TGGGGACCACAACATGCTG 
 Reverse TCAGGGCAGATGAATGCACTG 
ACTB Forward ACAGAGCCTCGCCTTTGC 
 Reverse CATCACGCCCTGGTGCC 
Table 3.1 - List of primers used for qPCR expression profiling of differentiation markers in iPSC-derived neurons 
3.2.4 Functional analysis of neurite dynamics of iPSC-derived neurons  
iPSCs PD models were generated as previously described (3.2.2) with 4 biological replicates 
for each condition. Differentiating iPSC-derived neurons were plated onto 2 coverslips for 
each biological replicate group. Overall,  5 cells per biological replicate groups (20 for each 
condition) were analysed for neurite length, number of primary neurites and number of 
branching points.  Neurons were stained for TH, TUJ1 and 6His-tag on day 35 of differentiation 
and neurite dynamics were analysed using the Neurite tracer plugin for ImageJ (Figure 3.1).  
Cells which co-expressed TH, TUJ1 and 6His-tag were analysed and one-way ANOVA was 
performed to determine statistical significance of the results. 
 
Figure 3.1 – Neurite analysis in iPSC-derived neurons. A) Neurite analysis of  hiPSC-derived cultures on day 35 of 
differentiation. Immunoflourescent merge and constituent panels from top to bottom: 6His-tag (Green) for exogeneous 
α-synuclein, Tyrosine Hydroxylase (Red) and β-tubulin (Purple) is shown, as well as the 8-bit image used for analysis. B) 





3.3.1 Generating a SH-SY5Y model of PD for translating ribosome affinity purification 
3.3.1.1 Optimisation of promoter usage in lentiviral vector constructs 
Promoter optimisation experiments were performed to establish the best promoter for long-
term, stable expression of transgenes in SH-SY5Y cells. A literature search was conducted to 
identify a list of suitable promoters for use in transduction of neuronal or specifically SH-SY5Y 
cells (Table 3.2). 
Cells transduced Promoter used Percentage transduction Paper 
Primary mouse 
cerebellar neurons 




Unquantified but suggests 
highest efficiency by CMV 
(Li et al. 2010) 
Differentiated hESCs EF1α 30-48% (Gropp et al. 2003) 
hiPSC-derived 
dopamine neurons 
PGK 70-90% (Seibler et al. 2011) 
Rat substantia nigra 
neurons 
PGK Unquantified (Bianco et al. 2002) 
hESCs-derived 
dopamine neurons 
PGK Unquantiied (Grealish et al. 2014) 
Table 3.2 - Literature review of studies that have employed lentiviral vectors to express transgenes in neuronal models 
and percentage transduction where available. CMV, cytomegalovirus; PGK, phosphoglycerate kinase; EF1- α, elongation 
Factor 1-α; CAG, CMV/chicken-β Actin; hESC, human embryonic stem cells; hiPSC, human induced pluripotent stem cells.  
Based on the above literature, lentiviral transfer plasmids were cloned to express enhanced 
green fluorescent protein (EGFP) using the cytomegalovirus (CMV), phosphoglycerate kinase 
(PGK), elongation Factor 1-α (EF1- α) and CMV/chicken-β Actin (CAG) promoters (Figure 3.2A). 
After cloning, transfer vector plasmids with different promoters were co-expressed, 
separately, with packaging, envelope and regulatory plasmids in HEK293T cells to generate 
lentiviral vector particles (described in section 2.1). Once lentiviral vector particles were 
isolated and titred by flow cytometry, lentiviral vector transduction efficiency was performed 
to determine a suitable MOI for efficient transduction (Figure 3.2B). Undifferentiated SH-SY5Y 
cells were transduced at MOIs of 2 and 5 and flow cytometry was employed to analyse the 




negative untransduced control and transduction efficiencies ranging between 27.1-58.0% for 
transductions using an MOI of 2 and between 55.6-84.6% for transductions using an MOI of 
5 (Figure 3.2B). 
 
Figure 3.2 – Lentivirus promoter transduction efficiencies. A) Schematic for the 4 viral plasmids used to generate lentiviral 
particles for testing in SH-SY5Y lines.  Each plasmid contains a different promoter (CMV, CAG, EF1α, PGK) to express EGFP.  
B) Table shows the percentage of cells expressing EGFP, as determined by flow cytometric analysis, for each viral 
promoter, used at an MOI of 2 and 5 in undifferentiated SH-SY5Y cells (n=1). 
The results suggest that there is increased transduction efficiency with increasing MOI. 
However, as these experiments will be used to inform later experiments such as 
overexpressing a-synuclein or L10a ribosomal subunit protein fused to EGFP, the MOI of 2 
was deemed sufficient for further analyses of stable long-term expression of EGFP. At an MOI 




perturbing cell function, for example the translation machinery due to elevated levels of 
exogeneous EGFP protein in the ribosomal compartment. 
3.3.1.2 Promoter optimistation in differentiated SH-SY5Y cells 
SH-SY5Y cells were transduced with lentiviral vectors harbouring the 4 different promoters 
used to express EGFP at an MOI of 2 (Figure 3.3A). EGFP expressing cells were sorted by flow 
cytometry and differentiated by Retinoic Acid (RA) treatment for 14 days (Figure 3.3 
andFigure 3.4B) and analysed for EGFP expression by immunofluorescence at the end of the 
differentiation protocol (Figure 3.4C). Cell counts were performed, and mean percentage 
expression was determined for each vector at the end of the differentiation protocol (Figure 
3.4D). 
 
Figure 3.3 -Differentiation of SH-SY5Y cells. FACS sorted SHSY5Y cells transduced with a lentivirus that drives L10a-EGFP 
fusion protein under the control of the CMV promoter, at an MOI of 2 on day 0 and day 15 of differentiation with Retinoic 





Figure 3.4 –Promoter testing in SH-SY5Y cells. A) Schematic of the protocol for testing promoters for long-term stable 
transduction in SH-SY5Y cells.  Cells were transduced with lentiviral vectors expressing an EGFP reporter at an MOI of 2.  
Transduced cells were FACS sorted to generate a population of EGFP expressing cells and then cultured and taken through 
a 14-day differentiation protocol to produce neuron-like cells.  Immunoflourescent staining at day 14 was employed to 
determine the percentage of cells expressing EGFP at the end of the experiment. B) FACS sorting was performed on 
transduced cultures of SH-SY5Y cells, under regulation by different promoters.  C) Representative images from day 14 
differentiated SH-SY5Y cells transduced using different promoters. DAPI (blue) stained cells, representing total number of 
cells, and EGFP expression (green) by different promoters in SH-SY5Y cultures. D) Graph shows average number of cells 




Analysis shows that the highest percentage of cells (73.2 ±3.0%) expressing EGFP at the end 
of the 14-day SH-SY5Y differentiation protocol was achieved with the CMV-EGFP construct as 
compared to CAG-EGFP (59.9 ± 6.6%), EF1α-EGFP (65.0 ± 3.0%) and PGK-EGFP (44.4 ± 7.5%) 
promoter constructs (Figure 3.4C, D). This suggests that the CMV-EGFP construct was best 
able to maintain long-term stable expression of transgenes in SH-SY5Y cells. Although cells 
were FACS sorted prior to differentiation, the percentage of cells expressing EGFP at the end 
of the differentiation period was observed to decline in all promoter conditions. Some of this 
loss may be from silencing of transgene expression during differentiation and technical error 
such as cell aggregates being harder to visualise individually for EGFP due to its presence in 
the cytoplasm. Nonetheless, from these results the CMV promoter was significantly more 
efficient for long term expression of transgenes in SH-SY5Y cells and was subsequently used 
to generate the α-synuclein and the L10a-EGFP fusion protein constructs. 
3.3.1.3 Expression of WT and A53T mutant α-synuclein in SH-SY5Y cells 
Having established that the CMV promoter was most efficient for expressing transgenes in 
our SH-SY5Y cells, independent cultures were transduced with lentiviral particles expressing 
WT and A53T mutant α-synuclein at an MOI of 5. To validate α-synuclein protein production 
in these cells, Western blotting was performed. Protein analysis showed expression of α-
synuclein in transduced SH-SY5Y cells. No endogenous α-synuclein expression was detected, 
which is in keeping with literature suggesting low expression rate in the SH-SY5Y cell line 
(Figure 3.5A)(Kumar et al. 2017). Densitometry analysis showed that WT (41.8±0.91) and A53T 
(42.3±0.22) α-synuclein protein expression was comparable and both were significantly 
higher than to control untransduced cultures (p<0.001, one-way anova with Tukey post-hoc 






Figure 3.5 – α-synuclein protein expression analysis in SH-SY5Y cells. A) Western blot of α-synuclein and α-tubulin from 
undifferentiated SH-SY5Y cultures. C1-C3 represent untransduced cells, while and WT 1-WT 3 and A53T 1 – A53T 3 
represent cells transduced with lentiviral particles expressing WT and mutant A53T α-synuclein respectively.  B) ImageJ 
densitometry analysis of Western blot showed that there was no significant difference between mean WT and A53T α-
synuclein expression (±SD) and both WT and A53T α-synuclein expression were significantly higher than to control 
untransduced cultures. One-way ANOVA, Tukey post-hoc test (n=3). *** p<0.001 
3.3.1.4 Production of synuclein SH-SY5Y cells expressing L10a-EGFP  
Having established that the WT and A53T synuclein expressing SH-SY5Y cells were producing 
similar and robust levels of synuclein, they were transduced with lentiviral vectors to express 
L10a-EGFP fusion protein, under the regulation of the CMV promoter at an MOI of 2.  3 days 
after transduction, cells were harvested in FACS sorting buffer and 200,000 cells were isolated 
based on expression of EGFP from each individual sample (Figure 3.6). Gating was kept 
constant such that these cells would produce similar expression levels of L10a-EGFP fusion 
protein. These lines were then ready to be used for the translating ribosome affinity 





Figure 3.6 – Representative FACS tracing showing gating for the isolation of EGFP expressing cells from experimental 





3.3.2 Generating an iPSC model of PD 
3.3.2.1 Preliminary differentiation of iPSCs towards a midbrain dopaminergic cell fate 
The differentiation protocol established by Kirkeby et al. was used to obtain dopaminergic 
neurons from NAS2 iPSCs. Cells were monitored by microscopy throughout the specification 
of iPSC towards mDA neurons (Figure 3.7A). Cells were passaged onto coverslips, at day 22, 
in technical triplicate. At day 30 and day 45 of differentiation, cultures were stained for the 
floorplate marker FOXA2 and dopaminergic marker TH (Figure 3.7B). Cell counts were 
undertaken, and analysis showed 76.9±6.2% and 87.4±4.3% of cells were seen to express 
FOXA2 and 17.6±4.40% and 28.7±5.0% to express TH on day 30 and 45 respectively (Figure 
3.7C). A t-test was employed and showed no significant differences between day 30 and 45 
for both differentiation markers (p>0.05). It was noted that at high densities, these cells had 
a tendency to form clusters and thus cell counts were difficult to undertake. However, most 
cells were clearly seen to express FOXA2 and cells with neurite-like processes stained 





Figure 3.7 - Differentiation of NAS2 iPSCs into mDA neurons. A) Brightfield images monitoring the differentiation process 
through specification stages (day 0-14). Scale bars from left to right: 400μm, 200 μm, 200μm and 100μm. B) 
Immunoflourescent analysis of floorplate marker FOXA2 (green), mature DA neuronal maker TH (Red) and nuclear marker 
DAPI (Blue). Scale bar = 100μm.  C) Mean cell counts (±SD) showed a high proportion of cells coexpressing FOXA2 and TH, 
indicative of successful differentiation protocol (n=3). 
3.3.2.2 Lentiviral vector transduction of iPSC-derived dopaminergic neurons 
To test promoters for stable expression of transgenes in iPSC-derived cultures, NAS2 iPSCs 
were transduced at an MOI of 2, on day 22 of differentiation and analysed for EGFP expression 
on day 35.  The promoters that were tested included CAG, CMV, EF1α and PGK promoters as 
well as the human neuron specific synapsin1 promoter (hSYN1). The hSYN1 promoter was 




populations within the heterogenous cell population in an iPSC culture. Cell cultures were 
stained for EGFP, TUJ1 (neuronal marker), TH (dopaminergic marker) and DAPI (nuclear 
staining) (Figure 3.8A). This allowed the analyses of EGFP expression within neuronal and non-
neuronal cells. The percentage of neuronal and non-neuronal cells that expressed EGFP were 
assessed separately to ascertain whether EGFP was preferentially expressed in certain 
populations, due to either preferential transduction or promoter activation. The percentage 
of TUJ1+ cells expressing GFP ranged from 69.1±10.5% for the CMV-GFP lentiviral construct 
to 48.2±5.3% for the PGK-GFP construct, with no significant differences in expression 
between the constructs. As expected, viral particles with the hSYN1 promoter showed 
expression of GFP in TUJ1 expressing cells on day 10 (58.2%±3.1) whilst only a small fraction 
of TUJ1 negative cells expressed EGFP under the control of the hSYN1 promoter on day 10 
(8.6%±1.4), which was statistically significantly lower than all other promoters (p<0.05) 
(Figure 3.8B). Thus, for transducing differentiating iPSCs, the hSYN1 promoter will be used as 







Figure 3.8 –Differentiated iPSC neurons expressing EGFP from lentiviral vectors containing different promoters. A) 
Representative immunofluorescent staining of differentiating iPSC cultures transduced with various lentiviral constructs 
expressing EGFP 13 days post transduction.  DAPI nuclear stain is shown in blue, EGFP staining in green, TH staining in red 
and TUJ1 staining in purple. Scale bar = 100μm. B) Left: Mean percentage of cells co-expressing TUJ1+ and EGFP 
concordantly (±SD) and Right: percentage of TUJ1- cells expressing EGFP 10 days post-transduction. One-way ANOVA, 




3.3.2.3 Transduction of WT, A53T and G51D α-synuclein into differentiating iPSCs and 
characterising differentiation for miRNA profiling 
Although control and PD (α-synuclein triplication) iPSC lines are available, to control for 
variation on a genetic and technical level, it was decided to generate an alternative iPSC PD 
model using lentiviral vectors to overexpress WT as well as mutant A53T and G51D synuclein 
(section 3.2.2). Thus, lentiviral particles were generated to express WT and mutant α-
synuclein under the control of the hSYN1 promoter (lentivirus generation is described in 
section 2.1). Generation of lentiviral vectors to express wild-type and mutant α-synuclein 
involved cloning both hSYN1 promoters and synucleins into lentiviral transfer vectors and co-
expressing along with packaging, envelope and regulatory lentiviral plasmids in HEK293T cells, 
to generate lentiviral particles.  Isolated lentiviral vector particles were titred by a qPCR-based 
method.  
Cells were transduced at day 11, upon completion of the specification stage of the protocol 
and entry into terminal differentiation, with lentiviral particles expressing α-synuclein under 
the control of the hSYN1 promoter, at an MOI of 5 (n=4). Cultures were passaged onto plates 
on day 25 for protein isolation and onto coverslips for immunofluorescent analysis. Cells were 
harvested on day 30, 19 days post transduction, and Western blotting was used to analyse 
protein expression in transduced and untransduced lines (Figure 3.9A). Western blot analysis 
showed elevated relative expression of α-synuclein in WT (41.4±17.1), A53T (34.0±11.9) and 
G51D (47.1±10.1) cultures compared to control cultures. There was significantly higher 
expression of synuclein in WT and G51D-transduced cultures compared to control culture 
(p<0.0017 and p<0.0006 respectively, one-way ANOVA Tukey post-hoc test) (Figure 3.9B). 




(p<0.067), possibility due to large variation; however, there were no significant differences in 
α-synuclein expression between the 3 α-synuclein constructs. 
In parallel, a non-transduced control was differentiated towards an mDA fate and cells 
harvested on days 0, 11, 23 and 35 for qPCR analysis of floorplate (LMX1A, FOXA2), 
dopaminergic (Dopa-decarboxylase (DDC) and neuronal (microtubule-associated protein 2 
(MAP2)) markers (Figure 3.9C).  All markers were seen to increase from day 0 to day 23 and 
continued to increase to day 35, except for FOXA2 which showed a small decrease in 
expression from day 23 to day 35. 
Immunofluorescent staining was used to probe for expression of TUJ1 and TH in all cultures, 
independently at day 30 of differentiation (Figure 3.9D). From experience, further culturing 
would result in dense clustering of cells due to neuronal migration and proliferation making 
cell counting difficult. To identify any perturbations to the differentiation process owing to 
expression of transgenes, cells from individual samples were passaged onto coverslips on day 
25 of differentiation, and cell counts were performed on day 30. Figure 3.9E shows average 
percentage expression of TUJ1 and percentage of TUJ1 co-expressing the dopaminergic 
marker TH. The percentage of TUJ1 expressing cells ranged from 26.7% to 31.8% whilst the 
percentage of these cells which expressed TH was 33.6% to 40.7% and was not significantly 
changed between conditions, as determined by one-way Anova (p<0.05) with Tukey’s 





Figure 3.9 - Characterisation of day 30 differentiating iPSC-models. A) Western blot of synuclein expression in day 30 iPSC 
differentiated cultures overexpressing WT (W1-4), A53T (A1-4), and G51D (G1-4) α-synuclein, as well as an empty controls 
(C1-4), at an MOI of 5 (n=4). B) Densitometry analysis of mean expression of the 3 α-synuclein constructs (±SD). One-way 
ANOVA, Tukey post-hoc test (n=4). *p<0.05, ** p<0.01, *** p<0.001. C) qPCR to determine differentiation potential of 
iPSCs towards a midbrain dopaminergic fate (LMX1A, FOXA2, MAP2, DDC) (n=1). D) Immunofluorescent staining of 
experimental cultures at day 30 of differentiation for DAPI, TUJ1 and TH (n=4; scale bar = 100μm). E) Differentiation 
characterisation by cell counts to identify average percentage (±SD) of cells expressing TUJ1 and, of these, percentage also 





As approximately only 30% of cells stained for a neuronal marker, this begs the question as 
to what these other cells may be, and it was thought that they may be of a glial origin, as 
these stem from the same progenitor population. Thus, immunofluorescent staining was 
performed for glial fibrillary acid protein (GFAP), a marker for astrocytes, which have the 
ability to self-renew and proliferate (Bruttger et al. 2015). Indeed, staining showed 
widespread GFAP expression in our differentiating iPSC culture (Figure 3.10) which is typical 
of iPSC-derived mDA differentiated cultures (Kriks et al. 2011; Martí et al. 2017). The cultures 
seem to recreate the normal CNS environment of a heterogenous population of cells, in a 
neuronal network which includes both neurons and glial cells. These glial cells allow for the 
recapitulation of the activation of neuroinflammatory pathways in cultures (Hui et al. 2016). 
 
 
Figure 3.10 – Immunofluorescent staining of experimental cultures at day 30 of differentiation for DAPI (nuclear marker), 




3.3.3 Neurite dynamics in iPSC-derived dopaminergic neurons  
It has been reported in literature that perturbed α-synuclein expression can result in 
dysfunction in neuronal microtubule dynamics. Thus, we thought to analyse neurite dynamics 
in our iPSC-derived PD models which includes WT as well as A53T and G51D synuclein 
overexpression. As our exogeneous α-synuclein also contains a 6xhistidine (6xHis) tag, neurite 
dynamics can be monitored using endpoint immunofluorescent analysis for DAPI (nuclear), 
6xHis (exogenous α-synuclein), TUJ1 (neuronal) and TH (dopaminergic). In this way, it was 
possible to trace neurites from cells which co-stain for all markers, i.e. transduced 
dopaminergic neurons (Figure 3.11A). 
In parallel, a non-transduced control was differentiated towards an mDA fate and cells 
harvested on days 0, 11, 23 and 35 for qPCR analysis of floorplate (LMX1A, FOXA2), 
dopaminergic (DDC) and neuronal (MAP2) markers (Figure 3.11B). All markers were seen to 
increase from day 0 to day 23 and either continued to increase (LMX1A), plateau (MAP2, DDC) 
or showed a slight decrease from day 23 to day 35.   
Cells that were positive for 6xHis, TUJ1 and TH were analysed for neurite length, number of 
primary and number of branching neurites (Figure 3.11C-F). Here we found that there was no 
statistically significant increase in the number of primary neurites, i.e. neurites originating 
from the soma, in cells overexpressing WT (1.5±0.3), A53T (1.4±0.3) and G51D (1.3±0.1) α-
synuclein compared to control (1.1±0.1) (Figure 3.11C).   
Total primary neurite length per cell was significantly increased in control lines (454.0±55.6) 
compared to WT (253.4±23.8) and G51D (254.4±41.0) overexpression models (Figure 3.11D). 
Although there was a trend to a decrease in A53T α-synuclein expressing cultures 




into account how many primary neurites are stem from a single neuron. Thus, it was decided 
to also look at total neurite length per cell normalised to the number of primary neurites; i.e. 
mean neurite length (Figure 3.11E). Similar to total neurite length, mean neurite length was 
also significantly decreased in WT (168.9±8.4) and G51D (193.2±24.2) cultures compared to 
control (408.6±30.9), with a non-statistically significant decrease noted for A53T (278.9±49.6) 
cultures (Figure 3.11E). 
The total number of branching neurites was also seen to be higher in control (1.8±0.5) 
compared to G51D (0.2±0.1) overexpression models (Figure 3.11F). The number of branching 
neurites in control cultures was also noted to be higher than in WT (0.7±0.2) and A53T 
(1.2±0.2) cultures compared, this was not statistically significant (Figure 3.11F). The mean 
number of branching neurites per primary neurite was significantly higher in control (1.6±04) 
compared to both WT (0.5±0.2) and G51D (0.2±0.1) overexpression cultures. Although control 
culture mean branching neurites were higher than A53T (0.9±0.2), this was not statistically 
significant  (Figure 3.11G).  
In summary, expression of both WT and mutant α-synuclein protein in iPSC-derived neuronal 
cultures had no effect on the number of average primary neurites nor the total neurite length. 
However, upon closer examination of the data, the complexity of neurite branching was 
affected by overexpression of both WT and G51D mutant synucleins, as the number of 
branching neurites and total length per cell was lower compared to control cultures. Although 
there was an observed trend for reduced complexity in both these metrics for the A53T α-









Figure 3.11 – Neurite analysis of iPSC-derived dopaminergic neurons and characterisation of day 35 differentiating iPSC 
neurons transduced with lentiviral vectors to overexpress WT (W1-4), A53T (A1-4), and G51D (G1-4) α-synuclein, at an 
MOI of 5 (n=4). A) Immunofluorescent staining of experimental cultures at day 35 of differentiation for DAPI, 6xHis, TUJ1 
and TH (n=4; scale bar = 100μm). B) qPCR to determine differentiation potential of iPSCs towards a midbrain dopaminergic 
fate using primers for LMX1A, FOXA2, MAP2 and DDC (n=1). C-G) Graphs and tables showing average (±SD) (n=4) results 
for: C) the average number of primary neurites, D) total neurite length, E) average neurite length, F) total branching 
neurites and G) average number of branching neurites per primary neurite. One-way ANOVA, Tukey post-hoc test (n=4). 
*p<0.05, ** p<0.01, *** p<0.001. 
3.4 Discussion 
The aim of this study was to develop a cellular PD model for use in translating ribosome 
affinity purification (TRAP) for the investigation of the pathogenesis of PD associated with α-
synuclein perturbations. Lentiviral particles were generated and used to express transgenes, 
specifically α-synuclein in SH-SY5Y and iPSC-derived neurons. In generating the lentiviral 
constructs, promoter usage was considered and some promoters that have been used in 
literature to express transgenes in neuronal/neuron-like cells include the CAG promoter, 
EF1α, PGK and hSYN1 (Kumar et al. 2017)(Table 3.2). Here we show that SH-SY5Y cells were 
able to express EGFP from the variety of promoters used, and that the CMV promoter was 
the most robust at producing EGFP expression throughout the culture and differentiation of 
SH-SY5Y cells. 
One study specifically explored the ability of different promoters to induce transgene 
expression in SH-SY5Y cells using the pRRL.SIN lentiviral backbone with CMV, PGK and FCIV 
promoters to express EGFP in undifferentiated and 7 days differentiated SH-SY5Y cells (Li et 
al. 2010). It was noted that the CMV promoter was best able to produce robust EGFP 
expression. Our studies thus support this observation. 
To further these studies, lentiviral particles were generated to stably express exogeneous WT 
or A53T mutant α-synuclein, under the control of the CMV promoter. SH-SY5Y cultures were 
transduced, at a MOI of 5, and overexpression characterised by protein and transcript 




levels of α-synuclein protein compared to untransduced controls. The MOI of 5 was chosen 
as the initial test using CMV-EGFP lentiviral particles at an MOI of 5 produced ~80% 
transduction efficiency and lentiviral MOI ranges between 2-30 have previously used in 
studies using iPSC-derived neuronal cultures and neuronal-like cells, such as SH-SY5Y cells 
(Desplats et al. 2009; Prots et al. 2013; Mazzulli et al. 2016; Vogiatzi et al. 2008; Lee et al. 
2017). These cells were subsequently transduced with the L10a-EGFP fusion protein 
construct. Enrichment of these cells via FACS produced a population of SH-SY5Y cells that 
stably expressed the fusion protein and WT or mutant synuclein, and this provided a source 
of material for subsequent TRAP experiments as described in Chapter 4.   
The use of iPSC-derived mDA neurons overexpressing synuclein was also explored.  Lentiviral 
promoters that have been used to express transgenes in undifferentiated and differentiated 
stem cells include EF1α (Gropp et al. 2003) and PGK (Seibler et al. 2011)(Table 3.2).  iPSC 
cultures were differentiated with the Kirkeby protocol to derive mDA neurons that were also 
tested with the lentiviral constructs containing the above 4 promoters with the inclusion of 
the hSYN1 to provide cell-specific expression in neurons.  hSYN1 was chosen as the promoter 
to express transgenes specifically in differentiating iPSC-derived neurons, though it was not 
clear if the levels of expression would be comparable to constitutive promoters. This 
construct was observed to express the reporter gene EGFP at a similar efficiency to the other 
promoters used, and as expected, non-neuronal cells were transduced at a statistically 
significant lower level compared to neurons. Based on this data, lentiviral particles were 
generated to express WT, A53T and G51D α-synuclein, under the control of the hSYN1 
promoter. iPSC-derived neurons were transduced separately with these lentiviral vectors, and 




overexpression in the A53T synuclein overexpressing cells was not significantly increased 
compared to control untransduced cells, this was not significantly different to α-synuclein 
protein levels in WT and G51D overexpression models.   
Differentiation of iPSCs to mDA neurons was characterised by a transcriptomic increase of 
LMX1A and FOXA2, two critical floorplate markers, as well as DDC, a dopaminergic marker 
and MAP2, a neuronal marker. Furthermore, cells were shown to express FOXA2, TH and TUJ1 
at a protein level by immunofluorescent analysis. Characterisation of differentiation capacity 
was further analysed in these iPSC-derived neurons by determining the number of TUJ1 and 
TH positive cells, as differentiation potential and maturation capacity have been reported to 
be perturbed in α-synuclein stem cell models, within 30 days of differentiation (Schneider et 
al. 2007; Oliveira et al. 2015). However, no statistically significant changes in average number 
of neurons or dopaminergic neurons were noted. It may be that the differentiated cells were 
not left for a sufficient amount of time to show reduced maturation capacity in these cultures. 
Further studies could be undertaken to determine the effect of perturbed α-synuclein 
expression on differential expression of dopaminergic neuron differentiation markers, such 
as nuclear receptor related 1 protein (NURR1) and G-protein-regulated inward-rectifier 
potassium channel 2 (GIRK-2). 
As increased age is one of the main factors in PD susceptibility, another limitation of iPSC-
derived cultures is that reprogramming is thought to revert cells to a younger phenotype, 
based on analysis of age-related phenotypic markers such as telomere length (Lanza et al. 
2000). Whilst donor age has been found to be linked to a decrease in reprogramming 
efficiency (Sardo et al. 2017), iPSCs from older donor samples do not show dysfunction in 




to parental fibroblasts (Lapasset et al. 2011; Miller et al. 2013). Thus, it is difficult to model 
late-onset neurodegenerative diseases derived from iPSCs in vitro. Some researchers have 
identified pharmacological agents to reduce telomerase activity in mDA neurons, 
recapitulating age-associated phenotypes (Vera et al. 2016). Furthermore, the use of proteins 
associated with premature ageing have been developed to recapitulate cellular age in stem 
cell-derived models for modelling age-related diseases (Miller et al. 2013; Zhang, Wang, et al. 
2005). Another strategy would be to age cells in culture and longer-term culturing and 
maturation of human iPSC-derived neurons has been described for over 100 days (Lam et al. 
2017). 
The heterogeneity of iPSC-derived neurons could present a limitation to our experiments. 
Cellular heterogeneity is attributed to the presence of non-neuronal cells such as astrocytes 
and oligodendrocytes, and indeed we have shown that some of these non-neuronal cells in 
our cultures were glial associated protein GFAP positive indicating the presence of astrocytes. 
However, one advantage of a heterogenous culture is that the interactions between multiple 
cell types can be studied and this may be a more accurate reflection of the cellular events 
that take place during disease progression. In support of this a recent study has shown that 
glial cells are required to activate neuroinflammatory processes in mouse primary cultures 
(Hui et al. 2016). As α-synuclein is thought to activate microglia, these interactions are 
thought to be important for the initiation or progression of pathology in PD (Zhang, Wang, et 
al. 2005; Su et al. 2008). 
Finally, neurite dynamics in iPSC-derived mDA neurons were functionally analysed by staining 
differentiated cultures for markers for exogeneous α-synuclein (6xHis), TUJ1 and TH.  Analysis 




neurons compared to controls. This is in keeping with a recent report that suggested that 
overexpression of WT, A30P and A53T α-synuclein in primary midbrain neurons led to a 
significantly higher number of primary neurites (Koch et al. 2015). The results presented in 
this chapter suggest that overexpression of both WT and mutant G51D α-synuclein resulted 
in a significant decrease in the total length of all primary neurites, as well as the mean length 
of primary neurites. And, whilst a decrease by trend was observed for A53T overexpressing 
cells in both metrics, this may be related to the decreased expression of the A53T mutant α-
synuclein relative to control cultures as compared to WT and G51D overexpression, as 
determined by protein expression analysis. Studies have shown reduced neurite outgrowth 
in WT overexpression models (Takenouchi et al. 2001) including in an iPSC model (Oliveira et 
al. 2015), in support of our results. 
Furthermore, mDA neurons are thought to form dense axonal arborisations and a recent 
study has reported evidence for a decrease in synaptic connections in an A53T α-synuclein 
iPSC-derived PD model (Kouroupi et al. 2017). If branching neurites can be taken as a proxy 
for synaptic connections, our results suggest decreased branching in response to WT and 
G51D α-synuclein overexpression. However, overexpression of A53T α-synuclein did not 
result in a significant decrease in branching neurites in these iPSC-derived cultures although 
there was a decrease by trend, possibly associated with the relatively lower expression of 
A53T α-synuclein compared to the other overexpression models. These results suggest that 
overexpression of WT and mutant G51D α-synuclein can result in perturbations in axonal 
elongation and branching dynamics which may represent early degenerative phenotypes in 




Some limitations that were presented during this study included the need to choose cells in 
areas of lower density to be able to manually follow neurites accurately. As our cultures were 
of relatively high density and produced complex neuronal networks as well as intertwined 
axons, this was challenging. Studies have shown that lower density neuronal cultures induce 
an increase in synaptic sprouting compared to high density cultures, producing an increased 
synapse to neuron ratio due to cell-cell interactions (Cullen et al. 2010; Biffi et al. 2013). 
Although we have developed a method to analyse only transduced neurons, the levels of 
expression, at a single cell level, could not be determined using this platform. Furthermore, 
studies have also identified a role for glial cells in neurite complexity (Lieth et al. 1990; 
Kanemaru et al. 2007). Future studies should look at the expression of microtubule associated 
proteins such as kinesin and dynein to further elucidate the molecular mechanisms associated 
with perturbed α-synuclein expression.   
3.5 Conclusion 
SH-SY5Y PD models were generated using lentiviral vectors expressing α-synuclein and 
characterised for use in subsequent translating ribosome affinity purification (TRAP) 
experiments described in the next chapter. The CMV promoter was found to be the optimal 
promoter for use in long-term expression of exogenous transgenes in SH-SY5Y cultures and 
was used in generating the α-synuclein overexpression models. As yields of mRNA from SH-
SY5Y cells from TRAP were very low, and producing enough cells for use of TRAP in an iPSC-
derived model would be both much more expensive and challenging, the use of iPSC-derived 
neurons as a source of TRAP was not further developed. 
iPSC-derived PD models were also generated for analysis of functional phenotypes associated 




optimal promoter for use in long-term and cell-specific expression of transgenes in neurons.  
Functional phenotypes included metrics such as differentiation capacity and neurite 
dynamics. Functionally, whilst differentiation capacity was unchanged in the iPSC-derived 
models, neurite dynamics were observed to be perturbed in iPSC-derived models of PD. These 
models will be further employed in the study of miRNA differential expression associated with 





Chapter 4 – Translating ribosome affinity purification and RNA 
sequencing to study genome-wide gene expression changes 
induced by α-synuclein 
4.1 Introduction 
4.1.1 Next generation sequencing and Parkinson’s disease research 
Advancements in methodological and computational techniques, such as the advent of next 
generation sequencing (NGS) have revolutionised the field of biological research. This was 
accompanied by improvements in the generation of sequencing data and computational 
algorithm for data analysis, as well as improved molecular biology methods to isolate diverse 
species of DNA such as genomic DNA, histone-bound DNA (ChIP) and cDNA from RNA sources 
ranging from total cellular RNA to small RNAs such as miRNA and ribosome-bound mRNA. 
Furthermore, the GRCh38 (Genome Reference Consortium Human genome build 38), which 
is generated and assembled from whole genome reference sequences of multiple individuals, 
provided a valuable map to which sequencing data can be aligned.   
Microarray hybridisation technologies were the first to be employed to generate large 
datasets of transcriptomic information (Lockhart et al. 1996). Using this platform, studies 
have identified genome-wide differential expression from diverse PD models identifying the 
involvement of multiple pathways including: Ubiquitin-Proteasome system (UPS), oxidative 
stress and vesicle trafficking (Scherzer et al. 2003; Grünblatt et al. 2004; Zhang, James, et al. 
2005; Miller et al. 2006; Yoo et al. 2003; Simunovic et al. 2008; Simunovic et al. 2010). 
Concordance analyses, to evaluate the reproducibility of microarray PD study data sets, have 
been able to identify a transcriptomic profile which may be ‘characteristic’ of PD (Oerton et 




designed to only contain known genetic sequences and may exclude novel transcripts due to 
RNA splicing or editing.   
RNA sequencing (RNA-seq) technology allows for sequencing of individual transcripts without 
the need for hybridisation and associated biases such as non-specific hybridisation and probe 
redundancy (Zhao et al. 2014). As it does not rely on pre-designed complementary sequences, 
this allows for the detection of novel transcripts and transcript isoforms. RNA-seq further has 
the advantages of allowing for quantification of larger data sets, limited only by sequencing 
depth, thus able to achieve a larger dynamic range of expression levels, and greater ability to 
detect low abundance transcripts (Wilhelm et al. 2009). However, with these larger datasets, 
a considerable bioinformatics challenge is created, requiring more complex data analysis. 
An early study employing RNA-seq in neurodegenerative research identified differential 
expression of apolipoprotein splice variants in Alzheimer’s disease brains compared to 
controls (Twine et al. 2011). Another early RNA-seq study analysed control human iPSC-
derived neurons, at different stages of differentiation, identifying several novel long non-
coding RNA (lncRNA) whose expression was drastically changed through the differentiation 
process, suggesting a role in neurogenesis (Lin et al. 2011). In the study of PD, RNA-seq 
analyses of PD patient blood leukocytes (Soreq et al. 2014)(Yasuo 2018), skin (Planken et al. 
2017), CSF (Hossein-Nezhad et al. 2016) and patient derived iPSC neurons (Kouroupi et al. 
2017; Woodard et al. 2014; Lin et al. 2011) as well as non-human models (Hook et al. 2018) 
elucidated systemic disease processes that are not restricted to neurons. PD post-mortem 
brain samples have been analysed using RNA-seq and analysis has found links between 




vesicle release, oligodendrocyte function and immune function (Dumitriu et al. 2015; Riley et 
al. 2014; Henderson-Smith et al. 2016). 
4.1.2 Translatome profiling techniques and advantages over transcriptome analysis 
One of the limitations of RNA-seq transcriptomic analysis is that total mRNA levels do not 
always correlate with the levels of the protein encoded by the mRNAs. Protein abundance is 
regulated by post-transcriptional and translational regulatory mechanisms as well as protein 
degradation (Schwanhäusser et al. 2011; Vogel et al. 2012). In fact, a recent study that 
performed an integrative analysis of the transcriptome and proteome from prefrontal cortex 
of PD patient and control brains showed relatively little overlap between the generated 
transcriptomic data and proteomics data. The authors suggest that this discrepancy could be 
due to the sensitivity of the genome-wide mass spectrometry proteomics technique used 
which has a smaller dynamic range of detection and is unable to characterise and identify as 
many protein coding genes (3558 unique proteins) compared to RNA-seq (17,580 protein 
coding genes) (Dumitriu et al. 2015). Furthermore, the authors mention that post-
transcriptional regulation of mRNAs may also play a role in discordance between the two 
datasets.  
Methods have been developed to analyse the translatome and the actively translating mRNA 
by NGS technologies; these include polysomal profiling, ribosomal profiling and ribosome 
affinity purification techniques. These techniques can be employed to identify disease 
associated translational pathways and are more likely to generate data that correlate better 
to the proteome than whole transcriptome profiling (Wang et al. 2013). Protein synthesis is 
regulated by ribosomal complexes, with each eukaryotic ribosome composed of a large 60S 




separation of ribosome bound mRNAs by sucrose gradient centrifugation, using specialised 
equipment and a highly labour-intensive methodology. Furthermore, these techniques 
require a high amount of cellular starting material, and do not allow for running samples in 
parallel (Mašek et al. 2011; Ingolia et al. 2012).   
To enable cell type-specific profiling of ribosomes from heterogeneous tissues, translating 
ribosome affinity purification (TRAP) was developed (Heiman et al. 2008). This technique 
relies on immunoprecipitation of ribosomes that are tagged by expression of L10a ribosomal 
subunit protein fused with EGFP. This enables affinity purification of the mRNA associated 
with ribosomes. A further refinement to this technique is the expression of the L10a-GFP in 
defined cell populations using cell-specific promoters. This method can be quick and efficient 
and require much less starting material than polysomal or ribosomal profiling. An early 
application of this technique was the study of translational profiles of nigrostriatal neurons 
by use of the dopamine receptor promoter to drive expression of L10a-EGFP fusion protein 
(Doyle et al. 2008). This resulted in the identification of distinct subsets of genes which 
distinguish nigrostriatal neurons from closely related neurons. More recently, a transgenic 
mouse line that expresses L10a-EGFP fusion protein under the control of the TH promoter has 
been generated to monitor mRNA translational profiles of dopaminergic neurons (Dougherty 
2017). mDA neurons are thought to be able to co-release GABA (Tritsch et al. 2012) and, using 
this transgenic mouse model in conjunction with microarray technologies, researchers were 
able to identify an upregulated novel enzyme possibly linked to GABA production in these 
cells (Dougherty 2017).  
Studying mRNAs that are actively being translated should lead to a better understanding of 




Identifying actively translated transcripts that are differentially expressed in PD models will 
help us gain a better understanding of the mechanisms involved in α-synuclein pathology, 
with the ultimate aim of developing therapeutic gene targets or novel biomarkers for PD.  
4.1.3 Library preparation for raw data sequencing acquisition 
NGS analysis of the differentially expressed transcripts requires building of a fragment library 
for sequencing. Library preparation is dependent on research goals and experimental set-up 
such as the species of origin and cellular compartment of the starting material and amount of 
raw data reads required for specific analyses (differential gene expression, novel isoform 
identification). These then inform the decision on choice of sequencing platform used i.e. the 
chemistry of the sequencing technology, with many different commercially available library 
preparation protocols available. 
The choice of sequencing platform should consider research goals and budget, with longer 
reads and paired end reads costing significantly more but achieving more reliable information, 
for example for isoform identification, ease of mapping and transcript identification. 
However, for well annotated genomes, shorter reads are usually readily mapped and 
identified thereby longer reads may not be necessary. Longer read lengths and paired-end 
reads allow for the identification of transcript rearrangements such as single nucleotide 
variants, novel transcripts and gene fusions. As the aim of this study was to look at globally 
differentially expressed genes (DEGs), 50bp single-end reads are sufficient. Furthermore, a 
large data-set is required to generate enough raw reads for DEG analysis, especially for low 
abundance transcripts. However, it is important to note that studies have shown that 
increasing biological replicates is more efficient at achieving robust differential expression 




sample giving diminishing returns on ability to discern differential expression (Liu 2014; 
Schurch 2016). The RNA-seq platform used in this study resulted in approximately 20 million 
reads of 50bp length per sample with 3 biological repeats for each condition, to produce 
robust differential gene expression analysis.  
4.1.4 RNA-seq analysis analysis platform and pipelines  
Interpretation of RNA-seq data requires analysis pipelines which include computer tools and 
algorithms to guarantee quality of raw reads, accurate mapping to the reference genome, 
estimation of transcript expression levels, normalisation and DEG identification (Figure 4.1).  
 
Figure 4.1 – Schematic outlining the processing and steps towards the generation of differential expression analysis from 
TRAP-derived mRNA.  mRNA is first amplified and reverse transcribed to generate a cDNA fragment library.  Library 
preparation is performed by ligating universal and index adapters and amplicons sequenced.  Sequencing raw data reads 
are checked for integrity and mapped to a reference genome. A transcriptome assembly is created and merged together 
and used to normalise expression levels and normalised to produce a list of differentially expressed genes. 
For differential gene expression analysis, many RNA-seq analysis pipelines have been 
developed to produce efficient and reproducible analysis of data.  The tools to analyse 
genomic data can be run on more complex coding software such as R statistical programming 




source web-based platform Galaxy (Giardine et al. 2005) and commercial packages such as 
the Partek suite of analysis tools. With such a compendium of softwares available for the 
complicated analysis required for DEG analysis, there is yet no consensus about which 
methodology produces the most robust and reproducible analysis data. Studies that have 
compared analysis packages have shown the importance of package choice, as their 
integration of different normalisation algorithms can markedly affect data analysis in 
differential gene analysis in terms of specificity and sensitivity of differentially expressed gene 
detection (Conesa et al. 2016; Costa-Silva et al. 2017; Zhang, Jhaveri, et al. 2014; Rapaport et 
al. 2013). These comparative studies note that no single method produces clearly superior 
analyses and have further suggested that the integration and consensus between different 
packages may be best analysed for robust specificity and sensitivity of detection. In this study, 
the Tuxedo package of analysis software (Figure 4.2) was used primarily as it has been 
developed for wet-lab researchers without necessitating the learning of complex 
programming languages. The Tuxedo suite (Trapnell et al. 2012) pipeline (outlined in Figure 
4.2) was used with different combinations of alignment algorithms and reference annotation 
datasets (Figure 4.2 in red) to test the reproducibility of our analysis which is a strategy used 
in RNA-seq, i.e. to compare the results of analysis by different pipelines (Guo et al. 2014). The 
published pipeline consists of software 3 main modules; an alignment module (Tophat), a 





Figure 4.2 -– Schematic outlining pipeline for RNA-seq raw data towards differential expression analysis using Tuxedo 
pipeline (adapted from (Trapnell et al. 2012)) using the Galaxy or Partek platforms.  Input files were parsed and quality of 
reads quality determined using FASTQC.  Reference annotation used was the ENCODE project’s Gencode human hg38 
library which was used to align the raw reads with Tophat or STAR splice-junction aware aligner to produce general 
alignment statistics.  Reads were assembled into a transcriptome assembly and merged by Cufflinks.  Differential 
expression and statistics were determined by the CuffDiff module. 
Raw reads from RNA-seq are initially aligned to a reference genome, with the newer 
generation of aligners such as STAR (Dobin et al. 2013) and Tophat (Kim, Pertea, et al. 2013) 
being able to recognise splice-junctions and map exon-intron junctions to detect alternatively 
spliced transcripts. Currently, the Genome Reference Consortium human reference 38 
(GRCh38) build is the primary genome assembly used for aligning raw reads and contains 
alternative sequences for genomic regions where variability and complexity has been noted.  
Once raw reads have been aligned, they require assembling together to full-length 
transcripts, a process known as transcriptome assembly or reconstruction. Tools that have 
been developed to assemble transcripts include Cufflinks (Trapnell et al. 2012), Scripture 
(Guttman et al. 2010) and Stringtie (Pertea et al. 2015). Transcript assembly and merging can 
be undertaken with or without a reference annotation, usually depending on the availability 
of well-annotated transcriptomes for the species being studied. For humans, several 
reference transcript annotation datasets exist, including Refseq, Ensembl and Gencode. 
Gencode is an additive set of annotations which merges the European EMBL-EBI Ensembl 




as part of the ENCODE project’s follow up to the Human Genome Project whilst RefSeq 
annotations have been developed by the American NCBI (Pruitt et al. 2006). The individual 
transcriptome assemblies are then merged together giving a single merged assembly to 
normalise transcript expression. These full-length transcripts are then quantified and 
normalised to measure relative abundances.   
Finally, for differential expression analysis, the reads and the merged transcriptome assembly 
are run through an algorithm to calculate expression levels in multiple sample conditions and 
tests the statistical significance of these changes. Programs commonly used for differential 
expression analysis include Cuffdiff, DESeq and EdgeR (Anders et al. 2010; Trapnell et al. 2012; 
Robinson edgeR 2009). These programs differ in the type of statistical models used to 
calculate relative abundance and expression with Cufflinks using a read-normalisation 
strategy whereas DESeq and EdgeR use ‘read count-based methods’ (see review (Guo et al. 
2014)), although there is no consensus on the best statistical strategy for DEG analysis (Anders 
et al. 2010).  
4.1.5 Aims 
In this Chapter, I will determine differential gene expression in α-synuclein overexpressing 
SH-SY5Y models that were generated as described in Chapter 3. The aims of the experiments 
are to: 
1) successfully prepare an RNA-seq library from an enriched population of translating 
mRNAs using the TRAP platform; 
2) perform NGS to determine genes that are differentially expressed due to wild-type or 




3) validate differentially expressed genes using molecular and cellular biology techniques 




4.2 Materials and Methods  
4.2.1 Lentiviral transduction of L10a-EGFP into SH-SY5Y PD models 
Lentiviral particles that express the L10a-EGFP fusion protein from the CMV promoter were 
used to transduce undifferentiated control, wild-type and mutant A53T α-synuclein 
overexpression SH-SY5Y cells (generated as described in section 3.2.2), at an MOI of 2. FACS 
sorting was performed as described in section 3.2.1 (Appendix 3). 250,000 cells per sample 
were collected and re-plated onto T25 flasks, separately for each sample.  
4.2.2 Translating ribosome affinity purification and mRNA purification 
FACS sorted samples were passaged and cultured and differentiated (section 2.2.2) on 10cm2 
plates (Corning; #430591). Cells were differentiated for 14 days prior to TRAP processing. 
After 14 days, TRAP was started using the protocol adapted from the original publication 
(Figure 4.3)(Heiman et al. 2014). 
 
Figure 4.3 - Schematic outlining protocol for extracting mRNAs in translating polysomes. L10a, a 60S ribosomal protein 
fused to EGFP is transduced into undifferentiated SH-SY5Y cells. Cells are lysed in buffer spiked with RNase-inhibitors, 
cycloheximide to stall translation and DHCPs to retain polysomes in complex.  These isolated polysome complexes can be 
purified by adding EGFP conjugated magnetic beads to isolated polysome complexes from total RNA 
Briefly, on the day of TRAP, cells had 100µg/ml cycloheximide (Sigma; #C7698) added to 
culture media and incubated for 15mins. Cells were then washed, on ice, with PBS with 
100µg/ml cycloheximide and then lysed with lysis buffer (Table 4.1). Cells were incubated on 




and centrifuged at 2000g for 10mins at 4°C. The supernatant was transferred into a fresh 
chilled microcentrifuge tube with 1/9 volume 300mM DHPC (Avanti Polar Lipids; #850306P) 
and mixed by inversion and incubated for 5mins on ice. To clear the lysate, samples were 
centrifuged at 20000g for 15mins at 4°C and transferred supernatant into fresh chilled 
microcentrifuge tubes. 
Cell-lysis Buffer 
High Salt (0.35M KCl) 
Wash Buffer 
Low Salt (0.15M KCl) 
Wash Buffer 
Manufacturer and Cat. 
No. 
20mM HEPES (pH7.3) 20mM HEPES (pH7.3) 20mM HEPES (pH7.3) VRW; 169241 
150mM KCl 350mM KCl 150mM KCl 
Applied Biosystems; 
AM9640G 
10mM MgCl 10mM MgCl 10mM MgCl 
Applied Biosystems; 
AM9530G 
NP-40 1% (vol/vol) NP-40 1% (vol/vol) NP-40 1% (vol/vol) AG Scientific P1505 
RNase-free H2O RNase-free H2O RNase-free H2O Ambion; AM9938 
Add fresh: Add fresh: Add fresh:  
0.5mM DTT 0.5mM DTT 0.5mM DTT Sigma; D9779 
100g/ml cycloheximide 100g/ml Cycloheximide 100g/ml Cycloheximide Sigma; C7698 
10l/ml RNasin RNasin 1l/1ml RNasin 1l/1ml Promega; N2515 
10l/ml Superasin   
Applied Biosystems; 
AM2694 
EDTA-free protease inhibitor (1 
tablet in 10ml)   Roche; 11836170001 
Table 4.1 – Lysis and wash buffers utilised in TRAP methodology 
300μl of Pierce Protein L magnetic beads (ThermoFisher; #88849) were washed three times 
with 3% w/v nuclease-free BSA in nuclease-free PBS, using a magnetic tube holder. Beads 
were then resuspended in high-salt buffer (Table 4.1). To this, 50µg of each of anti-EGFP 
antibodies 19F7 & 19C8 (Rockafeller Institute) was incubated on a slow-tilt rotator for 1 hour. 
Beads were then collected on a magnet and washed 2 more times with 1ml low-salt buffer 
(Table 4.1). Antibody coated beads were then resuspended in 180µl low-salt buffer with 20µl 
300mM DHPC. Beads in low-salt buffer were added to freshly extracted RNA samples and 
incubated at 4°C overnight on a rocker. 
After overnight incubation of antibody coated beads and RNA samples, beads were collected 




collected by magnet and resuspended in 100µl Agilent absolute RNA Nanoprep kit lysis buffer 
(Agilent; #400753), vortexed and incubated for 10mins at RT to remove beads from polysomal 
complexes. Beads were collected by magnet and RNA, now in lysis buffer, was transferred 
into a fresh chilled microcentrifuge tube and purified using the Agilent absolute RNA 
nanoprep kit, according to manufacturer’s instructions, and resuspended in 30µl RNase-free 
H2O and quantified on a nanophotometer (Geneflow; IMPLEN P300). RNA quality was 
determined using the high sensitivity RNA ScreenTape (Appendix 4)(Agilent; #5067-5579) 
platform on the Agilent 2200 TapeStation (Agilent; #G2964AA).   
4.2.3 RNA amplification and cDNA library preparation for next generation sequencing 
on illumina platform 
cDNA library preparation for NGS requires a choice of sequencing platform, as workflow will 
be determined by this choice. The well-established lllumina platform technology was chosen 
for this study. To begin preparation for entry into the NGS workflow, for the lllumina platform 
requires 4 steps: 1) Having enough starting material; 2) Blunting and A-Tailing of mRNA 3) 
Ligation of adapters that can be read by the RNA-seq machinery and 4) Amplification of ligated 





Figure 4.4 - Schematic outlining the processing of TRAP samples from amplification of RNA to library preparation and 
pooling towards sequencing 
A limitation of the TRAP technique is the low yields of RNA isolated that is not sufficient for 
preparation of cDNA libraries. Thus, in this study, the Seqplex RNA amplification kit (Sigma; 
SEQR) was employed using 10ng of starting material from each sample. The resultant dsDNA 
(150-400 base pairs (bp) fragments) was amplified with PCR in a 96 well qPCR plate (Applied 
Biosystems; #4346906) with SYBR Green (Sigma; #S9430) diluted in 10mM Tris-HCl (Sigma; 
T3038) to monitor the amplification process, in the StepOne quantitative qPCR system 
(Applied Biosystems; #4376357). At this point, the samples were cleaned up with the 
GenElute PCR Cleanup Kit (Sigma; #NA1020), according to manufacturer’s instructions, and 
eluted in 50µl nuclease-free H2O. Amplified samples were treated with primer removal 
enzyme and QC by qPCR as per manufacturer’s instructions and quantified by 
nanophotometry and assayed on the D1000 ScreenTape (Agilent; #5067-558), using the 
Agilent 2200 TapeStation system (Appendix 5).  
Blunting/filling-in and A-tailing was performed in one reaction mixture. Here, 150ng of cDNA 




England Biolabs; #M0203S) and 0.5µl Taq polymerase with 3µl 10x Taq buffer (New England 
Biolabs; #M0273S) with 1µl of 10mM dNTPs (equimolar solution of dATP, dCTP, dGTP and 
dTTP; New England Biosciences; #N0440S, #N0441S, #N0442S, #N0443S) in a 30µl reaction in 
PCR tubes, for each sample separately. This mix was assembled on ice and then incubated at 
12°C for 30 minutes (end polishing), 75°C for 20 minutes (heat inactivate the T4 DNA 
polymerase) and 72°C for 10 minutes (activate A-tailing by Taq polymerase) in a gradient 
thermal cycler (Techne; TC512). 
Adapters compatible with the Illumina hiseq platform were formed by annealing equimolar 
(500µM) concentrations of a universal and index oligonucleotide with 1x Fast digest buffer 
2.1 (New England Biolabs; #B7202S) (Figure 4.5) made up to 50µl in nuclease-free H2O 
(Ambion; #AM9938). The tubes were placed on a heatblock (Techne; DB2D) at 95°C for 3 
minutes. The heat block was removed from the apparatus and allowed to cool to RT slowly 
for 60 minutes. 100ng of end repaired, A-tailed DNA fragments was mixed with 1µl DNA ligase 
(New England Biolabs; #M0202S) and 1µl 10µM annealed oligonucleotides and 10µl 10x ligase 
buffer (provided with DNA ligase) made up to 100µl in nuclease-free H2O.and incubated for 1 
hour at 16°C. Finally, the reaction mix was column purified using the Genelute PCR Clean-up 
kit and eluted in 30µl H2O, ready to proceed to further amplification and library QC. 
              AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
GTTCGTCTTCTGCCGTATGCTCTAXXXXXXCACTGACCTCAAGTCTGCACACGAGAAGGCTAG/5Phos/ 
Figure 4.5 -Sequences of the universal adapter (top) and index adapter (bottom). In blue is the complementary portion of 
the 2 sequences and the unique 6bp index region in the index adapter in red. 2 of these are ligated to flank A tailed 
fragment from TRAP samples. The index adapter includes a 5’ phosphate group to aid in ligation of the adapter to the DNA 
fragments. 
Adapter ligated fragments were amplified using primers which recognise the first 20bps of 
the universal adapter sequence (Amp1) and the first 20bps of the index adapter (Amp2) 




50µl Phusion master mix enzyme (ThermoFisher; #F548S) with 100ng of adapter ligated 
fragments, made up to 100µl with nuclease-free H2O and divided into 5 separate PCR tubes 
for each sample. The PCR tubes (Alpha Labs; #LW2510) were placed in a thermal cycler and 
cycles set to denature at 98°C for 1s, anneal at 60°C for 5s and extend at 72°C for 15s. The 
PCR tubes were removed separately at cycle 9, 11, 13, 15, and 17. 
Molar concentrations were determined for the range of cycles using the NEBnext library 
quant kit for Illumina (New England Biolabs; #E7630) which contains primers which target the 
P5 and P7 Illumina adaptor sequences and as such will quantify only those fragments which 
have had adapters ligated successfully (Appendix 6). The amplification was carried out using 
high ROX conditions in the StepOne qPCR system. Cycle 15 was chosen for pooling and 
analysed on the TapeStation 2200 using the D1000 ScreenTape to work out average library 
size for use in quantification (Appendix 7). Equal quantities of each sample were pooled 
together and purified with the Genelute PCR clean-up system and eluted in 32µl nuclease-
free H2O and concentration determined for the pooled library using the NEBNext library quant 
kit. This sample was stored at -20C and sent away for sequencing. 
4.2.4 Gene expression analysis 
When raw reads are generated, the first step is to assess the raw data for its integrity for 
quality control purposes by programs such as FastQC (Andrews 2010). This program gives an 
overview of potential problems with raw sequencing data before further analysis by 
producing: basic statistics, sequencing quality per base, GC content, sequence duplication, 
overrepresented sequences and kmer content analysis. 
Sequencing results were aligned to a reference genome, GRCh38, using 2 validated alignment 




Software (Ion Torrent; #4485102), to give alignment statistics of mapped reads (Figure 4.6). 
Mapped reads were then assembled to create a final transcriptome assembly using Cufflinks 
and differential expression of genes and transcripts was quantified using Cuffdiff, which form 
the Tuxedo Suite protocol for RNA-seq (Trapnell et al. 2012). In parallel, the Galaxy platform 
for RNA-seq analysis was also used with TopHat and following the tuxedo protocol (Goecks et 
al. 2010) (Figure 4.6).   
         
 
Figure 4.6 - Schematic outlining pipeline for RNA-seq raw data towards differential expression analysis using Partek Flow 
and Galaxy platform using the Tuxedo pipeline  
4.2.5 – Validation of differentially expressed genes by transcript expression analysis by 
RT-qPCR using SYBR Green 
RNA was extracted from day 14 differentiated SH-SY5Y PD models using the mirVana RNA 
extraction kit (Invitrogen; #AM1560) as per manufacturer’s instructions. For cytoplasmic RNA 
purification and isolation, the RNeasy minikit, according to manufacturer’s instructions. RNA 
concentration was measured and 2μg of cDNA was generated with the SuperScriptIII reverse 
transcriptase cDNA kit (Invitrogen; #4376357) using random hexamer priming. Differentially 
expressed genes (DEGs) were chosen from RNA-seq analysis and primers prepared (Sigma) 
for validation by qPCR expression analysis (Table 4.2).  
Choice of normalisation housekeeping gene was determined by running qPCR reactions, for 




SY5Y cells: β-Actin (ACTB), human 60S acidic ribosomal protein P0 (hRPLP0) and 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Španinger et al. 2013). Thus, these 
housekeeping genes were analysed for using Bestkeeper algorithm, which calculates the 
coefficient of variance and standard deviation (SD) of the raw quantitation cycle (Cq) values 
and works out the geometric mean of the Cq values (Pfaffl et al. 2004). This averaged 
geometric mean is then compared with each housekeeping gene separately to establish the 
housekeeping gene with the best correlation to the geometric mean of all selected 
housekeeping genes. Thus, in this study gene expression was normalised to β-Actin (ACTB) 
housekeeping gene. 
  
Table 4.2 -List of primers for validation of DEGs from RNA-seq analysis 
4.2.6 – Protein expression analysis using Western Blot 
Western Blotting was employed to analyse protein expression in SH-SY5Y synucleinopathy 
models for DEGs, as determined by RNA-seq analysis and as described in section 4.2.4. 




#sc271056; 1:1000), UNC119B (Proteintech; #26201-1-AP; 1:1000), CRADD (Santa Cruz; #sc-
377080; 1:1000), SNCA (BDBioscience; #610787; 1:1000), TOMM40 (gift from Prof. Collinson, 







4.3.1 TRAP and library preparation 
4.3.1.1 Translating ribosome affinity purification 
At the end of the 14-day differentiation of the L10a-EGFP transduced SH-SY5Y PD models 
(described in Chapter 3), mRNA in translating polysome complexes were immunoprecipitated 
by TRAP and mRNA was extracted as described in Section 4.2.2. The RNA structural integrity 
in the samples were analysed on the Agilent RNA tapescreen. All samples had a RNA integrity 
number (RIN) (Appendix 4) of over 7 which indicates relatively intact RNA and were deemed 
suitable for further processing (Table 4.3).  





Control 1 6.0 8.2 195 213 
Control 2 12.0 8.0 190 232 
Control 3 17.2 7.9 197 239 
Wildtype 1 13.2 7.9 194 325 
Wildtype 2 13.2 7.9 188 319 
Wildtype 3 18.8 7.6 193 320 
Mutant A53T 1 33.5 7.3 184 320 
Mutant A53T 2 18.8 7.8 189 318 
Mutant A53T 3 18.8 7.5 195 236 
Table 4.3 – Table shows the concentration and RIN of TRAP-derived mRNA, average dscDNA insert fragment size and 
average adapter ligated amplicon size and amplified dscDNA fragment analysis by capillary gel electrophoresis.  
4.3.1.2 NGS library preparation 
RNA amplification was employed to produce double stranded cDNA for processing into a 
sequencing library. The resultant dsDNA was made up of random, overlapping 150-400 base 
pair (bp) fragments and cDNA concentration was quantified by a nanophotometer and Agilent 
DNA Tapestation was used to visualise average size of the fragments (Table 4.3). Thus, 




recommended 150-200bp range, and concentrations were sufficient to proceed with library 
preparation. The library preparation protocol is outlined in section 4.2.3. 
cDNA amplified from TRAP-derived RNA was taken through the library preparation protocol 
and an equimolar concentration of from each sample was pooled together after 
quantification of adapter-ligated amplicons using qPCR. The RNA-seq library was analysed 
using Agilent Bioanalyzer prior to sequencing and this showed a small peak which corresponds 
to primer or primer-dimer contamination (Figure 4.7A). This type of contamination can be 
especially detrimental to achieving accurate sequencing data as smaller sized amplicons are 
preferentially sequenced, thus yielding low quality data. Therefore, a bead-based size 
selection protocol was applied to the pooled sample to remove smaller fragments (<100bp) 
(Figure 4.7B).  
 
Figure 4.7 - Fragment size selection on pooled adapter ligated amplicon.  A) Before size selection with 2 small sized peaks 




4.3.2 RNA-seq Analysis 
4.3.2.1 Raw read general read statistics 
Raw reads were returned as multiple “.fastq” files that contain both the sequencing and 
quality scores. The FASTQC (Babraham Bioinformatics; 
https://www.bioinformatics.babraham.ac.uk/index.html) module on Galaxy was used to 
assess the quality of raw reads and identify any flags in quality of raw data (Figure 4.8). 
Overall, average Phred quality scores for all samples was >38. These scores are logarithmically 
linked to error probability such that a Phred score of 30 represents a 99.9% (1:1000) base call 
accuracy and a score of 40 (1:10000) represents 99.99% base call accuracy. A Phred score of 
over 30 suggests high quality of reads.   
 
Figure 4.8 – Outline of FASTQC module summary output page.  Raw data quality are analysed including: Basic statistics, 
per base sequencing quality, per tile sequence quality, per sequence quality scores, per base sequence content, per 
sequence GC content, per base N content, sequence length distribution, sequence duplication levels, overrepresented 
sequences, adapter content and Kmer content. 
The FASTQC module did however identify flags for per base sequence content at the start of 




the first few bases due to our amplification method. Duplicated sequences and 
overrepresented sequences were also flagged, with sequence BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) showing some of the duplicated sequencing reads 
as a result of rRNA overrepresentation associated with ribosomal preparations such as TRAP. 
Kmer content was also flagged which suggested an enrichment or overrepresentation of 
certain motifs which is linked to duplicated signals. These general read statistics suggested 
good quality of reads but with some overrepresented/overamplified sequences.  This is most 
likely due to the unavoidable need for initial amplification of RNA from a less diverse source 
such as the ribosomal compartment compared to overall total mRNA.     
4.3.2.2 Alignment and general alignment statistics 
In the first instance, both STAR and Tophat splice-aware aligner were used to align the raw 
data to the human genome (GRChg38) and generate mapping alignment statistics for 
individual samples (Figure 4.9). 240 million Illumina HiSeq raw data reads were sequenced 
and showed comparable total reads generated from individual samples ranging from 
2.13x107-2.72x107 with an average of 2.44x107±2.00x106. Mapping and alignment of reads to 
human genome was consistently above 90% for all samples (91.8-94.5% for Tophat and 94.1-
97.0% for STAR). The majority of these reads were uniquely aligned (54.2-62.0% for Tophat 
and 57.8-65.8% for STAR). Multi-aligned reads made up a significant portion of the non-
uniquely aligned reads for both aligners. It is normal for some reads to align to several 
genomic loci due to repetitive sequences or common domains of gene paralogues (Conesa et 





Figure 4.9 – Graph and table showing overall alignment statistics including percentage unique, multi-mapped and unmapped reads using both A) Tophat and B) STAR alignment tool, aligned 





4.3.2.3 Differential expression analysis 
Differential expression analysis was determined using the Tuxedo RNA-seq pipeline, using the 
Galaxy and Partek flow platforms with slight modifications in aligner and reference transcript 
sequence databases (Figure 4.10A). A list of DEGs was generated (q-value <0.05) which 
compared two experimental conditions: 1) Control compared to WT overexpression (effect of 
increased α-synuclein) and 2) WT compared to A53T overexpression models (effect of mutant 
synuclein) from each pipeline. The modified pipelines were compared to determine the 





Figure 4.10 – Pipeline analysis. A) Schematic of the processing of raw data using the Tuxedo suite, with modifications used, 
for determining DEGs from raw data. B,C) A comparison of DEG lists, generated by pipelines outlined in A, for B) Control 
compared to WT α-synuclein overexpression and C) WT α-synuclein compared to A53T α-synuclein (n=3, q>0.05).  Tables 
show Total number of DEGs and number of DEGs showing greater than 2 fold change as well as number and percentage 




The different pipelines (1, 2, 3) revealed 197, 184 and 161 DEGs respectively when control 
samples were compared to WT-synuclein expressing cells (Figure 4.10B). When the WT 
population was compared to the mutant A53T population, the highest number of DEGs in 
analysis for WT compared to A53T was observed in pipeline 2 (425), followed by pipeline 1 
(360) and then pipeline 3 (343) (Figure 4.10C). Regardless of the pipeline used, there were 
more DEGs between WT and A53T populations, compared to control versus WT populations. 
The use of Tophat aligner with either Genode or Ensembl reference transcript annotations 
yielded more DEGs compared to the use of STAR aligner with the Ensembl reference dataset. 
Although the Gencode dataset contains more annotated genes such as pseudogenes that are 
not found in the Ensembl reference annotation, this was not associated with an increase in 
observed DEGs.   
DEGs common between pipelines were also determined. When WT cells were compared to 
control samples, pipeline 1 shared 54.3% and 39.1% of overall DEGs with pipelines 2 and 3 
respectively whilst pipelines 2 and 3 shared the highest amount of common overall DEGs, 
56.5%. Therefore, the use of the same reference transcript annotation here yielded the 
highest number and percentage of common overall DEGs although the use of the same aligner 
with the different reference transcript annotation also showed similar levels of common 
DEGs. Thus, the synergistic effect of the use of a different reference annotation and aligner 
created less reproducibility of DEGs.   
When WT synuclein cells were compared to A53T cells, pipeline 1 shared 50.8% and 42.8% of 
overall DEGs with pipelines 2 and 3 respectively, whilst pipelines 2 and 3 shared 45.0% of 
overall DEGs.  Here, the use of a common aligner yielded the highest number and percentage 




annotation. Again, the use of both a different aligner and reference genome annotation 
created the least reproducibility in common DEGs. This analysis shows how the use of 
different reference transcript annotation datasets and aligners can affect DEG analysis. 
Analysis also suggests that the synergistic effects of the use of a different reference transcript 
annotation and aligner yields the lowest reproducibility in DEGs. 
Overall, DEG analysis identified 33.5% of DEGs common to all 3 pipelines for control compared 
to WT cells and 32.9% for WT compared to A53T populations. However, there were also many 
DEGs identified by only 1 pipeline. As Gencode annotations are the most highly curated, the 
lists generated using this pipeline (pipeline #1) were used as the basis for choice of DEGs taken 
forward and validated by further techniques, with DEGs that were reproduced by more than 
one pipeline prioritised for validation. The top 10 upregulated and downregulated genes 





Figure 4.11 – Top 10 significantly (p<0.05) up-regulated (Green) and down-regulated (Blue) protein coding DEGs, as 
determined using Tuxedo pipeline on the Galaxy platform with Gencode reference annotation, with fold changes and 
functions, between Control and WT (top) and WT and A53T overexpression (bottom)  conditions (n=3). 
4.3.2.4 Pathway analysis 
Gene Ontology (GO) groups together genes of a common pathway to determine biological 
phenotypes (Ashburner et al. 2000). These enrichment analyses included GO terms related to 
cellular and biological function or mapping onto protein interaction and signalling networks 




enrichment analysis for statistical significance (q value <0.05) and for fold changes (> +2 or -
2). DEGs generated from this study were categorised based on their related functions by GO 
and KEGG enrichment using Enrichr online software (Figure 4.12 & Tables 4.3 & 4.4) (Chen, 
Tan, et al. 2013; Kuleshov et al. 2016). KEGG analyses showed non-statistically significant 
enrichment of genes associated with Lysine degradation, Glycerolipid metabolism and 
synthesis and degradation of ketone bodies as well as genes involved in protein processing 
differentially expressed in WT overexpression cultures compared to control (Figure 4.12A). 
KEGG analysis showed a statistically significant enrichment of genes associated with ECM-
receptor interaction, as well as non-statistically significant differential expression of genes 
associated with Notch signalling and Alzheimer’s disease from A53T overexpression 
compared to WT overexpression analysis (Figure 4.12B). Cellular component and biological 





Figure 4.12 - KEGG pathway analysis for DEGs which were >2 fold significant differentially expressed determined by 
Tuxedo with Gencode transcript annotation for conditions A) Control compared to WT α-synuclein overexpression, B) WT 






Table 4.4 – Gene ontology gene set enrichment analysis for cellular component related genes.  Genes were grouped 
together based on common pathways with a p value assigned using Fisher’s exact test proportion test. 
 
Table 4.5 - Gene ontology gene set enrichment analysis for biological function related genes.  Genes were grouped 





4.3.3 Validation of Differentially expressed genes determined by RNA-seq  
4.3.3.1 Evidence based choice of suitable housekeeping gene  
Selection of reference gene is important for qPCR analysis and commonly used housekeeping 
genes such as the 60S acidic ribosomal protein large P1 (RPLP1), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and beta-actin (ACTB) have been identified as being suitable 
endogenous controls in SH-SY5Y cells (Španinger et al. 2013). Many studies have suggested 
that reference housekeeping genes may be differentially expressed between cell types and 
disease conditions and thus it is best to determine the most reliable and stable reference gene 
for use in these cells and experimental conditions. Thus, 3 commonly used housekeeping 
genes were analysed using Bestkeeper (Pfaffl et al. 2004). BestKeeper calculates the 
coefficient of variance and standard deviation (SD) of the raw quantitation cycle (Cq) values 
and establishes the BestKeeper index, which is the geometric mean of the Cq values of 
candidate housekeeping genes. Linear regression analysis showed that the candidate 
reference gene with the highest correlation to the BestKeeper index, with a coefficient of 
correlation of 0.767 and p value of 0.016 was ACTB and the standard deviation was acceptable 
to the algorithm (Figure 4.13).
 
Figure 4.13 – Bestkeeper regression analysis of 3 candidate housekeeping genes: GAPDH, ACTB and HRPLP.  GAPDH (p 
0.047) and ACTB (p 0.016) were determined to have adequate coefficient of correlation, 0.674 and 0.767 respectively, to 
the Bestkeeper index.  Column data analysis including range of raw Cq values, SD and Coefficient of variation.  Graph to 




4.3.3.2 – Validation of DEGs 
cDNA generated from TRAP-derived RNA was used to validate DEGs with >2 fold change that 
were statistically significant (q value <0.05), based on potential links to pathological processes 
and pathways (Figure 4.11). Selected DEGs were confirmed by independent qPCR analysis 
using total RNA and TRAP-RNA and cytoplasmic-RNA which excludes nuclear RNA and 
represents a closer compartment to the TRAP samples. As TRAP measures changes in actively 
translating mRNAs, Western blot analysis was used to measure changes in protein expression 
where an appropriate antibody was available. 
Unexpectedly, one of the DEGs that was identified when WT and A53T samples were 
compared was α-synuclein itself, which showed an approximately 2-fold change increase in 
average α-synuclein transcript levels in the A53T mutant cultures compared to WT cultures 
(Figure 4.14A). To determine whether this was a bona fide result, qPCR analysis was employed 
to analyse transcripts in our cultures (Figure 4.14B). It does appear as though there is a 
difference between α-synuclein transcript expression levels in the A53T models (116.2±28.4) 
and the WT models (47.4±1.75). The difference between the WT and A53T α-synuclein 
transcript levels was not significant (p<0.06), as determined by one-way ANOVA using Tukey 
multiple comparisons testing. As this was determined subsequent to TRAP isolation and RNA 
sequencing, this does mean that downstream analysis should be interpreted with this result 





Figure 4.14 -A) RNA-seq analysis of differential expression of SNCA showing a 2 fold increase α-synuclein transcript 
expression in A53T compared to wild-type overexpression. B) qPCR transcript analysis (±SD) of SH-SY5Y cultures showing 
a significant increase in α-synuclein transcript levels between A53T and non-transduced cultures (p<0.006) and non-
significant change between WT and A53T and control and WT cultures. One-way ANOVA, Tukey post-hoc test (n=4).  ** 
p<0.01 (±SD) 
Thus, despite care during the experiment to ensure that the SH-SY5Y cells were transduced 
at equivalent MOI for the different vectors, approximately 2-fold increase was detected in 
A53T compared to WT overexpression models. The implication of this observation is that 
these models are not “perfect” and that DEGs that are detected between these two groups 
may be attributed to either increased synuclein expression or mutant synuclein expression, 
or both.  
4.3.3.2.1 – Cytoskeletal protein encoding genes 
There were a number of cytoskeletal protein coding genes that were found to be differentially 
expressed in our analysis. As neurite dynamics were perturbed in iPSC-derived PD models 
(described in Chapter 3.3.3), two cytoskeletal genes that were highly differentially expressed 




domain containing 3 protein, was found to be increased in WT and A53T samples compared 
to control by 14.72 and 7.21-fold, respectively (Figure 4.15A). FGD3 is involved in p75 
neutrophin receptor-mediated signalling and survival, and process formation in neurons 
(Hayakawa et al. 2008) and has previously been found to be upregulated in whole blood 
samples from AD patients compared to control samples by whole-genome microarray (Bai et 
al. 2014). 
The second DEG was SPON2, which was found to be decreased in WT and A53T samples 
compared to control by 4.63 and 5.35-fold, respectively (Figure 4.15A). SPON2 encodes an 
extracellular matrix protein that has been shown to promote outgrowth of neurites in 





Figure 4.15 – Gene expression analysis for DEGs which encode cytoskeletal proteins FGD3 and SPON2. A) RNA-seq results 
table showing Log2 fold change, fold change, q value and significance as well as number of different pipelines the DEG 
was identified in (n=3). Total, cytoplasmic and TRAP-RNA gene expression analysis (±SD) for B) FGD3 and C) SPON2 using 
the ΔΔCt method with ACTB used as a housekeeping control (n=3). One-way ANOVA, Tukey post-hoc test (n=4). *p<0.05, 
** p<0.01, *** p<0.001 
qPCR gene expression analysis for FGD3 showed a significant upregulation in A53T 
overexpressing cells (2.05±0.21) compared to both control (1.00±0.42) and WT 
overexpressing cells (0.80±0.08), in terms of total RNA samples (Figure 4.15B). However, no 
significant differences were observed in cytoplasmic RNA samples. Contradicting TRAP-RNA 
gene expression analysis showed a significant decrease in A53T overexpressing cells 
(0.73±0.04) compared to control (1.00±0.10) (Figure 4.15B).   
qPCR gene expression analysis for SPON2 showed a significant increase in A53T cells 




samples (Figure 4.15C). Expression of SPON2 in cytoplasmic RNA A53T overexpressing cells 
was also increased significantly (1.47±0.03) compared to control (1.00±0.12) and WT 
overexpressing cells (0.96±0.19) in cytoplasmic RNA samples. Both of these results 
contradicted RNA-seq analysis results where SPON2 was observed to be decreased, whilst no 
significant changes were observed in TRAP-RNA samples (Figure 4.15C).  
4.3.3.2.2 – Mitochondrial protein encoding genes 
PD has long been associated with mitochondrial dysfunction (described in section 1.4.7.2), 
with several disease association genes having been identified including Parkin and PINK1 
(described in section 1.5.2 and 1.5.3). Several mitochondrial protein encoding genes were 
differentially expressed in RNA-seq analysis and two of these were taken forward to 
validation.   
The first DEG chosen for validation was the translocase of outer mitochondrial membrane 40, 
TOMM40, which was identified to be increased in A53T overexpressing cells compared to 
control and WT overexpressing cells by 52.35 and 60.97-fold, respectively (Figure 4.16A). 
TOMM40 encodes the channel forming mitochondrial protein of the translocase of 
mitochondrial outer membrane complex. Downregulation of this protein has been associated 
with reduced mitochondrial protein import and increased mitophagy of outer mitochondrial 
membrane proteins by PINK/Parkin (Bertolin et al. 2013). Decreased TOMM40 mRNA has also 
been observed in PD patient brain and α-synuclein WT and mutant overexpression B103 rat 
neuroblastoma models (Bender et al. 2013). 
The second DEG SLC25A12 was identified to be increased in both WT and A53T overexpressing 
cells compared to control by 9.95 and 15.02-fold, respectively (Figure 4.16A). SLC25A12, 




malate-aspartate shuttle (MAS) activity (Ramos et al. 2003) and expressed in neurons (del 
Arco et al. 1998) and SH-SY5Y cells (Menga et al. 2015). SLC25A12-KO mouse models have 
been described to have deficits in motor coordination and a decrease in striatal dopamine 





Figure 4.16 - Gene expression and protein expression analysis for DEGs which encode mitochondrial proteins TOMM40 
and SLC25A12.  A) RNA-seq results showing Log2 fold change, fold change, q value and significance as well as number of 
different pipelines the DEG was identified in. Total, cytoplasmic and TRAP-RNA gene expression(±SD) analysis for B) 
TOMM40 and C) SLC25A12 using the ΔΔCt method with ACTB used as a housekeeping control (n=3).  Western blot protein 
expression analysis for D) TOMM40 and E) SLC25A12 as well as F) their respective densonometric analysis with ACTB (n=3). 




qPCR gene expression analysis for TOMM40 showed a significant increase in the A53T 
overexpressing cells (1.96±0.34) compared to both control (1.00±0.38) and WT 
overexpressing cells (0.85±0.12) when total RNA was analysed (Figure 4.16B). However, both 
cytoplasmic and TRAP-derived RNA samples did not show any significant differences in 
TOMM40 expression between the three groups (Figure 4.16B). Furthermore, protein 
expression analysis did not show any significant changes (Figure 4.16D, F). 
qPCR gene expression analysis for SLC25A12 showed a significant increase in A53T 
overexpressing cells (1.63±0.34) compared to control (1.00±0.06) and an increase nearing 
significance in WT overexpressing cells (1.48±0.06) compared to control cells when total RNA 
was analysed, replicating the RNA-seq results although with more modest fold changes 
(Figure 4.16C). No significant changes were observed however in both cytoplasmic or TRAP-
RNA samples although TRAP-RNA gene expression analysis did show a non-significant 
increase in WT (1.22±0.35) and A53T (1.76±0.54) overexpressing cells compared to control 
(1.00±0.07)(Figure 4.16C). Protein expression analysis showed no significant differences 
between samples (Figure 4.16E, F). 
4.3.3.2.3 – Protein transport and dopamine signalling protein encoding genes 
Impaired intracellular trafficking (reviewed in (Hunn et al. 2015) and described in section 
1.4.6.5) as well as perturbations in dopamine signalling pathways have been implicated in the 
pathology of PD. Thus, one DEG chosen for validation was UNC119B, which was identified to 
be increased in A53T overexpressing cells compared to both control and WT overexpressing 
cells by 54.57 and 47.18-fold (Figure 4.17A), respectively. This gene encodes a cargo adaptor 
transport factor (lipid-binding chaperone B) protein whose homologue in C. elegans is 




identified as co-aggregating with poly-GA dipeptide repeats in a primary rat cortical neuron 
model of amyotrophic lateral sclerosis (May et al. 2014).   
The other DEG chosen for validation was RGS8, which was significantly decreased in A53T 
overexpressing cells compared to WT overexpressing cells by 8.63-fold (Figure 4.17A). This 
gene encodes the regulator of G protein signalling protein which is expressed in the brain and 
densely so in Purkinje cells (Kuwata et al. 2008), and is thought to regulate potassium currents 
(Saitoh et al. 1997) and signalling via the G-protein-coupled receptors including the dopamine 
receptor DRD2 (Werner et al. 1996). Previously, NGS analysis showed reduced expression of 
RGS8 in a transgenic mouse model of Spinocerebellar ataxia type 2 neurodegeneration 
(Dansithong et al. 2015) and was predicted to cause perturbation, specifically an increase, in 
intracellular Ca2+ (Marambaud et al. 2009). 
qPCR gene expression analysis for UNC119B showed a significant increase in A53T 
overexpressing cells (1.69±0.32) compared to control (1.00±0.21) in total RNA samples as well 
as a non-significant increase between A53T (1.43±0.22) and control (1.00±0.22) in TRAP-RNA 
samples, as observed in the RNA-seq results (Figure 4.17B). Protein expression analysis also 
showed non-significant increases in WT and A53T overexpressing cells compared to control 
(Figure 4.17D, E). 
qPCR gene expression analysis for RGS8 showed a significant decrease in WT (0.58±0.18) and 
A53T (0.40±0.00) overexpressing cells compared to control in total RNA samples (Figure 
4.17C).  However, cytoplasmic RNA samples showed a significant increase in WT 
overexpressing cells (1.81±0.38) compared to control (1.00±0.10) (Figure 4.17C). TRAP-RNA 
gene expression analysis showed non-significant decreases in both WT and A53T 





Figure 4.17 - Gene expression and protein expression analysis for DEGs which encode protein transport and dopamine 
signalling proteins UNC199B and RGS8. A) RNA-seq results showing Log2 fold change, fold change, q value and significance 
as well as number of different pipelines the DEG was identified in. Total, cytoplasmic and TRAP-RNA gene expression 
analysis (±SD) for B) UNC119B and C) RGS8 using the ΔΔCt method with ACTB used as a housekeeping control (n=3). D) 
Western blot protein expression analysis for UNC119B as well as E) respective densonometric analysis (n=3). One-way 





4.3.3.2.4 – Oxidative stress response and apoptosis signalling encoding genes 
Oxidative stress response (described in section 1.4.7.2) as well as apoptotic pathways have 
been implicated in cellular loss in PD. FOXO1 was identified to be significantly decreased in 
WT cells compared to control by 59.95-fold (Figure 4.18A). FOXO1 encodes the forkhead box 
protein 1 which is a member of the FOXO transcription factors that are thought to promote 
expression of genes associated with autophagy and UPS (Webb et al. 2014). Autophagy genes 
are activated in neurons in response to FOXO1 nuclear localisation in mice (Xu et al. 2011). 
Whole human genome microarray of prefrontal cortex tissue from PD patients showed FOXO1 
was significantly increased in PD patients, compared to control (Dumitriu et al. 2012). 
Another DEG chosen for further validation was CRADD which was found to be significantly 
higher in A53T compared to WT overexpressing cells by 12.13-fold (Figure 4.18A). CRADD 
encodes an adapter protein which contains a caspase recruiting domain and is a part of the 
caspase-2 activating complex (Ribe et al. 2012). Mutations in CRADD that result in loss of 
CRADD/caspase-2 mediated apoptosis are associated with megalencephaly due to 
perturbations in developmental neuronal apoptosis (Di Donato et al. 2016). Overexpression 
of CRADD is associated with increased caspase-2 dependent apoptosis as well as formation of 
perinuclear aggregates (Jabado et al. 2004) and a recent study suggested a role for CRADD-
targetting peptides in protecting against rotenone-induced neurotoxicity in SH-SY5Y cells with 
possible therapeutic use as a novel neuronal cell apoptosis inhibitors (Jang et al. 2016).  
qPCR gene expression analysis for FOXO1 showed a significant increase in A53T cells 
(1.90±0.21) compared to WT overexpressing cells (0.76±0.05) and control (1.00±0.41) in total 
RNA samples, however these were contradictory to the decreases identified from RNA-seq 
experiments (Figure 4.18B).  TRAP-RNA gene expression analysis however showed no 




qPCR gene expression analysis for CRADD showed very significant upregulation in A53T 
overexpressing cells (2.95±0.33) compared to both control (1.00±0.32) and WT 
overexpressing (0.91±0.05) in total RNA samples (Figure 4.18C). TRAP-RNA gene expression 
analysis and protein analysis showed a modest yet non-significant increase in A53T 
overexpressing cells (1.45±0.42) compared to control (1.00±0.16) and WT overexpressing 
cells (1.20±0.15) (Figure 4.18C). Furthermore, protein analysis also showed a similar, modest 
yet non-significant increase in A53T overexpressing cells (1.45±0.84) compared to control 
(1.00±0.35) and WT overexpressing cells (1.17±0.54) (Figure 4.18D, E). This increase in CRADD 





Figure 4.18 - Gene expression and protein expression analysis for DEGs which encode oxidative stress response and 
apoptotic proteins FOXO1 and CRADD. A) RNA-seq results showing Log2 fold change, fold change, q value and significance 
as well as number of different pipelines the DEG was identified in. Total  and TRAP-RNA gene expression analysis (±SD) 
for B) FOXO1 and C) CRADD using the ΔΔCt method with ACTB used as a housekeeping control (n=3). Western blot protein 
expression analysis for D) CRADD as well as F) respective densonometric analysis (n=3). One-way ANOVA, Tukey post-hoc 




4.3.3.2.5 – microRNA biogenesis encoding gene 
microRNA (miRNA) dysregulation has been previously identified as associating with disease 
and many miRNAs have been found to be differentially expressed in neurodegenerative 
conditions including PD (described in chapter 5). A very important component of the miRNA 
biogenesis pathway is DGCR8. Deletion of DGCR8 in 22q11.2 deletion multisystem syndrome 
has been associated with schizophrenia (Merico et al. 2014) and early onset PD with mDA loss 
and LB formation (Butcher et al. 2017). Furthermore, a recent study using a neural stem cell 
line from DGCR8-KO mouse embryonic brains observed that the cells were unable to 
differentiate towards any neuronal phenotypes, with RNA-seq analysis identifying a 
perturbation in multiple cellular functions (Liu et al. 2017). DGCR8 was identified as being 
significantly downregulated in WT overexpressing cells by 9.58-fold compared to control as 
well as non-significantly lower in A53T overexpressing cells by 3.94-fold compared to control 
(Figure 4.19A).   
qPCR gene expression analysis in total RNA samples showed a significant increase in A53T  
overexpressing cells (1.85±0.08) compared to both control (1.00±0.46) and WT 
overexpressing cells (0.74±0.07), which was contradictory to the RNA-seq data (Figure 4.19B). 
However, no significant changes were detected in either cytoplasmic RNA samples and TRAP 
RNA-samples (Figure 4.19B). Furthermore, protein expression analysis showed a modest 
decrease in both WT (0.88±0.57) and A53T (0.52±0.41) overexpressing cells compared to 






Figure 4.19 – Gene expression and protein expression analysis for DGCR8 which encode a protein involved in miRNA 
biogenesis. A) RNA-seq results table showing Log2 fold change, fold change, q value and significance as well as number of 
different pipelines the DEG was identified in. B) Total, cytoplasmic and TRAP-RNA gene expression analysis (±SD) for 
DGCR8 using the ΔΔCt method with ACTB used as a housekeeping control (n=3). C) Western blot protein expression 
analysis for DGCR8  as well as D) respective densonometric analysis (n=3). One-way ANOVA, Tukey post-hoc test (n=4). 
*p<0.05, ** p<0.01. 
4.3.3.2.6 – Conclusions from validation studies 
RNA-seq validation produced some replication of the results, although the majority of 
analyses were inconclusive or conflicting. For instance, the increase in FGD3 expression in WT 
and A53T overexpressing cells from RNA-seq analysis was only partially validated in total RNA 




opposite result was observed in TRAP-RNA, with a decrease in expression in A53T 
overexpressing cells compared to control.  
Overall, the observed changes in TOMM40, SLC25A12, UNC119B and CRADD genes in the 
RNA-seq experiments were only partially validated in total RNA samples, but not in qPCR 
analyses of cytoplasmic or TRAP RNA, nor protein expression analyses. In the TRAP-RNA 
samples, SLC25A12, UNC119B and CRADD showed a trend towards significance in replicating 
the observed RNA-seq data. In the case of RGS8, qPCR analyses of total and cytoplasmic RNA 
partially replicated the RNA-seq results and there were also non-significant trends in the same 
direction using TRAP-RNA. 
Gene expression analysis for FOXO1 showed contradictory results in comparison to RNA-seq 
data in both total and TRAP-RNA whilst the observed changes in DGCR8 in RNA-seq 
experiments could be not validated in any of the RNA or protein samples. 
4.4 Discussion 
In this chapter, RNA sequencing was undertaken to identify mRNAs that may be differentially 
expressed when wild-type (WT) or mutant (A53T) a-synuclein is overexpressed in SH-SY5Y 
cells, using the TRAP technique to isolate putative mRNAs that were being actively translated 
in translating ribosome complexes. The lists of DEGs were analysed bioinformatically and a 
selection of genes were validated by qPCR and Western blot analyses. 
During the bioinformatic analysis, raw reads from the sequencing were validated using the 
FastQC module. As mentioned, several flags were identified, most notably duplicated 
sequences and overrepresented sequences. These sequences were mostly rRNA sequences, 




Duplication is also a common artefact of starting NGS experiments using low input 
translatome samples, with lower duplication indicating a higher complexity of the samples 
(Song et al. 2018). Notably, high fold changes (up to Log2x15 i.e. >30000 fold change) were 
observed in all three pipelines and furthermore, the different pipelines showed only partial 
overlap of DEGs between the different groups. This raised some concern regarding the quality 
of the RNA-seq analysis however, research has suggested that ribosomal preparations, as 
compared to total RNA NGS experiments, are likely to create decreased diversity and 
complexity of transcripts as pre-mature mRNAs are eliminated (Zhang et al. 2015). Whilst 
these flags suggested that there may be some compromise to the raw data quality, power 
and false discovery rate (FDR) a recent study has suggested that PCR duplication from pre-
amplification and amplicon amplification, paired with single-end reads produces up to 66% of 
reads are PCR-duplicates (Parekh et al. 2016). 
Another possible explanation as to why the duplication and overrepresented sequences flags 
were raised is the fact that pre-amplification was required due to the low starting yield of 
RNA from TRAP.  Amplified low input RNA-seq is thought to further decrease the overall 
complexity of library preparations. High duplication rates have been reported, across all 
amplification platforms tested, in recent studies comparing commercial RNA amplification 
kits. The SeqPlex kit that was used in this experiment has been shown to generate relatively 
high PCR duplicates and rRNA duplication (Shanker et al. 2015). However, according to the 
manufacturer’s literature, the SeqPlex amplification kit amplifies rRNA less efficiently than 
mRNA. Furthermore, SeqPlex performed well in rRNA depletion, read alignments as well as 
other measures such as coverage in a comparative study of RNA amplification kits (Mao et al. 




duplications and rRNA contamination is an expected and common result of both translatome 
profiling and the amplification processes required for taking such low yield RNA samples 
towards NGS sequencing. A recent study comparing pre-amplification kits suggested that 
biases arising from RNA amplification protocols can easily confuse or mask true biological 
effects (Mao et al. 2014).   
Differential gene expression analysis was performed using slight modifications on the Tuxedo 
RNA-seq analysis pipeline, which is a commonly used, well characterised pipeline. The Tuxedo 
pipeline uses the most well annotated reference transcript assembly (Gencode) and this 
generated a list of DEGs for further validation. Differential expression analysis using this 
pipeline showed that α-synuclein perturbations resulted in the up/down-regulation of many 
genes: 197 DEGs for Control versus WT cells and 360 DEGs for WT versus A53T cells. 
Unfortunately, as mentioned in this chapter, RNA-seq analysis also detected an increase in 
expression of A53T mutant α-synuclein compared to expression of WT α-synuclein in the WT 
overexpression model which may confound the analysis. 
Analysis of the reproducibility of DEGs between pipelines showed only some common DEGs 
between all 3 pipelines employed. Overall 33.5% of genes were detected in all 3 pipelines for 
Control compared to WT analysis and 32.9% of genes were detected by all 3 pipelines in WT 
and A53T analysis.  The least reproducibility was observed when using both a different aligner 
and a different reference transcript annotation dataset together. Furthermore, there are 
many more factors which can affect the reproducibility of analysis which were not tested. 
Increasing the number of biological repeats has been identified as being important to 
improving the robustness of DEG analysis. A recent study comparing two conditions has 




identified by the total 48 biological replicates used in the study were detected (using 11 
different pipelines) of (Schurch et al. 2016). To reproduce >85% of DEGs determined by 48 
replicates required over 20 biological replicates. Thus, for increased DEG detection sensitivity, 
further biological repeats would be advantageous. 
Enrichment analysis (or functional enrichment analysis) was performed on statistically 
significantly differentially expressed gene sets which showed >2 fold differential expression. 
This is a statistical method used to identify classes or pathways of genes which may be 
functionally related with disease phenotypes. KEGG pathway enrichment for control 
compared to WT synuclein overexpressing cells showed only one statistically significant 
enriched pathway, Lysine degradation. GO cellular pathway analysis showed significant 
enrichment of actin filament branch point genes/proteins, whilst GO biological function 
pathway analysis showed significant enrichment of regulation of transcription, dendrite 
extension and cellular response to UV-A pathways. Thus, enrichment analysis suggests a role 
for the lysine amino acid degradation process as well as actin filament and dendrite extension 
pathways, which are known to be perturbed in PD. As noted in section 3.2.3, neurite dynamics 
were determined to be perturbed in iPSC-derived mDA cultures. These results suggest that 
formation of neurites may play a part in α-synuclein-associated pathology, as has been 
previously described (Liu et al. 2013; Cartelli et al. 2016; Takenouchi et al. 2001). 
KEGG pathways enrichment analysis using genes differentially expressed in WT versus A53T 
overexpressing cells showed one statistically significant enriched pathway, the extracellular 
matrix-receptor interaction pathway. Furthermore, GO cellular pathway analysis showed 
significant enrichment of perinuclear endoplasmic reticulum lumen (where proteins are 




analysis showed significant enrichment of biofilm matrix organisation, paranodal junction 
assembly and ceramide metabolic processes. Thus, enrichment analysis for this analysis 
suggests a role for extracellular matrix related pathways as well as protein synthesis, actin 
body and assembly of the paranode junction (where myelinating glia meets neuronal axons).  
Validation was performed on some interesting targets that may be involved in variable 
pathological pathways, using qPCR transcript and Western blotting protein analysis 
techniques. Overall, these analyses were unable to replicate the high fold changes seen in 
RNA-seq analysis. An attempt was made to analyse the amplified cDNA product, prior to 
adapter ligation and further amplification, to attempt to identify whether this discrepancy 
arose due to amplification, but did not produce meaningful results (data not shown; very high 
error bars), most likely owing to the fragmented nature of the amplification product. 
Interestingly, the expression of α-synuclein at both the protein and transcript level was 
increased significantly using qPCR and Western blotting and this correlated well to RNA-seq 
analysis. 
4.5 - Conclusions 
The results presented suggest that adequate control, such as control of fragment size, 
amplicon concentration, primer-dimer removal, etc., was taken to produce the pooled library 
for sequencing. This resulted in the generation of raw data with relatively little differences in 
number of read, read quality control checks, and alignment statistics between samples. 
However, there may have been some overamplification associated with our library 
preparation protocol.  
RNA-seq DEG analysis showed differential expression of genes that may be related to α-




overrepresentation of several molecular, cellular and pathological pathways. Although some 
of the RNAseq data could not be reproducibly validated using gene expression or protein 
expression techniques, these could be studied in a more physiologically relevant model such 
as iPSC-derived neurons to confirm these results. Further analysis of the RNAseq data may 





Chapter 5 - miRNA profiling and differential expression analysis 
in iPSC-derived neurons 
5.1 Introduction 
5.1.1 miRNA biogenesis and function in mDA neurons 
miRNA are a class of small RNAs, originally discovered in C. elegans, that have been shown to 
be involved in a myriad of cellular regulatory mechanisms (Lee et al. 1993). miRNA biogenesis 
is initiated by RNA polymerase II mediated transcription to produce primary miRNAs that are 
processed by a miRNA processing complex containing the RNase III enzyme Drosha and 
DGCR8 into pre-miRNA that is subsequently exported from the nucleus by Exportin-5 (Yi et al. 
2003)(Figure 5.1). In the cytoplasm, pre-miRNAs are processed into ~22nt double stranded 
miRNAs by the RNase III enzyme Dicer (Bernstein et al. 2001). Strands unwind to produce one 
strand which functions as a mature miRNA by incorporating target mRNA into a 
ribonucleoprotein complex known as the RNA-induced silencing complex (RISC). The mature 
miRNA strand is usually associated with Argonaute 2 (Ago2) protein which is involved in target 
mRNA cleavage and degradation (Okamura et al. 2004; Ender et al. 2010). Mature miRNAs 
can downregulate target gene activity by binding to target sequences in 3’ untranslated 
region (UTR) or open reading frame (ORF) region of mRNAs, leading to inhibition of translation 
or initiating the cleavage and degradation of target mRNA (Figure 5.1). Inhibition or cleavage 
mechanisms are alternatively employed based on the degree of complementarity between 
the miRNA and target mRNA. A single miRNA may target multiple, possibly hundreds, of 
targets simultaneously and may act together synergistically to inhibit translation (Selbach et 
al. 2008). Likewise, protein encoding mRNA may have binding sites for several miRNAs. 
Furthermore, several miRNA have been observed to be contained together within clusters on 





Figure 5.1 – The miRNA processing pathway.  Primary miRNA are transcribed by RNA polymerase II and then cleaved by 
the Drosha-DGCR8 complex to generate a hairpin pre-miRNA.  Pre-miRNA is exported from the nucleus by Exportin-5 to 
the cytoplasm where the RNAse Dicer cleaves pre-miRNA to mature miRNA duplex.  The passenger strand is degraded and 
the functional miRNA strand can then be incorporated into the RNA-induced silencing complex (RISC) with Ago2 to target 
mRNA for translation repression or cleavage (Winter et al. 2009). 
The first reported association between miRNA regulation and mDA neuron function was 
described in a study in which a Cre-mediated deletion of Dicer in mDA neurons derived from 
mouse ESCs was generated (Kim et al. 2007). This deletion resulted in a near complete loss of 
dopaminergic neurons, due in part to increased apoptosis and reduced neurogenesis. These 
observations were replicated in vivo in a mouse model harbouring an mDA-specific deletion 
of Dicer, with behavioural studies revealing reduced locomotion in an open-field assay. 
Further studies in murine Dicer mDA-specific deletion models have observed additional 
evidence of dysregulation of mDA function with mDA neuron loss and behavioural deficits 
(Cuellar et al. 2008; Pang et al. 2014). These results suggested that miRNA regulatory proteins 
are essential for the terminal differentiation and/or maintenance of mDA neurons.   
Other miRNA biogenesis proteins have also been associated with perturbed mDA function. 




post-mortem analysis of patients with this syndrome exhibit mDA neuron loss (Butcher et al. 
2013). The syndrome has also been found to result in reduced motor function and 
parkinsonian symptoms (Roizen et al. 2010). 
Currently, studies have linked miRNAs to diverse PD-associated pathways, with the discovery 
of miRNAs associated with α-synuclein regulation (Junn, Lee, et al. 2009; Doxakis 2010), 
midbrain dopaminergic neuron differentiation (Yang et al. 2012), neuroinflammation (Thome 
et al. 2016) and mitochondrial function (Minones-Moyano 2011). Furthermore, differential 
miRNA expression has been observed in PD patients (Miñones-Moyano et al. 2011; Hoss et 
al. 2016) and various α-synuclein PD models (Kong et al. 2015; Thome et al. 2016). Specific 
mechanisms of potential miRNA-associated PD pathology are discussed in detail in the next 
section (5.1.2). 
5.1.2 miRNAs associated with PD mechanisms 
5.1.2.1 miRNA regulation of familial PD-associated genes 
miR-7 is mainly expressed in neurons and was the first miRNA shown to bind to the 3’UTR of 
α-synuclein mRNA inducing a downregulation of α-synuclein protein (Junn, Lee, et al. 2009). 
This observation was replicated in another study that showed that overexpression of miR-7 
significantly reduced α-synuclein mRNA and protein levels in murine cortical neurons (Doxakis 
2010). Furthermore, miR-7 has been shown to be reduced in PD patient brains and loss of 
miR-7 leads to accumulation of α-synuclein in an in vivo mouse model (McMillan et al. 2017). 
This miRNA has also been shown to inhibit neuronal apoptosis in SH-SY5Y PD models (Li et al. 
2016) and can target the Nod-like receptor protein 3 inflammasome and inhibit microglial 




miR34b and miR34c are located on chromosome 11q23 and transcribed as a single non-coding 
precursor. In a microarray screen, these two mature miRNAs were both found to be depleted 
in SNpc brain tissue of PD patients compared to control brains (Miñones-Moyano et al. 2011). 
Although the authors noted that this could be as a result of a loss of dopaminergic neurons in 
the PD patients, a reduction was also noted in frontal cortex and cerebellum, where little 
degeneration had occurred. This was coupled with a reduction in Parkin and DJ1 protein, two 
proteins associated with familial PD, as well as mitochondrial function and oxidative stress 
response pathways, respectively. Furthermore, more recent studies have also shown that 
inhibition of these miRNAs in SH-SY5Y cells can result in increased α-synuclein expression and 
that these miRNA can directly target the 3’UTR of α-synuclein mRNA (Kabaria et al. 2015).    
Direct binding of miRNA has been described for other PD-associated protein mRNAs. Loss of 
DJ-1 protein function is associated with autosomal recessive familial PD and miR-494 has been 
observed to directly bind to DJ-1 mRNA. miR-494 is highly expressed in mouse brain tissue 
and overexpression has been noted to repress expression of DJ1 protein in 3T3 cells, making 
them more susceptible to oxidative stress (Xiong et al. 2014). Furthermore, LRRK2 is 
upregulated in PD patient brains compared to controls and miR-205 was determined to 
regulate LRRK2 expression by direct targeting of its mRNA in primary neuronal cultures, with 
its overexpression downregulating LRRK2 protein expression (Cho et al. 2012). Moreover, 
miRNAs have been identified that may act on pathways that affect α-synuclein aggregation, 
for example miR-16-1 which is thought to target heat shock protein 70, a protein that is known 




5.1.2.2 miRNAs in mDA development and function 
The discovery of differential expression of miR133b in PD patient brain samples was coupled 
with a hypothetical model whereby miR-133b expression functions within a negative 
feedback circuit that suppresses paired-like homeodomain transcription factor 3 Pitx3 
expression and regulates mDA neuron differentiation or maintenance (Kim et al. 2007). 
Exosome-mediated miR-133b exchange, from rat mesenchymal stromal cells to primary 
cortical neurons, has also been reported to contribute to the regulation of neurite outgrowth 
(Xin et al. 2012). Furthermore, levels of miR-133b are reportedly reduced in the plasma of PD 
patients compared to control (Zhang, Yang, Hu, et al. 2017). 
miRNA expression profiling of brainstem samples from A30P transgenic mice identified 
miRNAs that were differentially expressed compared to control mice, including miR-132 
which was significantly downregulated in the transgenic mice (Gillardon et al. 2008). This 
miRNA was identified as potentially being involved in mDA function and has been shown to 
be enriched in neurons, with overexpression of this miRNA in rat primary cortical neurons 
able to induce neurite outgrowth and conversely inhibition attenuated outgrowth by 
regulation of levels of GTPase-activating protein, p250GAP (Vo et al. 2005). Another study 
conducted a miRNA array screen in mouse ESCs (mESCs), differentiated towards mDA 
neurons, and showed a significant increase in miR-132 expression during later stages of 
differentiation compared to progenitor stage mESCs. It was further shown that miR-132 is 
able to directly regulate Nurr1 expression, an important transcription factor during dopamine 
neuron development. Thus, inhibition of miR-132 was associated with a promotion of mDA 




Furthermore, miRNA sequencing in A30P α-synuclein Drosophila overexpression models 
identified another miRNA, miR-137, as being overexpressed in α-synuclein overexpression 
Drosophila models. This miRNA was shown to affect expression of several neuroactive-ligand 
receptors transcriptional targets including the dopamine receptor, which was downregulated 
in α-synuclein overexpression Drosophila models, and thus perturbing mDA function (Kong et 
al. 2015). 
5.1.2.3 miRNAs associated with neuroinflammation 
PD is characterised by chronic neuroinflammation which exacerbates mDA neuron 
degeneration.  Using an array-based approach to identify miRNAs associated with 
neuroinflammation in an AAV2-α-synuclein overexpression mouse model of PD, enhanced 
expression of miR-155 was detected as early as 2 weeks post transfection of AAV2-α-synuclein 
in SNpc tissue (Thome et al. 2016). Furthermore, a mouse model with complete deletion of 
miR-155 was found to have a reduced inflammatory response to AAV2-induced α-synuclein 
overexpression (Thome et al. 2016). miR-155 has further been shown to be released in 
exosomes from immune cells, namely bone marrow-derived dendritic cells, and taken up by 
recipient dendritic cells, in vivo and in vitro, inducing an upregulation of expression of pro-
inflammatory genes in response to activating lipopolysaccharide treatment (Alexander et al. 
2015).  Furthermore, miR-155 has also been shown to be upregulated in the hippocampus 
(Arena et al. 2017) and cortex (Guedes et al. 2014) of mouse models of Alzheimer’s disease 
corresponding with an increase in microglial and astrocytic activation. These observations link 
miR-155 with the pathophysiology of neurodegeneration through neuroinflammatory 




miR-21 was originally shown to be upregulated in tumours and has been shown to be 
increased in the cortices of a rat stroke model (Buller et al. 2010), acting to reduce apoptosis 
in cortical neurons of mice (Han et al. 2014; Huang et al. 2016).  However, in the context of 
PD, miR-21 overexpression in an MPP+ SH-SY5Y model resulted in significant reduction of 
lysosome-associated membrane protein 2 (LAMP2A) mRNA and protein levels and markedly 
increased levels of α-synuclein (Su et al. 2016). LAMP2A is the rate-limiting step in the 
chaperone-mediated autophagy pathway, known to be involved in the clearance of α-
synuclein (Vogiatzi et al. 2008). Furthermore, miR-21 has been reported to be secreted via 
exosomes from lung tumour cells and bind as ligands to Toll-like receptor (TLR) in immune 
cells to induce a prometastatic inflammatory response (Fabbri et al. 2012). miR-21 has also 
been observed to bind to TLRs in neurons, reducing hippocampal axon and dendrite growth 
(Liu et al. 2015). As PD is characterised by neuroinflammation, the prospect that these miRNAs 
may be involved in immune activation that is manifested prior to motor symptoms caused by 
degeneration is intriguing. 
Collectively, these observations indicate that miRNA dysregulation is involved in mDA 
development and function, inflammation, neurite outgrowth processes as well as regulating 
several proteins involved in the pathology of PD including α-synuclein itself. They also suggest 
that α-synuclein perturbations could induce dysregulation of specific miRNAs. These studies 
rely mostly on animal models, cell lines such as HEK and SH-SY5Y cells, or human tissue or 
plasma/serum. In this chapter we will study miRNA dysregulation in hiPSC-derived neuronal 




5.1.3 Extracellular miRNA 
While the majority of miRNAs are found intracellularly, extracellular miRNAs have been 
identified in a variety of extracellular fluids such as serum, plasma, saliva and urine (Weber et 
al. 2010). Moreover, expression profiles of extracellular miRNA have been linked to disease 
states and as such they have been studied for their potential use as novel clinical biomarkers 
(Alevizos et al. 2010), including in PD (Khoo et al. 2012; Cao et al. 2017). Extracellular miRNAs 
appear to be remarkably stable and protected from degradation by endogeneous RNase 
activity. Mechanisms that are thought to protect and stabilise extracellular miRNA include 
loading into high density lipoprotein (Tabet et al. 2014; Vickers et al. 2011), binding to Ago2 
protein (Arroyo et al. 2011; Turchinovich et al. 2011) and packaging into microvesicles (MVs) 
such as exosomes (Valadi et al. 2007). 
The majority of extracellular miRNA have been reported to be concentrated in either 
exosomes (Gallo et al. 2012) or associated with Ago2 protein (Turchinovich et al. 2012). 
Although Ago2 has been identified within MVs (Collino et al. 2010), Ago2-associated miRNAs 
outside of vesicles are thought to be released non-specifically, as a result of cell death 
(Turchinovich et al. 2012). Exosome-bound miRNA however are thought to be sorted 
specifically into exosomes and have been reported to be endocytosed by recipient cells, 
transferring miRNA and inducing target gene transcriptional regulation (Sohel et al. 2013; 
Simeoli et al. 2017). Thus, these mechanisms protect and stabilise miRNA in bodily fluids, 
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Table 5.1 - Studies that have assessed differentially expressed extracellular miRNA profiles for PD. Including differentially 
expressed miRNA, miRNA detection, normalisation and source. Cerebrospinal fluid (CSF). 
5.1.3.1 Exosomes 
Exosomes are lipid raft enriched extracellular 30-120nm vesicles released from cells by 
exocytosis upon fusion of multivesicular bodies with the plasma membrane (Mathivanan et 
al. 2010) (Figure 5.2). These vesicles can be secreted by most cell types and are present in 
most biological fluids. They have been found to contain various proteins and nucleic acids 
such as mRNAs and miRNAs. It has been widely reported that α-synuclein can be secreted and 
transmitted in a cell-to-cell manner leading to the spread of the neurodegenerative 
phenotype. Thus, it is not surprising that α-synuclein protein has been identified within 
extracellular exosomes, and cell-to-cell transmission of α-synuclein oligomers by this 
mechanism has been demonstrated to propagate α-synuclein pathology (Danzer et al. 2012; 
Shi et al. 2014; Ngolab et al. 2017)Shi 2014; Ngolab 2017). Exosome-mediated transfer of RNA 




deliver RNA cargo to recipient cells, to effect transcriptional regulation in recipient cells, has 
been demonstrated (Valadi et al. 2007; Hunter et al. 2008; Skog et al. 2008) (Figure 5.2A). In 
fact, pluripotent stem cell-derived exosomes have been shown to induce a protective effect 
on cardiac insult models through miRNA-associated mechanisms and are being developed as 





Figure 5.2 miRNA biogenesis and release via exosomes. A) miRNA biogenesis and extracellular release of miRNA.  After 
transcription by RNA pol II and processing by Drosha, pre-miRNA are exported to from the nucleus to cytoplasm, where 
they are processed by Dicer into mature miRNAs. Mature miRNA can be bound to Ago2, actively sorted into exosomes or 
associated with high-density lipoprotein prior to extracellular release. Figure taken from (Sohel 2016). B) Exosomes are 
contained within multivesicular bodies, released upon fusion with the cell membrane.  Exosomes carry diverse cargo 
which includes various proteins and nucleic acids.  The bi-lipid membrane is composed of tetraspanin (CD9, CD63, CD81) 
transmembrane proteins. Figure taken from (Jung et al. 2017). 
As mentioned, it has been suggested that specific endogenous miRNAs are selectively 
exported within extracellular vesicles. Comparing miRNA profiles from parent cells and their 




exosomes compared to parent cells (Guduric-Fuchs et al. 2012). Furthermore, individual 
exosomal miRNAs have been shown to be differentially expressed in various physiological 
states, for example exosomes derived from PD patient cerebro-spinal fluid (CSF) compared to 
healthy control CSF-derived exosomes (Gui et al. 2015). Furthermore, an active sorting 
mechanism for miRNA into exosomes has been proposed, though this remains to be fully 
elucidated (Villarroya-Beltri et al. 2013; Kosaka et al. 2013; Guduric-Fuchs et al. 2012).  
Studies that have attempted to identify novel extracellular miRNA biomarkers have used 
different sources, assay types and normalisation techniques, generating variable results 
(Table 5.1). Many of these studies have used patient blood, CSF, plasma, serum. Moreover, 
there is no consensus on how to normalise extracellular miRNA levels, although one study 
identified a combination of Let-7d, Let-7g and Let-7i (Let-7d/g/i) as being stably expressed in 
human serum (Chen, Liang, et al. 2013). Normalisation is especially challenging in the case of 
exosomes, as miRNA are thought to be sorted specifically, but may be more relevant to cell-
to-cell signalling processes than non-exosomal miRNA. Thus, it is important when studying 
extracellular, and specifically exosomal miRNA, to have a robust normalisation strategy. 
5.1.4 - Aims 
miRNA have been shown to regulate several biological pathways associated with mDA 
function and disease progression. The results of the RNA-seq analysis, described in Chapter 
4, showed differential expression of a key gene involved in the biogenesis of miRNA. The aim 
of the experiments described in this chapter are to: 
1) employ iPSC-derived mDA neurons, overexpressing wild-type and mutants A53T and 
G51D α-synuclein, to determine intra- and extracellular exosomal miRNA profiles in 




2) isolate and characterise extracellular exosomes by transmission electron microscopy 
(TEM) and nanoparticle tracking analysis (NTA) to determine whether perturbed α-
synuclein expression in these cultures resulted in a change in exosome release 
dynamics, and to aid in normalisation of exosomal miRNA expression.  
Thus, the identification of dynamics of miRNA expression, in a physiologically relevant human 
model such as iPSC-derived mDA neurons, may help in the understanding of the role of miRNA 
in PD disease progression and the identification of novel disease biomarkers.   
A schematic for the generation of iPSC-derived mDA neurons overexpressing α-synuclein, 
characterisation and timeline of characterisation of miRNA expression profiles is shown in 
Figure 5.3. 
 
Figure 5.3 - Schematic of the timeline of generation of iPSC-derived mDA neurons and characterisation of transduction 
and differentiation. Characterisation of exosomes by nanoparticle tracking analysis (NTA) and intracellular and 





5.2 Materials and methods 
5.2.1 Isolation of exosomes from iPSC-derived neuronal cultures 
NAS2 iPSC lines were cultured and subjected to the mDA differentiation protocol described 
in section 2.2.4. Conditioned media from these cultures was collected, rather than aspirated, 
for subsequent exosome isolation and characterisation (day 32), and miRNA isolation (day 
35), and stored at -80°C. To isolate exosomes, a rapid purification kit was employed, the 
miRCURY Exosome Kit (Exiqon; #300102) on 1ml of conditioned media as per manufacturer’s 
instructions.  This protocol uses a buffer which precipitates exosomes by diminishing the 
hydration of subcellular particles, which can then be collected by centrifugation. Briefly, 1.1ml 
of conditioned media from both day 32 or day 35 differentiated iPSC-derived PD models was 
spun down at 10,000 x g, to remove cellular debris, and 1.0ml of supernatant transferred into 
a new centrifuge tube. 400μl Precipitation Buffer B was then added and mixed by vortexing 
and tube incubated for 60 minutes at 4˚C. The mixture was then centrifuged at 10,000 x g for 
30 minutes at room temperature, to collect exosomes, which were resuspended in 100μl of 
PBS. The protocol was originally performed on a control non-transduced day 30 differentiated 
iPSC-derived mDA culture sample of conditioned media, to test the ability of this protocol to 
isolate exosomes by TEM characterisation. The supernatant from iPSC-derived PD models 
(described in section 2.2.4) with isolated exosomes were either lysed (day 35) by the mirVana 
kit (as per section 5.2.4) and prepared for miRNA characterisation or resuspended in PBS (Day 
32) for NTA analysis (section 5.2.5). Furthermore, day 30 samples from non-transduced 




5.2.2 Characterisation of isolated exosomes by Transmission Electron Microscopy 
2µl of exosomes in PBS was transferred onto a formvar-carbon coated 300 mesh electron 
microscopy grids (Agar Scientific) and left for 2 minutes. Once specimen had adsorbed onto 
formvar-carbon coated grid, a 100µL drop of H2O was placed on a metal plate covered with 
parafilm on ice, and grid was washed by transfer of grid with the sample membrane side 
facing down using clean forceps for 20 seconds. Sample on grid was transferred to a 20 µL 
drop of a 1:10 ratio of a mixture of 3% uranyl acetate and 1.8% methyl cellulose, respectively, 
for 5 minutes. The grids were removed with stainless steel loops and excess fluid dragged 
gently, at a 90° angle, on Whatman no.1 filter paper.  Grids were left to dry and stored in grid 
storage boxes. 
Grid-mounted exosomes, sample side facing down, were incubated in 100μl of 0.1% 
acetylated BSA (Aurion) in PBS for 10 minutes on parafilm. Grids were then incubated in 
primary antibody for CD63 and CD81 in 0.1% BSA in PBS for 1 hour at room temperature and 
then washed in PBS for 2 minutes, 5 times. Grids were then incubated in a 1:20 dilution of 
10nm secondary gold antibody (Aurion) in 100μl 0.1% BSA in PBS. Grids were finally washed 
in PBS for 2 minutes, 5 times and then sample on grid was transferred to a 20 µL drop of a 
1:10 ratio of a mixture of 3% uranyl acetate and 1.8% methyl cellulose, respectively, for 5 
minutes. The grids were removed with stainless steel loops and excess fluid dragged gently, 
at a 90° angle, on Whatman no.1 filter paper. Grids were left to dry and stored in grid storage 
boxes. Grids were observed with a TEM (Tecnai 12 - FEI 120kV BioTwin Spirit) equipped with an 
FEI Eagle 4k x4k CCD camera. Images were analysed for the presence of lipid membranes of 





5.2.3 Isolation of intracellular and exosomal miRNA 
The isolation of small RNA molecules from cell cultures and isolated exosomes, in this study, 
was performed using mirVana™ miRNA Isolation Kit (ThermoFisher; #AM1561) with acid-
phenol (ThermoFisher; #AM9720), which is specifically designed for the purification of miRNA 
in natural populations. Briefly, 1ml of conditioned media from differentiating iPSCs was 
subjected to the exosome isolation as described in section 5.2.1. Once exosomes had been 
pelleted samples were disrupted in a denaturing lysis buffer. At this stage, 2 fmole of a 
synthetic miRNA found only in Caenorhabditis elegans, cel-miR-39-3p (Exiqon; #203203), was 
spiked into lysis buffer to act as a technical control. Next, samples are subjected to Acid-
Phenol:Chloroform extraction, as per manufacturer’s instructions. Total RNA was eluted in 
50µl nuclease-free H2O and quantified using the Nanodrop 2000 UV-Vis spectrophotometer 
(ThermoFisher).  
 
5.2.4 cDNA generation and qPCR expression profiling by Taqman small RNA assays for 
intracellular and extracellular miRNA 
TaqMan Small RNA Assays were employed to detect and quantify mature microRNAs 
(miRNAs) in a two-step PCR reaction. Firstly, cDNA from 2ng of total RNA is reverse 
transcribed (RT) using a small RNA-specific, stem-loop RT primer from the TaqMan Small RNA 
Assays (Applied Biosystems; #4427975) and reagents from the TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems; #4366596).  In the PCR step, PCR products are amplified 
from cDNA using the TaqMan Small RNA Assay together with the Taqman Universal PCR 
Master Mix II (Applied Biosystems; #4440040).   
In the first instance, qPCR was performed on two prospective small RNA normalisation genes, 




4.2.5. miRNA small RNA assays for use in this study are shown in Table 5.2. ΔΔCt method used 









RNU6B 001093 7 000386 
RNU24 001001 21 000397 
cel-miR-39-3p 000200 34b 000427 
  34c 000428 
  132 000457 
  133b 002247 
  137 000593 
  155 002623 
  494 002365 
 
Table 5.2 - List of control miRNAs and miRNAs of interest with roles associated with PD, development of mDA neurons 
and neuroinflammation 
 
5.2.5 Nanoparticle tracking analysis (NTA) for determining isolated exosomes from 
iPSC-derived PD models 
The NanoSight NS300 NTA (Malvern) uses laser of particles in suspension samples, passing 
through the laser at a constant rate.  A video is taken and scattered light from particles is 
analysed for concentration and size based on Brownian motion, using the Stokes-Einstein 
equation. NTA concentration determination from exosomal samples isolated from day 32 





5.3.1 Differential miRNA expression in iPSC-derived PD models 
5.3.1.1 – Selection of miRNA for profiling 
Target Mechanism/Function Model Publications 
mir-7 
Direct binding to α-
synuclein mRNA 
Overexpression of miR-7 suppresses α-
synuclein expression at protein and 
mRNA levels 
HEK and rat/murine 
cortical neurons (Doxakis 2010) 
HEK cells (Junn, Lee, et al. 2009) 
miR-34b/c 
Direct binding to α-
synuclein mRNA 
Decreased miR-34b/c in PD brain even at 
premotor stages PD brain samples 
(Miñones-
Moyano et al. 
2011) 




(Kabaria et al. 
2015) 
miR-494  
Direct binding to DJ1 
mRNA 
Overexpression of miR-494 decreased 
DJ1 on a protein level 
3T3 and MPTP mouse 
models 
(Xiong et al. 
2014) 
miR-133b 
Targets Pitx3 & RhoA 
(mDA development 
& regulation of 
neurite outgrowth) 
Reduced in SNpc of PD patients. 




mouse primary mDA 
(Kim et al. 
2007) 
Exosome mediated transfer of mir-133b 
from MSCs to primary cortical cultures 
increased neurite outgrowth 
Rat MSCs to primary 
rat cortical cultures 
(Xin et al. 
2012) 
miR-132   





Increased in A30P α- synuclein 





al. 2008; Vo et 
al. 2005) 
Increased during mESC mDA 
differentiation. Downregulation of miR-
132 promoted mDA differentiation 
mDA differentiated 
mESCs 





Increased in PD α-synuclein 
overexpressing flies. Brain enriched and 
highly conserved. 
Drosophila model (Kong et al. 2015) 
miR-155 
(Inflammation) 
Overexpression of α-synuclein induces 
expression miR-155 in mouse model 
Mouse AAV2-α-
synuclein & miR 155-/- 
transgenic mice 
(Thome et al. 
2016) 
miR-21 




Increased miR-21 reduced levels of 
LAMP2A protein and mRNA levels and 
increased α-synuclein protein 
Mouse models or SH-
SY5Y cells (Su et al. 2016) 
Table 5.3 – List of PD-associated miRNA targets chosen from literature with their proposed mechanism, models used and 
respective publications for screening in iPSC-derived PD models.  Blue represents direct binding to mRNA which encode 
familial PD-associated proteins, Green represents miRNA involved in mDA differentiation and function and Red represents 




iPSC-derived PD models that overexpress WT, A53T and G51D α-synuclein were developed 
and described in Chapter 3. These cells were differentiated to dopamine neurons for 35 days 
and then harvested for total RNA isolation. Differential miRNA expression analysis was 
subsequently performed by small RNA qPCR (Taqman). The miRNAs that were selected for 
analysis were determined following a literature review and illustrated in Table 5.3. 
5.3.1.2 – Selection of housekeeping gene for normalisation of differential expression analysis 
As differential regulation of miRNAs in certain disease conditions and cell types has been 
reported, the choice of a standardised housekeeping or reference gene is critical prior to 
quantitative polymerase chain reaction (qPCR) analysis. Generally, small non-coding RNAs 
such as small nuclear and small nucleolar RNAs are used as housekeeping genes. One of the 
most commonly used reference genes, RNU6B, has been seen to fluctuate and be highly 
variable in certain cell types (Xiang et al. 2014; Benz et al. 2013; Lamba et al. 2014). Another 
small RNA, RNU24 has been identified as a more suitable housekeeping gene in PD blood 
samples (Serafin et al. 2014). We determined the housekeeping gene of choice for our specific 
experimental requirements by performing qPCR with RNU6B and RNU24.  Linear regression 
analysis of these candidate housekeeping genes was determined using Bestkeeper software. 
There was relatively good correlation between both candidate genes and the BestKeeper 
index, with a coefficient of correlation of 0.996 for RNU6B and 0.964 for RNU24 (Figure 5.4). 
However, as RNU6B was expressed at a relatively lower level (average Cq 33.41) compared to 
RNU24 (average Cq 25.49), this resulted in high SD in RNU6B analysis (±1.28) which excluded 





Figure 5.4 – Bestkeeper regression analysis of 2 candidate housekeeping genes: RNU6B and RNU24.  The BestKeeper index 
is determined using the geometric mean of raw Cq values of all candidate housekeeping genes.  Both RNU6B and RUN24 
candidate reference genes had high coefficient of correlation, 0.996 and 0.964 respectively, with a p value of 0.001 based 
on the Pearson’s correlation coefficient analysis.  Column data analysis including range of raw Cq values, SD and Coefficient 
of variation.  Graph to visualise raw Cq variation (n=1). 
5.3.1.3 – Differential expression analysis of miRNAs involved in direct regulation of familial PD-
associated genes 
qPCR analysis was undertaken to determine differential expression of selected miRNAs (Table 
5.3 in blue).  Analysis of intracellular miRNA showed no significant differences in miR-7 
expression between all groups (p>0.05)(Figure 5.5A).   
There was however, a significant increase in miR-34b expression in iPSC-derived mDA neurons 
overexpressing WT α-synuclein (3.82±0.67) compared to control (1±0.32), A53T (1.14±0.50) 
and G51D (0.37±0.07) samples (Figure 5.5B). There was also a similar trend in miR-34c, with 
WT overexpressing iPSC-derived cultures expressing significantly elevated levels of miR-34c 
(4.74±0.58) compared to control (1±0.34), A53T (1.38±0.53) and G51D (0.46±0.13) cultures 
(Figure 5.5C). Although there was also a decrease in both miRNAs in G51D overexpressing 
cultures compared to control and A53T, this was only significant for miR34c expression in 
G51D expressing cells compared to A53T cells (Figure 5.5C). Thus, analysis showed a 





miR-494 expression was also, more modestly, increased in iPSC-derived mDA neurons 
overexpressing WT α-synuclein (1.59±0.55) compared to A53T (0.77±0.28) and G51D 
(0.89±0.17) cultures (Figure 5.5D). However, miR-494 was not significantly decreased in 
control iPSC-derived mDA cultures (1±0.15) compared to overexpressing WT α-synuclein 
cultures.  
Thus, miRNAs associated with direct binding of both α-synuclein and DJ1 were observed to 
be perturbed with significant upregulation associated with the overexpression of WT α-
synuclein.  These perturbations may be associated with endogeneous cellular responses to 
increased α-synuclein load.  
 
Figure 5.5 - Differential expression analysis for miRNAs involved in direct binding of familial PD-associated gene targets 
(miR-7, -34b, -34c and -494). Day 35 qPCR analysis, using Taqman small RNA assays, for iPSC-differentiated cultures 
overexpressing WT (W1-4), A53T (A1-4), and G51D (G1-4) α-synuclein, as well as controls (C1-4), at an MOI of 5 (n=4) and 
analysed using the ΔΔCt method relative to the small nucleolar RNA RNU24. (n=4). One-way ANOVA, Tukey post-hoc test 




5.3.1.4 – Differential expression analysis of miRNAs involved in mDA development and function 
qPCR analysis was also undertaken to determine differential expression of selected miRNAs 
that have been previously associated with regulation of mDA development and functional 
pathways such as neurite outgrowth and dopamine receptor function (Table 5.3 in green). 
The miRNAs analysed were miR-132, miR-133b and miR-137. Interestingly, none of these 
miRNAs were found to be differentially expressed in cells overexpressing WT or mutant α-
synuclein, compared to control cells (Figure 5.6A-C).   
 
Figure 5.6 - Differential expression analysis for miRNAs involved in mDA development and function (miR-132, -133b and -
137). Day 35 qPCR analysis, using Taqman small RNA assays, for iPSC-differentiated cultures overexpressing WT (W1-4), 
A53T (A1-4), and G51D (G1-4) α-synuclein, as well as controls (C1-4), at an MOI of 5 (n=4) and analysed using the ΔΔCt 
method relative to the small nucleolar RNA RNU24. (n=4). One-way ANOVA, Tukey post-hoc test (n=4). 
5.3.1.5 – Differential expression analysis of miRNAs involved in neuroinflammatory processes 
qPCR analysis was undertaken to determine differential expression of selected miRNAs that 




5.3 in red). Whilst expression of miR-21 was not changed between controls and wild-type, 
and mutant α-synuclein overexpressing cells (Figure 5.7A), miR-155 expression was 
significantly increased in iPSC-derived mDA neurons overexpressing WT α-synuclein 
(2.58±0.74) to control (1±0.21), A53T (0.81±0.40) and G51D (0.81±0.16) samples (Figure 5.7B) 
WT α-synuclein overexpressing cultures.   
 
 
Figure 5.7 - Differential expression analysis for miRNAs associated with modulation of neuroinflammation (miR-21 and -
155). Day 35 qPCR analysis, using Taqman small RNA assays, for iPSC-differentiated cultures overexpressing WT (W1-4), 
A53T (A1-4), and G51D (G1-4) α-synuclein, as well as controls (C1-4), at an MOI of 5 (n=4) and analysed using the ΔΔCt 
method relative to the small nucleolar RNA RNU24. (n=4). One-way ANOVA, Tukey post-hoc test (n=4). *p<0.05, ** p<0.01, 
*** p<0.001. 
5.3.1.6 Summary of intracellular miRNA analysis 
In conclusion, these results suggest that overexpression of WT α-synuclein induces 
upregulation of miRNAs involved in α-synuclein direct post-transcriptional regulation (miRs 
34b and 34c) and neuroinflammation (miR-155), compared to both control and A53T and 
G51D mutant overexpressing iPSC-derived mDA cultures. Further, miR-34c was also 
downregulated in G51D samples compared to A53T suggesting some differential effect of 
these two mutant α-synuclein species. Furthermore, miR-494 expression appears to be 




to WT α-synuclein overexpression, although there is a non-significant trend for lower 
expression in control samples.   
5.3.2 Characterisation of extracellular vesicles isolated from cultured media from iPSC-
derived neuronal PD models 
5.3.2.1 Transmission electron microscopy 
Exosomal miRNA can be released from cells and affect expression of target mRNAs in recipient 
cells.  Exosomes are characterised by the presence of common proteins such as the 
tetraspanin proteins CD9, CD63 and CD81 by biochemistry techniques and visualised by 
negative staining transmission electron microscopy as having a cup-shaped morphology 
(Simons et al. 2009; Mathivanan et al. 2010). We isolated exosomes produced by iPSC-derived 
dopaminergic neurons in culture and characterised these by negative staining transmission 
electron microscopy (TEM).   
Firstly, negative staining TEM was used to identify the presence of extracellular vesicles 
isolated from conditioned media from untransduced day 30 differentiated iPSC-cultures 
(Figure 5.8). The appearance of structures with an extracellular vesicle-like, cup-shaped 
morphology object was observed (Figure 5.8A). Further characterisation of these vesicle-like 
structures using immunogold staining for exosomal transmembrane proteins CD63 and CD81 
showed that exosomes isolated from differentiating stem cells were clearly identifiable with 
TEM and immunogold staining showed localisation with extracellular vesicle-like objects 
(Figure 5.8B, C). Thus, isolation of exosomes from differentiating iPSC-derived neuronal 






Figure 5.8 - Transmission electron microscopy (TEM) images of isolated extracellular vesicle-like structures isolated from 
1ml cultured media by miRCURY exosome isolation kit from NAS2 iPSC cultures on day 30 of mDA differentiation (yellow 
arrows).  Structures show bilayered membranes characteristic of extracellular vesicles and average size was approximately 
90nm.  (A) TEM without staining and TEM showing co-localisation of EV-like structures with (B) CD63 and (C) CD81 
antibodies by immunogold staining. 
5.3.2.2 Nanoparticle tracking analysis 
Nanoparticle Tracking Analysis (NTA) was performed to further characterise exosomes that 
were secreted by iPSC-derived mDA neurons expressing wild-type and mutant synuclein 






Figure 5.9 – NTA analysis of conditioned media samples from day 32 differentiating iPSC-derived cultures overexpressing 
WT (W1-4), A53T (A1-4), and G51D (G1-4) α-synuclein, as well as controls (C1-4), at an MOI of 5 (n=4). A-E) NTA analysis 
showing distribution of concentration based on specific size ranges A) 30-60nm, B) 60-90nm, C) 90-120nm, D) 120-210nm 
and the cumulative concentration and size of all particles E) 30-120nm in length representing exosome size ranges (n = 4). 
One-way ANOVA, Tukey post-hoc test (n=4). *p<0.05, ** p<0.01. 
NTA analysis revealed a decrease in the concentration of 30-60nm (Figure 5.9A) and 60-90nm 
(Figure 5.9B) particles in iPSC-derived mDA neurons overexpressing A53T and G51D mutant 
α-synuclein compared to control iPSC-derived mDA cultures, on day 32 of differentiation. 
Furthermore, a decrease in concentration of particles ranging between 90-120nm (Figure 
5.9C) and 120-210nm (Figure 5.9D)(larger microvesicles) was observed from the conditioned 
media of iPSC-derived neurons overexpressing WT α-synuclein as compared to control iPSC-




is the prospective exosome size range, there was a significant decrease in all experimental 
synuclein overexpression models compared to control. Thus, it appears that in our PD models, 
there is a decrease in exosome number as a result of perturbed α-synuclein expression, 
suggesting that increased α-synuclein leads to a change in exosomal release dynamics. 
Furthermore, these changes appear within different subpopulations of exosomes, as 
determined by size of particles, in response to different strains of α-synuclein such that 
overexpression of mutant strains induce a deficiency in the release of smaller (30-90nm) 
particles whilst overexpression of wild-type α-synuclein induces a deficiency in the release of 
larger (90-120nm and 120-210nm) particles. 
5.3.3 Exosomal miRNA profiling isolated from iPSC-derived neuronal culture 
conditioned media 
Exosomes were purified from conditioned media of iPSC-derived neuronal cultures on day 35 
of differentiation and qPCR was performed on miRNA isolated from exosomes. All 9 selected 
miRNAs listed in Table 1 were tested for differential expression using a spiked-in C. elegans 
exogenous reference miRNA (cel-39-3p). Expression changes were also normalised to the 
average exosomal concentration for each culture condition, as determined by NTA analysis. 
Results showed that many of these miRNAs (miRNAs 7, 34b, 133b, 155 and 494) were 
undetectable in the exosomal preparations, suggesting that they were expressed at low 
concentrations that were beyond detection thresholds.     
A few miRNAs were within the detectable range for qPCR analysis (miRNAs 21, 34c, 132, 137). 
The results showed that there was a trend for miR-21 and miR-132 expression to be elevated 
in iPSC-derived neurons overexpressing G51D compared to control neurons, although this did 




no statistically significant differences in levels between control and α-synuclein-
overexpressing neurons (Figure 5.10D). Interestingly, there was a large increase in miR-34c in 
WT α-synuclein overexpressing cultures (7.50±6.10), compared to control (1±0.77), A53T 
(1.46±0.89) and G51D (1.34±0.99) cultures (Figure 5.10B) nearing significance compared to 
control (p=0.07). However, this did not reach statistical significance due to the large variation 
between samples. This observation replicated observed intracellular increase of miR-34c in 
response to WT α-synuclein overexpression. Thus, it appears as though a specific set of miRNA 
are enriched in exosomes derived from iPSC-derived neuronal cultures. 
 
Figure 5.10 – Extracellular miRNA expression profiling. Day 35 iPSC cultures differentiated towards an mDA fate, 
overexpressing WT (W1-4), A53T (A1-4), and G51D (G1-4) α-synuclein, as well as controls (C1-4), at an MOI of 5 (n=4).  
Exosomes were isolated from 1ml of conditioned media using Exiqon exosome isolation kit. miRNA differential expression 
analysis was performed using Taqman small RNA assays for all 9 selected miRs and analysed using the ΔΔCt method 





miRNAs have been shown to play critical roles in the development of various diseases such as 
PD; implicating their potential use as novel therapeutic agents or biomarkers. Translatomic 
changes associated with perturbed α-synuclein expression have been studied, using TRAP and 
RNA-sequencing, identifying significant differential expression of a critical protein component 
involved in miRNA biogenesis, DGCR8, however, this could not be validated using other 
analysis techniques. As post-transcriptional regulation of mRNA can be regulated by miRNA, 
miRNA analysis was employed to determine prospective mechanisms of post-transcriptional 
regulation of PD-associated pathways, from intracellular and exosomal fractions derived from 
iPSC-derived PD models.   
5.4.1 Intracellular miRNA profiling in iPSC-derived PD models 
Intracellular miRNA profiles showed differential expression of miRs 34b/c, -155 and -494. 
Previous studies have identified an association between decreased miR-34b/c levels with PD 
patient SNpc tissues, and this was thought to affect the post-transcriptional regulation of α-
synuclein. Here we showed an increase of miR-34b/c in WT synuclein overexpression cultures 
compared to control and mutant α-synuclein overexpressing cells. A very recent study of 
miRNA expression using whole transcriptome miRNA sequencing in iPSC-derived neurons 
from patients with 22q11.del syndrome, which includes a loss of DGCR8, showed a 
downregulation of nearly all miRNA except for miR-34b/c which were upregulated, although 
this did not reach significance (Zhao et al. 2015). Thus, our results may be indicative of early 
regulatory processes in response to increased wild-type α-synuclein load or that increased α-
synuclein over time is part of a negative feedback loop inducing a decrease in levels of this 




Similarly, miR155 was also seen to be expressed at significantly higher levels in wild-type α-
synuclein overexpressing cultures compared to control and mutant α-synuclein 
overexpressing cells. miR155 has been identified as a regulator of microglial inflammatory 
responses and has been found to be upregulated in microglia and macrophages in response 
to proinflammatory cytokines (Cardoso et al. 2012). In the context of PD, an AAV-WT α-
synuclein overexpression mouse model identified an upregulation of miR-155 in the SNpc of 
α-synuclein overexpressing mice compared to control mice (Thome et al. 2016). Furthermore, 
it is thought that macrophages can regulate miR-155 expression during an immune response 
(Androulidaki et al. 2009). The observed increase in miR-155 expression in this study concurs 
with the observations of elevated miR-155 levels in the α-synuclein overexpression mouse 
model (Thome et al. 2016). As mentioned in Chapter 3, the iPSC-derived cultures showed a 
heterogenous mixture of neuronal and glial cells, as identified by GFAP expression.. It has 
been shown that neuronal cultures require non-neuronal cells to modulate the effects of 
neuroinflammation (Hui et al. 2016) and, a limitation of this study is that the non-neuronal 
cells were not characterised sufficiently to ascertain cell types due to lack of sample material. 
Further studies should aim to identify if cytokine expression is changed in response to 
perturbed α-synuclein in these models alongside miR-155 upregulation. Interestingly, 
overexpression of mutant α-synuclein species did not affect miR-155 levels, suggesting an 
ability of the WT species specifically to produce an inflammatory response at the stage of 
differentiation analysed. Inhibition of miR-155 may represent a therapeutic avenue for 
neurodegenerative diseases and is currently being developed as a therapy for amyotrophic 




As described in section 1.5.4 1, loss-of-function mutations in DJ1 protein are thought to be 
associated with autosomal recessive early-onset PD, related to a perturbed cellular response 
to oxidative stress (Bonifati et al. 2003). Moreover, DJ1 protein levels have been found to be 
reduced in human sporadic PD cortex samples (Nural et al. 2009). Overexpression of miR-494 
has been identified as being able to significantly downregulate DJ1 protein, by directly binding 
DJ1 mRNA and thus leaving cells more prone to oxidative stress and degeneration (Xiong et 
al. 2014). Our results showed that iPSC-derived mDA neurons overexpressing WT α-synuclein 
resulted in a statistically significant upregulation of miR-494 compared to mutant species 
models. Thus, compared to the mutant species, WT α-synuclein appears to induce an 
upregulation of a miRNA associated with downregulation of DJ1 protein and reduced cellular 
oxidative stress response. Therefore, an increase in miR-494, as observed in our analysis, may 
be able to induce a decrease in DJ1 protein levels which, can increase the susceptibility of 
neurons to oxidative stress-mediated degeneration. Protein expression analysis for DJ1 could 
be undertaken to validate this hypothesis, however there was not enough time to perform 
this analysis. 
Neurite outgrowth and differentiation potential were analysed in chapter 3 and showed no 
significant changes in differentiation potential, as determined by expression of neuronal and 
dopaminergic markers, whilst neurite growth was attenuated in cultures expressing WT and 
mutant α-synuclein as compared to control cultures.  Thus, it is not surprising that expression 
of miRNAs 133b and 137, which are associated with developmental regulation of mDA 
neurons, were not changed between cultures.  Furthermore, miRNA expression profiling 
suggests that the changes in neurite dynamics are not associated with perturbed expression 




miRNA profiling in iPSC-derived PD models was originally undertaken to interrogate RNA-seq 
results, showing differential expression of a key protein involved in miRNA biogenesis, DGCR8. 
Relating these results to RNA-seq differential expression analysis results, DGCR8 showed a 
significant downregulation in expression in WT overexpression models compared to control 
(Chapter 4). A non-significant decrease was also noted in A53T overexpression compared to 
control. However, DGCR8 is involved in the biogenesis of all miRNA and expression profiling 
results suggest that not all miRNAs are differentially expressed. If differential expression was 
linked to perturbed expression of DGCR8, a generalised perturbation of all miRNA, processed 
by the canonical pathway, would be expected. Studies employing DGCR8-KO mice have 
reported a downregulation of over 90% of miRNA compared to control mice (Zou et al. 2018). 
DGCR8-KO mESCs have been studied and showed a reduction in intermediate pre-miRNA and 
fully mature miRNA, giving further evidence of DGCR8-dependent miRNA processing (Wang 
et al. 2007). Thus, the pattern of specific miRNA differential expression may be due to another 
activated pathway resulting from perturbed α-synuclein expression in iPSC-derived cultures.  
As the model employed in this study appears to produce robust differential expression in 
certain miRNA, it would be very beneficial to attempt small RNA-sequencing, or newer 
platforms like the NanoString nCounter technology, to validate these results and look at 
genome-wide miRNA differential expression. Our results however do validate previous 
literature that has identified a role for the neuroinflammation-associated miR-155 and the α-
synuclein regulating cluster miRs-34b and 34c. An α-synuclein transgenic overexpression 
animal model would be ideal to characterise and validate these findings over different stages 




5.4.2 Extracellular miRNA profiling in iPSC-derived PD models 
Several studies have attempted to identify novel extracellular miRNA biomarkers, as well as 
miRNA within exosomes, in bodily fluids of PD patients compared to controls (Table 5.1). In 
this study, exosomal concentration was seen to decrease in α-synuclein overexpression 
cultures compared to control cultures. Although there is no evidence for exosome 
concentration changes in disease in literature, increased α-synuclein load may be 
dysregulating cellular functions involved in production or release of exosomes. Further 
mechanistic investigations would be interesting in the future.  
Extracellular miRNA profiles have been related to staging of the pathological process and may 
be employed clinically to identify disease progression in both PD and Alzheimer’s disease 
(Burgos et al. 2014). iPSCs can be an ideal source of biological material for these types of 
studies as they can be differentiated into the cells affected in PD and disease modelling can 
be achieved using genetic manipulation techniques, thus recapitulating certain disease 
phenotypes in-vitro. It is also important to make sure that the in vitro models used 
recapitulate the in vivo environment and processes for production of extracellular miRNA. In 
this case, miR-155 was upregulated in wild-type α-synuclein overexpressing cultures, and this 
may be able to mediate a response from GFAP expressing glial cells also observed in our 
cultures. Further studies could thus determine levels of inflammatory cytokines as a proxy for 
activation of microglia. Furthermore, whether exosome-mediated transfer is involved could 
be determined by culturing exosomes from wild-type overexpressing cells with control 
cultures and analysing activation of microglia. 
Thus, this study further aimed to identify miRNA expression profiles from exosomes isolated 




characterisation by TEM and NTA analysis. Results suggest that only a subset of the assayed 
miRNA are expressed at detectable levels in exosome fractions (miRs 21, 34c, 132 and 137). 
Profiling of exosomal miRNA may thus require the collection of increased volume of 
conditioned media for more robust expression analysis. Detectable miRNAs are thought to 
regulate a number of cellular processes such as protein degradation and inflammation, direct 
regulation of α-synuclein, differentiation and mDA function. Importantly, miR-21 is a miRNA 
which has been identified to be trafficked via exosomes and produce a pro-inflammatory 
response in immune cells (Fabbri et al. 2012) . As this miRNA is relatively highly expressed in 
exosomes from iPSC-derived models, miR-21 may have the potential to be regulated 
therapeutically to reduce neuroinflammation via cell-to-cell signalling pathways. 
Furthermore, although normalisation was controlled by exosome count and a spiked-in 
exogenous control, other factors such as method of exosome isolation and RNA isolation 
methods may hinder the identification of true biological effects (Eldh et al. 2012; Ding et al. 
2018). Future studies should identify the best normalisation strategy for the cell type being 
studied, which may require global miRNA profiling. Unfortunately, due to the low amount of 
miRNA which can be extracted from exosomes, small RNA sequencing may not be possible 
without prior amplification or upscaling of cultures to produce more exosomes for expression 
profiling.  
5.5 Conclusion 
In conclusion, the results contained within this chapter suggest that perturbed α-synuclein is 
associated with differential expression of multiple miRNA involved in regulation of mDA 
function or PD pathological processes. Exosome isolation from conditioned media of iPSC-




of exosomal miRNA. Furthermore, exosome concentration analysis by NTA suggests that 
levels of exosomes are decreased in α-synuclein overexpression models. Finally, certain 
miRNA were detected in exosomal isolates and these may mediate signalling between cells in 






Chapter 6 General Discussion 
6.1 - Parkinson’s disease and α-synuclein 
Parkinson’s disease (PD) is an etiologically heterogenous disease, with a diversity of causative 
molecular mechanisms proposed, ultimately resulting in the degeneration of midbrain 
dopaminergic (mDA) neurons of the substantia nigra pars compacta (SNpc). The death of 
these mDA neurons leads to dopamine deficiency in the striatum which clinically presents in 
patients as motor symptoms, although many other clinical non-motor symptoms have been 
described. As with many other neurodegenerative diseases, PD is accompanied by the 
presence of intracellular aggregates of misfolded protein. In the case of PD, these protein 
aggregates are primarily composed of misfolded α-synuclein protein (Lewy bodies and Lewy 
neurites). Indeed, aggregates of α-synuclein are thought to develop and propagate 
throughout the central nervous system (CNS), with evidence for loss of other CNS neurons 
during the different stages of disease development. Evidence has also been presented for the 
mechanisms of propagation of α-synuclein pathology, primarily by mechanisms of cell-to-cell 
transfer. The etiology of PD is linked to several factors including ageing, environmental 
exposures and several genomic loci which link PD to pathological mechanisms including 
mitochondrial dysfunction, response to oxidative stress, neuroinflammation and protein 
degradation. However, the presence of α-synuclein aggregates appears to be a 
pathognomonic hallmark of PD and thus perturbation of α-synuclein in cellular and animal 
models have been analysed using a variety of methods.    
6.2 - Development of a SH-SY5Y model for translating ribosome affinity 
purification 
The aim of the work presented was to design and implement a strategy towards the study of 




employed on a neuroblastoma SH-SY5Y model of synucleinopathy which express an EGFP 
tagged ribosomal protein. To express the tagged ribosomal protein, lentiviral particles were 
generated to test different promoters for robust expression in SH-SY5Y cells. This test 
identified the CMV promoter as the optimal promoter for use in this cell line from a test of 4 
different promoters and may aid in the choice of promoter for use in future studies employing 
this cell line. Furthermore, this test corroborates a previous study that proposed the CMV 
promoter as an ideal promoter in these cells (Li et al. 2010).  
The synucleinopathy models were generated using lentiviral particles to overexpress WT and 
mutant species of α-synuclein. α-synuclein protein expression was identified by Western blot 
protein expression. Furthermore, the FACS sorting for expression of the EGFP tagged 
ribosomal protein was employed to produce a purified population of cells for TRAP. 
6.3 - Translating ribosome affinity purification, RNA-seq library preparation and 
analysis 
The TRAP protocol was applied to these models and actively translating mRNAs were 
immunoprecipitated using anti-EGFP coated magnetic beads and used to prepare a NGS 
library for RNA sequencing. This involved amplification of the low yield translating mRNA and 
reverse transcription to cDNA fragments. Ligation of adapter sequences to cDNA fragments 
for multiplex sequencing was performed and adapter-ligated sequences were amplified and 
pooled together for sequencing. Trace analysis for each processing stage was employed to 
identify successful processing based on average fragment size and concentration.   
RNA-seq results were analysed using a commonly used RNA-seq analysis pipeline, namely the 
TUXEDO analysis pipeline (Trapnell et al. 2012). This pipeline was employed using slight 




expression analysis. As has been previously identified, these different pipelines lead to a slight 
divergence in identification of DEGs, with just over 30% of overall DEGs identified in all three 
pipelines. In Chapter 4, discussion of the limitations of the RNA-seq analysis was described. 
Although alignment statistics showed good alignment to the most recent human genome 
reference, some flags were raised with respect to overamplification. However, as RNA-seq is 
a relatively newly adopted analysis technique in the field of research, there is no definitive 
criteria for a “successful” RNA-seq experiment. Although these flags may represent a 
reduction in the depth of coverage, and the extent to which analysis may be compromised is 
difficult to characterise, they are known to be associated with pre-amplification and 
ribosomal samples. 
In this study, RNA-seq analysis produced a list of genes that were differentially expressed 
between control SH-SY5Y and wild-type and mutant A53T α-synuclein overexpression SH-
SY5Y cultures. Gene targets with significantly high fold changes were identified and classed 
based on prospective association with disease processes including: cytoskeletal, 
mitochondrial, protein trafficking, dopamine signalling, oxidative stress response and 
apoptosis regulation. Finally, these targets were validated using a variety of transcript level 
and protein level analyses. Unfortunately, validation using qPCR and Western blotting was 
only able to partially confirm the differential expression of a few targets including TOMM40, 
SLC25A12, UNC119B and CRADD.  
TOMM40 and SLC25A12 have both previously been associated with mitochondrial function 
and these results suggest that perturbed α-synuclein expression may produce a change in 
expression of proteins that regulate these functions. UNC119B has been linked to modulation 




intracellular trafficking has been associated with PD pathology and α-synuclein itself has been 
identified as acting as a chaperone protein for complexes that mediate synaptic vesicle 
exocytosis. Thus, UNC119B could potentially be a novel PD-associated target. Finally, CRADD 
was also partially validated in our SH-SY5Y models and is associated with the induction of 
caspase-2 dependant apoptosis. This protein has recently been identified as a novel 
therapeutic target to rescue neuronal cell death in neurodegenerative disease (Jang et al. 
2016). Transcriptomics has been employed in the study of PD and has resulted in the 
confirmation of several pathways including but not limited to mitochondrial function, 
oxidative stress, protein degradation, protein chaperones and neuroinflammation 
(Borrageiro et al. 2018; Cooper-Knock et al. 2012). Enrichment analysis further identified 
systemic changes in pathways including, significantly, extra-cellular matrix (ECM) proteins. 
Brain ECM is thought to regulate the neuronal environment and perturbation is linked to 
activation of microglia (Bonneh-Barkay et al. 2009). Furthermore, neuronal cells in culture are 
known to require ECM proteins for their survival and these proteins provide neuroprotection 
to neurons including specifically mDA neurons (Zhang, Yang, Toledo, et al. 2017). ECM 
proteins have also been associated with regulation of neurite dynamics such as outgrowth 
(Lamoureux et al. 1990; Tonge et al. 2012). Other altered pathways include actin filament 
branch point, dendrite extension and actin body pathways, with a striking number of 
differentially expressed genes in these pathways. These pathways and ECM pathways link 
together the important interplay between the actin cytoskeleton and the ECM which regulate 





Furthermore, a differentially expressed gene was identified which is known to play an 
important functional role within the microRNA biosynthesis pathway, DGCR8. This prompted 
us to look towards studying miRNA expression profiles, this time, within a more 
physiologically relevant model, iPSC-derived PD models.  
6.4 Development of an iPSC-model of synucleinopathy 
To generate iPSC-derived synucleinopathy models, iPSCs were preliminarily subjected to an 
mDA differentiation protocol and characterised by expression of midbrain, neuronal and 
dopaminergic markers. Analysis showed an enrichment of dopaminergic neurons with floor 
plate markers and thus this model would represent a physiologically relevant model for the 
study of PD in the cells that degenerate during pathology. The original intention was to use 
iPSC-derived cultures for TRAP, however, the low yield of immunoprecipitated mRNA from 
SH-SY5Y models, using many more cells than would be possible due to the costs involved with 
iPSC differentiation, this was deemed unfeasible.  
Thus, again several promoters were tested for their ability to express transgenes in iPSC-
derived mDA cultures. For this study, the hSYN1 promoter was used as it could be used to 
overexpress α-synuclein specifically in neurons. However, the other promoters were also 
seen to produce robust expression of transgenes in iPSC-derived neurons as well as non-
neuronal cells. Thus, overexpression of wild-type and mutant α-synuclein was achieved by 
generating lentiviral particles to overexpress wild-type, and A53T and G51D mutant α-
synuclein. Characterisation by protein analysis for α-synuclein showed robust overexpression 
in all models, although the expression of the A53T mutant was less than WT and G51D α-
synuclein. It was noted that α-synuclein overexpression in these cultures did not produce any 




phenomenon in response to elevated α-synuclein in an iPSC-derived model (Oliveira et al. 
2015). 
6.5 Functional characterisation of neurite dynamics 
As the RNA-seq results showed many differentially expressed genes related to cytoskeletal 
and ECM proteins, these cells were functionally characterised for neurite dynamics. Results 
showed significantly reduced neurite length and neurite branching in WT and G51D 
overexpressing iPSC-derived dopaminergic neurons. This is in keeping with previously 
published results showing decreased neurite extension in cells with elevated α-synuclein 
levels (Oliveira et al. 2015; Takenouchi et al. 2001). Thus, these results may represent a link 
between RNA-seq results and functional/structural disturbances leading to a reduction in 
neurite outgrowth and branching. Future studies should focus on biochemical expression of 
ECM proteins and expression of structural proteins associated with neurite dynamics.  
6.6 Intracellular and extracellular miRNA profiling 
As DGCR8 was seen to be differentially expressed from RNA-seq results, both intracellular and 
extracellular microRNA expression profiles were interrogated. For extracellular microRNA 
profiling, exosomes were isolated and characterised by both transmission electron 
microscopy and nanoparticle tracking analysis. These results validated the use of the 
commercially available kit for exosome isolation from conditioned media of iPSC-derived 
cultures. Furthermore, exosomal fractions, based on size, were differentially produced, with 
an overall decrease in α-synuclein overexpressing cells compared to control in the prospective 
exosomal size range. However, mechanistically, these insights remain to be elucidated.  
Thus, both the intracellular and extracellular miRNA profiles were interrogated via qPCR for 




intracellular expression profiling showed the differential expression of 4 miRNAs (miRs -
34b/c, -494 and -155). These results suggest that increased wild-type α-synuclein, in iPSC-
derived mDA neurons, results in an increase in specific miRNAs. These miRNAs are involved 
specifically in the regulation of α-synuclein and DJ1 expression and the modulation of 
neuroinflammation. miR-155, an important modulator of neuroinflammation, has previously 
been found to be elevated in an α-synuclein overexpression mouse model, corroborating 
results in this study (Thome et al. 2016). Whether this increase in miR-155 results in an 
increased activation of microglia remains to be studied and could be the focus of future 
studies. Thus, intracellular expression profiling identified miRNAs which may represent 
therapeutic targets for PD as well as other neurodegenerative diseases. Further studies that 
profile differential miRNA expression in α-synuclein overexpression models (for example 
using miRNA microarrays) may also help identify other miRNAs that potentially play important 
roles in PD pathology. 
Extracellular miRNA profiles showed no differential expression and only 4 miRNA (miRs -21, -
34c, -132 and -137) were within the detectable range for expression. This includes a miRNA 
involved in induction of neurite outgrowth (miR-132) and neuroinflammation (miR-21). miR-
21 from exosomes has been associated with activation of microglia and represents a possible 
mechanism for induction of neuroinflammation associated with PD. However, future studies 
would require the isolation of increased amounts of conditioned media for robust differential 
expression analysis. 
 6.7 Conclusions and future work 
In conclusion, the results presented show an array of transcriptomic changes in response to 




differential expression of genes associated with several pathways previously linked to PD. 
NGS technologies represent a relatively new technique and analysis algorithms are being 
modified and developed to produce robust, reproducible gene expression analysis. As it has 
been shown that reproducibility for DEG analysis requires many biological repeats (Schurch 
et al. 2016), the future of NGS technologies relies on the implementation of reproducible 
platforms which can be collected and analysed together for robust data analysis. A project 
similar to the 100,000 genomes project that was undertaken by the National Health Service 
to link genomic abnormalities to medical histories may be useful in this respect (Turnbull et 
al. 2018). A project of this scale in conjunction with genome-wide transcriptional and/or 
translational analysis may be able to produce a wealth of information (DEG analysis, 
alternative splicing, etc) for the development of disease diagnosis and new therapies. 
miRNA profiling also showed differential expression of multiple miRNAs in iPSC-derived 
synucleinopathy models. Transgenic mice with either knock out or overexpression of the 
specific miRNA may help in understanding the role of these miRNA. In situ hybridisation may 
be able to help in understanding dynamics of miRNA expression. Finally, multiple lines of 
enquiry show the involvement of neurite extension and branching in response to perturbed 
α-synuclein. These may represent pre-symptomatic alterations and possible therapeutic 
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VSMCs of adult mice results in loss of vascular reactivity, reduced blood pressure and 





Appendix 1 - SHSY5Y transduction with EGFP – flow cytometry - promoter test 
Untransduced Control 
Control MOI 2 MOI 5 
CMV 45.7 79.1 
CAG 47.3 84.6 
EF1 27.1 55.6 









CMV MOI 5 
 






CAG MOI 5 
 





EF1 MOI 5 
 











Appendix 2 – SHSY5Y promoter test – FACS sorting for EGFP expression 






























Appendix 3 – SHSY5Y PD model and control cells transduced with CMV-L10a-
EGFP lentivirus particles (MOI 2) – FACS sorted for EGFP expression 


















































































Appendix 4 – RNA integrity of affinity purified samples from SHSY5Y PD model 
 
 
Well RINe 28S/18S (Height) 
28S/18S 






A0 - - - 3550   Ladder - - 
B1 8.2 1.2 1.4 2430 C1   5.61 1.96 
C1 8.0 1.1 1.5 7910 C2   18.29 6.59 
D1 7.9 1.2 1.5 10800 C3   24.87 9.16 
E1 7.9 1.2 1.5 6630 W1   15.34 5.44 
F1 7.9 1.1 1.6 2900 W2   6.72 2.35 
G1 7.6 0.8 1.1 10500 W3   24.30 8.01 





range for RINe 
75.46 27.63 
A2 7.8 1.0 1.2 13200 A2   30.43 10.83 






Appendix 5 – RNA amplification – dsDNA 
D1000 
Contrast: 0.50 
Well Conc. [ng/µl] Sample Description Alert Observations 
A0 20.3 D1000 Ladder  Ladder 
A1 8.20 MK_C1   
B1 7.44 MK_C2   
C1 4.53 MK_C3   
D1 6.78 MK_W1   
E1 6.40 MK_W2   
F1 4.60 MK_W3   
G1 10.6 MK_A1   
H1 6.34 MK_A2   
A2 5.44 MK_A3   
























Area Peak Comment Observations 
25 6.05 - 372 -  Lower Marker 
42 4.61 - 167 56.15   
195 3.60 - 28.3 43.85   










Area Peak Comment Observations 
25 6.15 - 379 -  Lower Marker 
43 3.56 - 129 47.85   
190 3.88 - 31.3 52.15   














Area Peak Comment Observations 
25 6.16 - 379 -  Lower Marker 
43 2.90 - 105 63.91   











Area Peak Comment Observations 
25 6.05 - 372 -  Lower Marker 
42 4.78 - 173 70.39   
194 2.01 - 15.9 29.61   
















Area Peak Comment Observations 
25 6.06 - 373 -  Lower Marker 
42 3.60 - 131 56.20   
188 2.80 - 22.9 43.80   











Area Peak Comment Observations 
25 6.18 - 381 -  Lower Marker 
42 3.27 - 119 71.09   
193 1.33 - 10.6 28.91   















Area Peak Comment Observations 
25 6.23 - 383 -  Lower Marker 
42 4.00 - 147 37.64   
74 1.19 - 24.8 11.20   
182 5.43 - 45.9 51.16   











Area Peak Comment Observations 
25 6.14 - 378 -  Lower Marker 
42 4.54 - 166 71.55   
74 0.697 - 14.5 10.99   
189 1.11 - 9.00 17.46   























Area Peak Comment Observations 
25 6.40 - 394 -  Lower Marker 
42 4.05 - 148 74.52   
195 1.39 - 10.9 25.48   






Appendix 6 – Universal/index adapters, amplification primers and P5/P7 
adapter sequences 
Universal and index adapter sequences 




























































P5 and P7 primers: from NEBNext library quant kit for illumina platform (also used for sequencing by 
illumina chemistry) 
Primer Sequence 
P5:  5' AAT GAT ACG GCG ACC ACC GA 3'  










Well Conc. [ng/µl] Sample Description Alert Observations 
A0 20.3 D1000 Ladder  Ladder 
A1 0.848 MK_C1   
B1 0.701 MK_C2   
C1 1.28 MK_C3   
D1 1.01 KM_W1   
E1 0.748 KM_W2   
F1 0.925 KM_W3   
G1 1.00 MK_A1   
H1 1.17 MK_A2   
A2 1.25 KM_A3rep   































Area Peak Comment Observations 
25 7.40 - 455 -  Lower Marker 
65 0.204 - 4.82 24.02   
120 0.0243 - 0.313 2.87   
213 0.620 - 4.48 73.11   











Area Peak Comment Observations 
25 7.51 - 462 -  Lower Marker 
63 0.238 - 5.80 33.93   
115 0.0725 - 0.969 10.34   
232 0.391 - 2.59 55.72   















Area Peak Comment Observations 
25 7.07 - 435 -  Lower Marker 
66 0.179 - 4.20 14.04   
116 0.0620 - 0.820 4.86   
220 0.802 - 5.60 62.81   
313 0.204 - 1.00 15.99   
608 0.0293 - 0.0740 2.29   










Area Peak Comment Observations 
25 6.67 - 410 -  Lower Marker 
67 0.286 - 6.53 28.27   
121 0.0573 - 0.731 5.66   
325 0.669 - 3.17 66.07   





















Area Peak Comment Observations 
25 7.45 - 459 -  Lower Marker 
64 0.216 - 5.18 28.90   
118 0.0309 - 0.401 4.13   
319 0.501 - 2.42 66.97   











Area Peak Comment Observations 
25 6.78 - 417 -  Lower Marker 
67 0.383 - 8.83 41.42   
118 0.0725 - 0.947 7.84   
320 0.469 - 2.26 50.74   






















Area Peak Comment Observations 
25 7.56 - 466 -  Lower Marker 
65 0.224 - 5.34 22.38   
118 0.0601 - 0.786 6.00   
320 0.717 - 3.45 71.62   











Area Peak Comment Observations 
25 7.31 - 450 -  Lower Marker 
63 0.318 - 7.83 27.31   
117 0.0618 - 0.816 5.30   
318 0.786 - 3.80 67.39   






















Area Peak Comment Observations 
25 7.39 - 455 -  Lower Marker 
62 0.173 - 4.28 13.80   
112 0.114 - 1.57 9.13   
221 0.693 - 4.82 55.33   
307 0.272 - 1.36 21.74   
1,500 6.50 6.50 6.67 -  Upper Marker 
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